


**CUMULATIVE  
SUPPLEMENT 2  
FEBRUARY 2021**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**41st EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy**

**2021**

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**41<sup>th</sup> EDITION**

**Cumulative Supplement 2  
February 2021**

**CONTENTS**

	<i>PAGE</i>
<b>Contents</b>	
1.0 INTRODUCTION.....	v
1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT .....	vi
1.2 CUMULATIVE SUPPLEMENT CONTENT .....	vi
1.3 APPLICANT NAME CHANGES .....	vii
1.4 LEVOTHYROXINE SODIUM .....	viii
1.5 AVAILABILITY OF THE EDITION.....	ix
1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7 CUMULATIVE SUPPLEMENT LEGEND.....	xi
 <b>DRUG PRODUCT LISTS</b>	
Prescription Drug Product List .....	1-1
OTC Drug Product List .....	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List .....	3-1
Orphan Product Designations and Approvals List .....	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution .....	5-1
 <b>PATENT AND EXCLUSIVITY INFORMATION ADDENDUM</b>	
A. Patent and Exclusivity Lists .....	A-1
B. Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**41<sup>st</sup> EDITION**

**CUMULATIVE SUPPLEMENT 2  
FEBRUARY 2021**

**1.0 INTRODUCTION**

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

## 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME  
(FORMER ABBREVIATED NAME)

AKORN INC  
(AKORN)

AKORN INC  
(AKORN INC)

NEW APPLICANT NAME  
(NEW ABBREVIATED NAME)

AKORN OPERATING CO LLC  
(AKORN)

AKORN OPERATING CO LLC  
(AKORN)

## 1.4 LEVOTHYROXINE SODIUM<sup>1</sup>

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.<sup>2</sup>

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN GROUP HOLDINGS 4 LLC	0.3MG	N021116	RLD	-

<sup>1</sup> In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

<sup>2</sup> Please consult the Active Section of the Orange Book for information on other strengths.

AB4	LEVOTHYROXINE SODIUM <sup>3</sup>	MYLAN	0.3MG	A076187	-	RS
-----	-----------------------------------	-------	-------	---------	---	----

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,  
 Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,  
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

---

<sup>3</sup> Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).



The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

### REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2020</u>	<u>MAR</u> <u>2021</u>	<u>JUN</u> <u>2021</u>	<u>SEP</u> <u>2021</u>	<u>DEC</u> <u>2021</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	20478	2659			
	(13.0%)				
MULTISOURCE	17819				
	(87.0%)				
THERAPEUTICALLY EQUIVALENT	17746				
	(86.7%)				

NOT THERAPEUTICALLY EQUIVALENT	73 (0.4%)
EXCEPTIONS <sup>4</sup>	54 (0.3%)
NEW MOLECULAR ENTITIES APPROVED	22
NUMBER OF APPLICANTS	1185

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN <sup>5</sup>	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.

<sup>4</sup> Amino acid containing products of varying composition (see Introduction, page xx of the List).

<sup>5</sup> The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

ACETAMINOPHEN

POWDER; INTRAVENOUS  
ACETAMINOPHEN  
+ @ MYLAN LABS LTD 1GM/VIAL N206610 001 Jan 15, 2021 Jan NEWA  
SOLUTION; INTRAVENOUS  
ACETAMINOPHEN  
>A> +! B BRAUN MEDICAL INC 500MG/50ML (10MG/ML) N204957 001 Feb 18, 2021 Feb NEWA  
>A> +! 1GM/100ML (10MG/ML) N204957 002 Feb 18, 2021 Feb NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL  
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE  
>D> AA WRASER PHARMS LLC 300MG; 50MG; 40MG A206615 001 Aug 04, 2017 Feb CAHN  
>A> AA XSPIRE PHARMA 300MG; 50MG; 40MG A206615 001 Aug 04, 2017 Feb CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL  
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE  
AB NOSTRUM LABS INC 325MG; 50MG; 40MG; 30MG A075929 001 Apr 22, 2002 Jan CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL  
OXYCODONE AND ACETAMINOPHEN  
AA CHARTWELL 325MG; 5MG A207834 001 Aug 15, 2019 Jan CAHN  
AA 325MG; 7.5MG A207834 002 Aug 15, 2019 Jan CAHN  
AA 325MG; 10MG A207834 003 Aug 15, 2019 Jan CAHN  
ROXICET  
@ HIKMA 325MG; 5MG A087003 001 Jan DISC

ACETAZOLAMIDE

TABLET; ORAL  
ACETAZOLAMIDE  
>A> AB APPCO 125MG A211372 001 Feb 22, 2021 Feb NEWA  
>A> AB 250MG A211372 002 Feb 22, 2021 Feb NEWA

ACLIDINIUM BROMIDE

POWDER, METERED; INHALATION  
TUDORZA PRESSAIR  
>A> +! ASTRAZENECA 0.4MG/INH N202450 001 Jul 23, 2012 Feb CAHN  
>D> +! CIRCASSIA 0.4MG/INH N202450 001 Jul 23, 2012 Feb CAHN

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED; INHALATION  
DUAKLIR PRESSAIR  
>A> ASTRAZENECA 0.4MG/INH; 0.012MG/INH N210595 001 Mar 29, 2019 Feb CAHN  
>D> CIRCASSIA 0.4MG/INH; 0.012MG/INH N210595 001 Mar 29, 2019 Feb CAHN

ACYCLOVIR

SUSPENSION; ORAL  
ACYCLOVIR  
AB VISTAPHARM 200MG/5ML A213951 001 Jan 11, 2021 Jan NEWA

ACYCLOVIR SODIUM

INJECTABLE; INJECTION  
ACYCLOVIR SODIUM  
AP ZYDUS PHARMS EQ 50MG BASE/ML A206535 001 Aug 31, 2018 Jan CHRS  
AP ! EQ 50MG BASE/ML A206535 001 Aug 31, 2018 Jan CPOT

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL  
EPIDUO FORTE  
>D> AB +! GALDERMA LABS 0.3%; 2.5% N207917 001 Jul 15, 2015 Feb CTEC  
>A> +! 0.3%; 2.5% N207917 001 Jul 15, 2015 Feb CTEC

ADENOSINE

SOLUTION; INTRAVENOUS  
ADENOSINE

>D>	@ EMCURE PHARMS LTD	60MG/20ML (3MG/ML)	A202313	001	Sep 15, 2014	Feb	CMFD
>A>	AP	60MG/20ML (3MG/ML)	A202313	001	Sep 15, 2014	Feb	CMFD
>D>	@	90MG/30ML (3MG/ML)	A202313	002	Sep 15, 2014	Feb	CMFD
>A>	AP	90MG/30ML (3MG/ML)	A202313	002	Sep 15, 2014	Feb	CMFD

ALBENDAZOLE

TABLET; ORAL  
ALBENDAZOLE

AB	DR REDDYS	200MG	A211034	001	Jan 26, 2021	Jan	NEWA
	@ LUPIN LTD	200MG	A211636	001	Jun 10, 2020	Jan	DISC
AB	MSN	200MG	A213435	001	Jan 21, 2021	Jan	NEWA

ALBUTEROL SULFATE

TABLET; ORAL  
ALBUTEROL SULFATE

>D>	@ AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019	Feb	CMFD
>A>	AB	EQ 2MG BASE	A210948	001	Mar 15, 2019	Feb	CMFD
>D>	@	EQ 4MG BASE	A210948	002	Mar 15, 2019	Feb	CMFD
>A>	AB	EQ 4MG BASE	A210948	002	Mar 15, 2019	Feb	CMFD

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION  
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

	@ AUROBINDO PHARMA LTD	EQ 0.083% BASE; 0.017%	A206532	001	Jul 08, 2020	Jan	DISC
--	------------------------	------------------------	---------	-----	--------------	-----	------

ALPROSTADIL

INJECTABLE; INJECTION  
CAVERJECT

	+ @ PFIZER	0.005MG/VIAL	N020379	003	Jun 27, 1996	Jan	CAHN	
AP	+	0.01MG/VIAL	N020379	001	Jul 06, 1995	Jan	CAHN	
AP	+	0.02MG/VIAL	N020379	002	Jul 06, 1995	Jan	CAHN	
AP	+	0.04MG/VIAL	N020379	004	May 19, 1997	Jan	CAHN	
	CAVERJECT IMPULSE							
	PFIZER	0.01MG/VIAL	N021212	001	Jun 11, 2002	Jan	CAHN	
		0.02MG/VIAL	N021212	002	Jun 11, 2002	Jan	CAHN	
	PROSTIN VR PEDIATRIC							
AP	+	PFIZER	0.5MG/ML	N018484	001		Jan	CAHN

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL  
AMANTADINE HYDROCHLORIDE

	@ WOCKHARDT BIO AG	50MG/5ML	A075060	001	Dec 24, 1998	Jan	DISC
--	--------------------	----------	---------	-----	--------------	-----	------

TABLET; ORAL  
AMANTADINE HYDROCHLORIDE

	@ INVAGEN PHARMS	100MG	A207571	001	Jan 31, 2017	Jan	DISC
--	------------------	-------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL  
OSMOLEX ER

	+ ADAMAS PHARMA	EQ 129MG BASE	N209410	001	Feb 16, 2018	Jan	CAHN
	+ @	EQ 161MG BASE	N209410	004	Apr 22, 2020	Jan	CAHN
	+	EQ 193MG BASE	N209410	002	Feb 16, 2018	Jan	CAHN
	+	EQ 258MG BASE	N209410	003	Feb 16, 2018	Jan	CAHN
	+ ADAMAS PHARMS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Jan	CAHN
	+ @	EQ 161MG BASE	N209410	004	Apr 22, 2020	Jan	CAHN
	+	EQ 193MG BASE	N209410	002	Feb 16, 2018	Jan	CAHN
	+	EQ 258MG BASE	N209410	003	Feb 16, 2018	Jan	CAHN

AMINOCAPROIC ACID

SOLUTION; ORAL  
AMICAR

>A>	AA	+	AKORN	0.25GM/ML	N015230	002		Feb	CPOT
			AMINOCAPROIC ACID						
>A>	AA		AMNEAL	0.25GM/ML	A212780	001	Aug 23, 2019	Feb	CPOT
>A>	AA		LEADING PHARMA LLC	0.25GM/ML	A214140	001	Jan 26, 2021	Feb	CPOT
>A>	AA		TULEX PHARMS INC	0.25GM/ML	A212494	001	Aug 11, 2020	Feb	CPOT
>A>	AA		VISTAPHARM	0.25GM/ML	A212814	001	Feb 26, 2020	Feb	CPOT

SYRUP;ORAL  
AMICAR

>D>	AA	+! AKORN	1.25GM/5ML	N015230	002		Feb CPOT
AMINOCAPROIC ACID							
>D>	AA	AMNEAL	1.25GM/5ML	A212780	001	Aug 23, 2019	Feb CPOT
>D>	AA	LEADING PHARMA LLC	1.25GM/5ML	A214140	001	Jan 26, 2021	Feb CPOT
	AA		1.25GM/5ML	A214140	001	Jan 26, 2021	Jan NEWA
>D>	AA	TULEX PHARMS INC	1.25GM/5ML	A212494	001	Aug 11, 2020	Feb CPOT
>D>	AA	VISTAPHARM	1.25GM/5ML	A212814	001	Feb 26, 2020	Feb CPOT

TABLET;ORAL  
AMINOCAPROIC ACID

>A>	AB	LEADING PHARMA LLC	500MG	A213928	001	Feb 12, 2021	Feb NEWA
>A>	AB		1GM	A213928	002	Feb 12, 2021	Feb NEWA

AMIODARONE HYDROCHLORIDE

TABLET;ORAL  
AMIODARONE HYDROCHLORIDE

>A>	AB	RUBICON	100MG	A078578	002	Feb 26, 2021	Feb NEWA
>A>	AB		400MG	A078578	003	Feb 26, 2021	Feb NEWA

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL  
AMITRIPTYLINE HYDROCHLORIDE

>A>	AB	MANKIND PHARMA	10MG	A213999	001	Feb 19, 2021	Feb NEWA
>A>	AB		25MG	A213999	002	Feb 19, 2021	Feb NEWA
>A>	AB		50MG	A213999	003	Feb 19, 2021	Feb NEWA
>A>	AB		75MG	A213999	004	Feb 19, 2021	Feb NEWA
>A>	AB		100MG	A213999	005	Feb 19, 2021	Feb NEWA
>A>	AB		150MG	A213999	006	Feb 19, 2021	Feb NEWA

AMLODIPINE BESYLATE

TABLET;ORAL  
AMLODIPINE BESYLATE

@	WOCKHARDT	EQ 2.5MG BASE	A078500	001	Sep 06, 2007	Jan DISC
@		EQ 5MG BASE	A078500	002	Sep 06, 2007	Jan DISC
@		EQ 10MG BASE	A078500	003	Sep 06, 2007	Jan DISC

AMMONIA N-13

INJECTABLE;INTRAVENOUS  
AMMONIA N 13

AP	NUKEMED	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Jan CAHN
----	---------	------------------------------------	---------	-----	--------------	----------

AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL  
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	RHODES PHARMS	2.5MG;2.5MG;2.5MG;2.5MG	A213111	003	Jan 13, 2021	Jan NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A213111	005	Jan 13, 2021	Jan NEWA
AB		5MG;5MG;5MG;5MG	A213111	006	Jan 13, 2021	Jan NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL  
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A213111	001	Jan 13, 2021	Jan NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A213111	002	Jan 13, 2021	Jan NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A213111	004	Jan 13, 2021	Jan NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A213111	007	Jan 13, 2021	Jan NEWA

AMPHETAMINE SULFATE

TABLET;ORAL  
AMPHETAMINE SULFATE

AA	GLENMARK PHARMS LTD	5MG	A212186	001	Jan 27, 2021	Jan NEWA
AA		10MG	A212186	002	Jan 27, 2021	Jan NEWA
	@ MAYNE PHARMA	5MG	A213898	001	Jul 14, 2020	Jan DISC
	@	10MG	A213898	002	Jul 14, 2020	Jan DISC
AA	SPECGX LLC	5MG	A213583	001	Jan 22, 2021	Jan NEWA
AA		10MG	A213583	002	Jan 22, 2021	Jan NEWA
AA	SUN PHARM INDS INC	5MG	A214574	001	Jan 27, 2021	Jan NEWA
AA		10MG	A214574	002	Jan 27, 2021	Jan NEWA

APREMILAST

TABLET;ORAL

>A>		APREMILAST						
>A>	AB	UNICHEM	10MG	A211819	001	Feb 17, 2021	Feb	NFTG
>A>	AB		20MG	A211819	002	Feb 17, 2021	Feb	NFTG
>A>	AB		30MG	A211819	003	Feb 17, 2021	Feb	NFTG

ARGATROBAN

INJECTABLE; INJECTION  
ARGATROBAN

AP		CAPLIN	50MG/50ML (1MG/ML)	A214235	001	Jan 21, 2021	Jan	NFTG
----	--	--------	--------------------	---------	-----	--------------	-----	------

ARSENIC TRIOXIDE

INJECTABLE; INJECTION  
ARSENIC TRIOXIDE

AP		AMNEAL	1MG/ML	A210739	001	Jan 25, 2021	Jan	NEWA
>D>	AP	INGENUS PHARMS LLC	2MG/ML	A209315	002	Jan 14, 2021	Feb	DISC
>A>		@	2MG/ML	A209315	002	Jan 14, 2021	Feb	DISC
AP			2MG/ML	A209315	002	Jan 14, 2021	Jan	NEWA

>A> ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

>A>								
>A>								
>A>		INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)						
>A>	+	SANDOZ CANADA INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	002	Jan 29, 2004	Feb	CAIN

>D> ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL HYDROCHLORIDE; VITAMIN A; VITAMIN K

>D>								
>D>								
>D>		INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)						
>D>	+	SANDOZ CANADA INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	002	Jan 29, 2004	Feb	CAIN

ASENAPINE MALEATE

TABLET;SUBLINGUAL  
ASENAPINE MALEATE

>A>	AB	BRECKENRIDGE	EQ 5MG BASE	A205960	003	Mar 08, 2021	Feb	NEWA
-----	----	--------------	-------------	---------	-----	--------------	-----	------

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL  
ATOMOXETINE HYDROCHLORIDE

>A>		@ MYLAN	10MG	A079021	001	Feb 18, 2021	Feb	DISC
>A>		@	18MG	A079021	002	Feb 18, 2021	Feb	DISC
>A>		@	25MG	A079021	003	Feb 18, 2021	Feb	DISC
>A>		@	40MG	A079021	004	Feb 18, 2021	Feb	DISC
>A>		@	60MG	A079021	005	Feb 18, 2021	Feb	DISC
>A>		@	80MG	A079021	006	Feb 18, 2021	Feb	DISC
>A>		@	100MG	A079021	007	Feb 18, 2021	Feb	DISC

ATORVASTATIN CALCIUM

TABLET;ORAL  
ATORVASTATIN CALCIUM

AB		ALKEM LABS LTD	EQ 10MG BASE	A209288	001	Dec 21, 2018	Jan	CAHN
AB			EQ 20MG BASE	A209288	002	Dec 21, 2018	Jan	CAHN
AB			EQ 40MG BASE	A209288	003	Dec 21, 2018	Jan	CAHN
AB			EQ 80MG BASE	A209288	004	Dec 21, 2018	Jan	CAHN

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL  
LIPTRUZET

>D>	+	@ MERCK SHARP DOHME	EQ 10MG BASE;10MG	N200153	001	May 03, 2013	Feb	CAHN
>D>	+	@	EQ 20MG BASE;10MG	N200153	002	May 03, 2013	Feb	CAHN
>D>	+	@	EQ 40MG BASE;10MG	N200153	003	May 03, 2013	Feb	CAHN
>D>	+	@	EQ 80MG BASE;10MG	N200153	004	May 03, 2013	Feb	CAHN
>A>	+	@ ORGANON	EQ 10MG BASE;10MG	N200153	001	May 03, 2013	Feb	CAHN
>A>	+	@	EQ 20MG BASE;10MG	N200153	002	May 03, 2013	Feb	CAHN

	TABLET;ORAL							
	LIPTRUZET							
>A>	+ @	EQ 40MG BASE;10MG	N200153	003	May 03, 2013	Feb	CAHN	
>A>	+ @	EQ 80MG BASE;10MG	N200153	004	May 03, 2013	Feb	CAHN	
	<u>ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE</u>							
	TABLET;ORAL							
	DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE							
AA	WINDER LABS LLC	0.025MG;2.5MG	A211362	001	Jan 27, 2021	Jan	NEWA	
	<u>ATROPINE SULFATE; EDROPHONIUM CHLORIDE</u>							
	INJECTABLE;INJECTION							
	ENLON-PLUS							
	+ @ MYLAN	0.14MG/ML;10MG/ML	N019678	001	Nov 06, 1991	Jan	CAHN	
	<u>AVIBACTAM SODIUM; CEFTAZIDIME</u>							
	POWDER;INTRAVENOUS							
	AVYCAZ							
	+! ALLERGAN	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	Jan	CDFR	
	<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE</u>							
	SPRAY, METERED;NASAL							
	AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE							
>A> AB	PERRIGO UK FINCO	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	A208111	001	Feb 18, 2021	Feb	NEWA	
	<u>AZITHROMYCIN</u>							
	FOR SUSPENSION;ORAL							
	AZITHROMYCIN							
>D>	@ TARO	EQ 200MG BASE/5ML	A211521	001	Dec 11, 2019	Feb	CMFD	
>A> AB		EQ 200MG BASE/5ML	A211521	001	Dec 11, 2019	Feb	CMFD	
	INJECTABLE;INJECTION							
	AZITHROMYCIN							
>D> AP	MYLAN ASI	EQ 500MG BASE/VIAL	A065506	001	Mar 24, 2009	Feb	DISC	
>A>	@	EQ 500MG BASE/VIAL	A065506	001	Mar 24, 2009	Feb	DISC	
	TABLET;ORAL							
	AZITHROMYCIN							
>D>	@ YUNG SHIN PHARM	EQ 600MG BASE	A211068	001	May 08, 2020	Feb	CMFD	
>A> AB		EQ 600MG BASE	A211068	001	May 08, 2020	Feb	CMFD	
	<u>BACLOFEN</u>							
	INJECTABLE;INTRATHECAL							
	BACLOFEN							
AP	MAIA PHARMS INC	0.05MG/ML	A210777	001	Jan 15, 2021	Jan	NEWA	
	TABLET;ORAL							
	BACLOFEN							
>A> AB	KARTHA	5MG	A214374	001	Mar 05, 2021	Feb	NEWA	
>A> AB		10MG	A214374	002	Mar 05, 2021	Feb	NEWA	
>A> AB		20MG	A214374	003	Mar 05, 2021	Feb	NEWA	
	<u>BENAZEPRIL HYDROCHLORIDE</u>							
	TABLET;ORAL							
	LOTENSIN							
>D> AB	+ US PHARMS HOLDINGS I	5MG	N019851	001	Jun 25, 1991	Feb	CAHN	
>D> AB	+	10MG	N019851	002	Jun 25, 1991	Feb	CAHN	
>D> AB	+	20MG	N019851	003	Jun 25, 1991	Feb	CAHN	
>D> AB	+!	40MG	N019851	004	Jun 25, 1991	Feb	CAHN	
>A> AB	+ VALIDUS PHARMS	5MG	N019851	001	Jun 25, 1991	Feb	CAHN	
>A> AB	+	10MG	N019851	002	Jun 25, 1991	Feb	CAHN	
>A> AB	+	20MG	N019851	003	Jun 25, 1991	Feb	CAHN	
>A> AB	+!	40MG	N019851	004	Jun 25, 1991	Feb	CAHN	
	<u>BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE</u>							
	TABLET;ORAL							
	LOTENSIN HCT							
>D>	+ @ US PHARMS HOLDINGS I	5MG;6.25MG	N020033	001	May 19, 1992	Feb	CAHN	
>D> AB	+	10MG;12.5MG	N020033	002	May 19, 1992	Feb	CAHN	
>D> AB	+	20MG;12.5MG	N020033	004	May 19, 1992	Feb	CAHN	
>D> AB	+!	20MG;25MG	N020033	003	May 19, 1992	Feb	CAHN	
>A>	+ @ VALIDUS PHARMS	5MG;6.25MG	N020033	001	May 19, 1992	Feb	CAHN	
>A> AB	+	10MG;12.5MG	N020033	002	May 19, 1992	Feb	CAHN	
>A> AB	+	20MG;12.5MG	N020033	004	May 19, 1992	Feb	CAHN	
>A> AB	+!	20MG;25MG	N020033	003	May 19, 1992	Feb	CAHN	



BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB	!	PERRIGO ISRAEL	5%;1.2%	A090979	001	Jun 26, 2012	Jan	CHRS
		DUAC						
AB	+	STIEFEL	5%;1.2%	N050741	001	Aug 26, 2002	Jan	CHRS

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

>D>	AB		TARO	EQ 0.05% BASE;1%	A076493	001	Jul 28, 2004	Feb	CHRS
>A>	AB	!		EQ 0.05% BASE;1%	A076493	001	Jul 28, 2004	Feb	CHRS
>D>			LOTRISONE						
>D>	AB	+	! MERCK SHARP DOHME	EQ 0.05% BASE;1%	N020010	001	Dec 08, 2000	Feb	DISC
>A>			+ @	EQ 0.05% BASE;1%	N020010	001	Dec 08, 2000	Feb	DISC

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

	@	WOCKHARDT	5MG	A040532	001	Sep 29, 2003	Jan	DISC
	@		50MG	A040518	001	Sep 29, 2003	Jan	DISC

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

AB		TEVA PHARMS USA	75MG	A209931	001	Jan 14, 2021	Jan	NEWA
----	--	-----------------	------	---------	-----	--------------	-----	------

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

>A>		@	AKORN	0.03%	A203299	001	Nov 08, 2018	Feb	CAHN
AT	!		ALEMBIC PHARMS LTD	0.03%	A210263	001	Apr 12, 2019	Jan	CHRS
>D>		@	HI-TECH PHARMA CO	0.03%	A203299	001	Nov 08, 2018	Feb	CAHN
AT			LUPIN LTD	0.03%	A203991	001	Feb 20, 2015	Jan	CHRS

BOSENTAN

TABLET;ORAL

TRACLEER

>A>	AB	+	ACTELION	62.5MG	N021290	001	Nov 20, 2001	Feb	CAHN
>A>	AB	+	!	125MG	N021290	002	Nov 20, 2001	Feb	CAHN
>D>	AB	+	ACTELION PHARMS LTD	62.5MG	N021290	001	Nov 20, 2001	Feb	CAHN
>D>	AB	+	!	125MG	N021290	002	Nov 20, 2001	Feb	CAHN

TABLET, FOR SUSPENSION;ORAL

TRACLEER

>A>		+	!	ACTELION	32MG	N209279	001	Sep 05, 2017	Feb	CAHN	
>D>			+	!	ACTELION PHARMS	32MG	N209279	001	Sep 05, 2017	Feb	CAHN

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

PARLODEL

>D>	AB	+	US PHARMS HOLDINGS I	EQ 5MG BASE	N017962	002	Mar 01, 1982	Feb	CAHN
>A>	AB	+	VALIDUS PHARMS	EQ 5MG BASE	N017962	002	Mar 01, 1982	Feb	CAHN

TABLET;ORAL

PARLODEL

>D>	AB	+	US PHARMS HOLDINGS I	EQ 2.5MG BASE	N017962	001		Feb	CAHN
>A>	AB	+	VALIDUS PHARMS	EQ 2.5MG BASE	N017962	001		Feb	CAHN

BUDESONIDE

CAPSULE;ORAL

BUDESONIDE

	@	BARR LABS DIV TEVA	3MG	A090379	001	Apr 02, 2014	Jan	DISC
--	---	--------------------	-----	---------	-----	--------------	-----	------

BUPIVACAINE

SOLUTION, EXTENDED RELEASE;INFILTRATION

POSIMIR

>A>		+	!	DURECT	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	Feb	NEWA
-----	--	---	---	--------	----------------------	---------	-----	--------------	-----	------

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

>A>	AP	HIKMA PHARMS	0.25%	A205141	001	Feb 11, 2021	Feb NEWA
>A>	AP		0.5%	A205141	002	Feb 11, 2021	Feb NEWA
		BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE					
>A>	AP	HIKMA PHARMS	0.25%	A204842	001	Feb 11, 2021	Feb NEWA
>A>	AP		0.5%	A204842	002	Feb 11, 2021	Feb NEWA
>A>	AP		0.75%	A204842	003	Feb 11, 2021	Feb NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

@ MAYNE PHARMA INC

EQ 2MG BASE; EQ 0.5MG BASE

A206953 001 Jul 17, 2020 Jan DISC

@

EQ 8MG BASE; EQ 2MG BASE

A206953 002 Jul 17, 2020 Jan DISC

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

APLENZIN

>A>	+	BAUSCH	174MG	N022108	001	Apr 23, 2008	Feb CAHN
>A>	+		348MG	N022108	002	Apr 23, 2008	Feb CAHN
>A>	+		522MG	N022108	003	Apr 23, 2008	Feb CAHN
>D>	+	VALEANT PHARMS NORTH	174MG	N022108	001	Apr 23, 2008	Feb CAHN
>D>	+		348MG	N022108	002	Apr 23, 2008	Feb CAHN
>D>	+		522MG	N022108	003	Apr 23, 2008	Feb CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

@ TORRENT

100MG

A203969 001 Oct 31, 2014 Jan DISC

@

150MG

A203969 002 Oct 31, 2014 Jan DISC

@

200MG

A203969 003 Oct 31, 2014 Jan DISC

WELLBUTRIN XL

>A>	AB3	+	BAUSCH	150MG	N021515	001	Aug 28, 2003	Feb CAHN
>A>	AB3	+		300MG	N021515	002	Aug 28, 2003	Feb CAHN
>D>	AB3	+	VALEANT INTL	150MG	N021515	001	Aug 28, 2003	Feb CAHN
>D>	AB3	+		300MG	N021515	002	Aug 28, 2003	Feb CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

@ RUBICON

5MG

A075521 001 Apr 05, 2002 Feb CMFD

>A>	AB			5MG	A075521	001	Apr 05, 2002	Feb CMFD
>D>		@		10MG	A075521	002	Apr 05, 2002	Feb CMFD
>A>	AB			10MG	A075521	002	Apr 05, 2002	Feb CMFD
>D>		@		15MG	A075521	003	Apr 05, 2002	Feb CMFD
>A>	AB			15MG	A075521	003	Apr 05, 2002	Feb CMFD

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

>A>	AP	AM REGENT	6MG/ML	A202259	001	Dec 22, 2015	Feb CAHN
>D>	AP	LUITPOLD	6MG/ML	A202259	001	Dec 22, 2015	Feb CAHN

CABERGOLINE

TABLET; ORAL

DOSTINEX

+ @ PFIZER

0.5MG

N020664 001 Dec 23, 1996 Jan CAHN

CABOTEGRAVIR SODIUM

TABLET; ORAL

VOCABRIA

+! VIIV HLTHCARE

EQ 30MG BASE

N212887 001 Jan 21, 2021 Jan NEWA

CABOTEGRAVIR; RILPIVIRINE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

CABENUVA KIT

+! VIIV HLTHCARE

400MG/2ML (200MG/ML); 600MG/2ML

N212888 001 Jan 21, 2021 Jan NEWA

+!

600MG/3ML (200MG/ML); 900MG/3ML

N212888 002 Jan 21, 2021 Jan NEWA

(300MG/ML)

>A> CASIMERSEN  
 >A> SOLUTION;INTRAVENOUS  
 >A> AMONDYS 45  
 >A> +! SAREPTA THERAPS INC 100MG/2ML (50MG/ML) N213026 001 Feb 25, 2021 Feb NEWA

CEFDINIR

CAPSULE;ORAL  
 CEFDINIR  
 >A> AB ALKEM LABS LTD 300MG A210220 001 Feb 19, 2021 Feb NEWA  
 FOR SUSPENSION;ORAL  
 CEFDINIR  
 >A> AB ALKEM LABS LTD 125MG/5ML A210534 001 Feb 19, 2021 Feb NEWA  
 >A> AB 250MG/5ML A210534 002 Feb 19, 2021 Feb NEWA

CEFIXIME

FOR SUSPENSION;ORAL  
 CEFIXIME  
 >A> AB ALKEM LABS LTD 100MG/5ML A211775 001 Feb 19, 2021 Feb NEWA  
 >A> AB 200MG/5ML A211775 002 Feb 19, 2021 Feb NEWA

CEFOTAXIME SODIUM

INJECTABLE;INJECTION  
 CLAFORAN  
 >D> + @ US PHARM HOLDINGS EQ 500MG BASE/VIAL N050547 001 Feb CAHN  
 >D> + @ EQ 1GM BASE/VIAL N050547 002 Feb CAHN  
 >D> + @ EQ 2GM BASE/VIAL N050547 003 Feb CAHN  
 >D> + @ EQ 10GM BASE/VIAL N050547 004 Dec 29, 1983 Feb CAHN  
 >A> + @ VALIDUS PHARMS EQ 500MG BASE/VIAL N050547 001 Feb CAHN  
 >A> + @ EQ 1GM BASE/VIAL N050547 002 Feb CAHN  
 >A> + @ EQ 2GM BASE/VIAL N050547 003 Feb CAHN  
 >A> + @ EQ 10GM BASE/VIAL N050547 004 Dec 29, 1983 Feb CAHN  
 CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER  
 >D> @ US PHARM HOLDINGS EQ 20MG BASE/ML N050596 002 May 20, 1985 Feb CAHN  
 >D> @ EQ 40MG BASE/ML N050596 004 May 20, 1985 Feb CAHN  
 >A> @ VALIDUS PHARMS EQ 20MG BASE/ML N050596 002 May 20, 1985 Feb CAHN  
 >A> @ EQ 40MG BASE/ML N050596 004 May 20, 1985 Feb CAHN  
 CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER  
 >D> @ US PHARM HOLDINGS EQ 20MG BASE/ML N050596 001 May 20, 1985 Feb CAHN  
 >D> @ EQ 40MG BASE/ML N050596 003 May 20, 1985 Feb CAHN  
 >A> @ VALIDUS PHARMS EQ 20MG BASE/ML N050596 001 May 20, 1985 Feb CAHN  
 >A> @ EQ 40MG BASE/ML N050596 003 May 20, 1985 Feb CAHN

CEFTAZIDIME SODIUM

INJECTABLE;INJECTION  
 FORTAZ IN PLASTIC CONTAINER  
 >D> @ TELIGENT EQ 10MG BASE/ML N050634 001 Apr 28, 1989 Feb CAHN  
 >A> @ EQ 10MG BASE/ML N050634 001 Apr 28, 1989 Feb CAHN  
 >D> + @ EQ 20MG BASE/ML N050634 002 Apr 28, 1989 Feb CAHN  
 >A> + @ EQ 20MG BASE/ML N050634 002 Apr 28, 1989 Feb CAHN  
 >D> + @ EQ 40MG BASE/ML N050634 003 Apr 28, 1989 Feb CAHN  
 >A> + @ EQ 40MG BASE/ML N050634 003 Apr 28, 1989 Feb CAHN

CEFUROXIME SODIUM

INJECTABLE;INJECTION  
 ZINACEF  
 >D> AP +! TELIGENT EQ 1.5GM BASE/VIAL N050558 003 Oct 19, 1983 Feb CAHN  
 >A> AP +! EQ 1.5GM BASE/VIAL N050558 003 Oct 19, 1983 Feb CAHN  
 >D> AP +! EQ 7.5GM BASE/VIAL N050558 004 Oct 23, 1986 Feb CAHN  
 >A> AP +! EQ 7.5GM BASE/VIAL N050558 004 Oct 23, 1986 Feb CAHN  
 INJECTABLE;INTRAMUSCULAR, INTRAVENOUS  
 ZINACEF  
 >D> AB +! TELIGENT EQ 750MG BASE/VIAL N050558 002 Oct 19, 1983 Feb CAHN  
 >A> AB +! EQ 750MG BASE/VIAL N050558 002 Oct 19, 1983 Feb CAHN

CELECOXIB

CAPSULE;ORAL  
 CELECOXIB  
 AB UNICHEM 50MG A213301 001 Jan 12, 2021 Jan NEWA  
 AB 100MG A213301 002 Jan 12, 2021 Jan NEWA  
 AB 200MG A213301 003 Jan 12, 2021 Jan NEWA  
 AB 400MG A213301 004 Jan 12, 2021 Jan NEWA

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL  
CHLORHEXIDINE GLUCONATE

>D>	@ BAJAJ	0.12%	A 075561	001	Nov 14, 2000	Feb	CMFD
>A>	AT	0.12%	A 075561	001	Nov 14, 2000	Feb	CMFD

CHLORPROMAZINE HYDROCHLORIDE

TABLET;ORAL  
CHLORPROMAZINE HYDROCHLORIDE

AB	LANNETT CO INC	10MG	A 212996	001	Jan 22, 2021	Jan	NEWA
AB		25MG	A 212996	002	Jan 22, 2021	Jan	NEWA
AB		50MG	A 212996	003	Jan 22, 2021	Jan	NEWA
AB		100MG	A 212996	004	Jan 22, 2021	Jan	NEWA
AB		200MG	A 212996	005	Jan 22, 2021	Jan	NEWA

CHLORPROPAMIDE

TABLET;ORAL  
CHLORPROPAMIDE

@	RISING	100MG	A 088725	001	Aug 31, 1984	Jan	CAHN
@		250MG	A 088726	001	Aug 31, 1984	Jan	CAHN

CHOLESTYRAMINE

POWDER;ORAL  
CHOLESTYRAMINE

>A>	AB	TAGI	EQ 4GM RESIN/PACKET	A 209597	001	Mar 09, 2021	Feb	NEWA
>A>	AB		EQ 4GM RESIN/SCOOPFUL	A 209597	002	Mar 09, 2021	Feb	NEWA

CILOSTAZOL

TABLET;ORAL  
CILOSTAZOL

@	EPIC PHARMA LLC	50MG	A 077022	002	Mar 11, 2005	Jan	CMS1
AB	NOSTRUM LABS INC	50MG	A 077708	001	Sep 28, 2009	Jan	CAHN
AB		100MG	A 077708	002	Sep 28, 2009	Jan	CAHN

CIMETIDINE

TABLET;ORAL  
CIMETIDINE

>D>	@	DAVA PHARMS INC	300MG	A 074340	001	Jun 23, 1995	Feb	CAHN
>D>	@		400MG	A 074340	002	Jun 23, 1995	Feb	CAHN
>D>	@		800MG	A 074339	001	Jun 23, 1995	Feb	CAHN
>A>	@	NOVITIUM PHARMA	300MG	A 074340	001	Jun 23, 1995	Feb	CAHN
>A>	@		400MG	A 074340	002	Jun 23, 1995	Feb	CAHN
>A>	@		800MG	A 074339	001	Jun 23, 1995	Feb	CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION  
CISATRACURIUM BESYLATE

>D>	AP	ZYDUS PHARMS	EQ 2MG BASE/ML	A 213527	001	Aug 31, 2020	Feb	DISC
>A>	@		EQ 2MG BASE/ML	A 213527	001	Aug 31, 2020	Feb	DISC

CLARITHROMYCIN

TABLET;ORAL  
CLARITHROMYCIN

@	WOCKHARDT	250MG	A 065266	001	May 31, 2006	Jan	DISC
@		500MG	A 065266	002	May 31, 2006	Jan	DISC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL  
CLEOCIN HYDROCHLORIDE

>A>	AB	+	PFIZER	EQ 75MG BASE	N 050162	001	Feb	CAHN	
>A>	AB	+		EQ 150MG BASE	N 050162	002	Feb	CAHN	
>A>	AB	+	!	EQ 300MG BASE	N 050162	003	Apr 14, 1988	Feb	CAHN
>D>	AB	+	PHARMACIA AND UPJOHN	EQ 75MG BASE	N 050162	001	Feb	CAHN	
>D>	AB	+		EQ 150MG BASE	N 050162	002	Feb	CAHN	
>D>	AB	+	!	EQ 300MG BASE	N 050162	003	Apr 14, 1988	Feb	CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLEOCIN

>A>	AA	!	PFIZER	EQ 75MG BASE/5ML	A062644	001	Apr 07, 1986	Feb	CAHN
>D>	AA	!	PHARMACIA AND UPJOHN	EQ 75MG BASE/5ML	A062644	001	Apr 07, 1986	Feb	CAHN

CLINDAMYCIN PHOSPHATE

CREAM;VAGINAL

CLEOCIN

>A>		@	PFIZER	EQ 2% BASE	N050680	001	Aug 11, 1992	Feb	CAHN
>A>	AB	+	!	EQ 2% BASE	N050680	002	Mar 02, 1998	Feb	CAHN
>D>		@	PHARMACIA AND UPJOHN	EQ 2% BASE	N050680	001	Aug 11, 1992	Feb	CAHN
>D>	AB	+	!	EQ 2% BASE	N050680	002	Mar 02, 1998	Feb	CAHN

GEL;TOPICAL

CLEOCIN T

>A>	AB	+	!	PFIZER	EQ 1% BASE	N050615	001	Jan 07, 1987	Feb	CAHN
>D>	AB	+	!	PHARMACIA AND UPJOHN	EQ 1% BASE	N050615	001	Jan 07, 1987	Feb	CAHN

CLINDAMYCIN PHOSPHATE

	AB			GLENMARK PHARMS LTD	EQ 1% BASE	A214251	001	Feb 10, 2021	Jan	NEWA
	AB			PERRIGO UK FINCO	EQ 1% BASE	A212104	001	Dec 31, 2020	Jan	CAHN

INJECTABLE;INJECTION

CLEOCIN PHOSPHATE

>A>	AP			PFIZER	EQ 150MG BASE/ML	A062803	001	Oct 16, 1987	Feb	CAHN
>A>	AP	+	!		EQ 150MG BASE/ML	N050441	001		Feb	CAHN
>D>	AP			PHARMACIA AND UPJOHN	EQ 150MG BASE/ML	A062803	001	Oct 16, 1987	Feb	CAHN
>D>	AP	+	!		EQ 150MG BASE/ML	N050441	001		Feb	CAHN

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

>A>		+	@	PFIZER	EQ 6MG BASE/ML	N050639	001	Aug 30, 1989	Feb	CAHN
>A>		+	@		EQ 12MG BASE/ML	N050639	002	Aug 30, 1989	Feb	CAHN
>A>		+	@		EQ 18MG BASE/ML	N050639	003	Apr 10, 1991	Feb	CAHN
>D>		+	@	PHARMACIA AND UPJOHN	EQ 6MG BASE/ML	N050639	001	Aug 30, 1989	Feb	CAHN
>D>		+	@		EQ 12MG BASE/ML	N050639	002	Aug 30, 1989	Feb	CAHN
>D>		+	@		EQ 18MG BASE/ML	N050639	003	Apr 10, 1991	Feb	CAHN

CLINDAMYCIN PHOSPHATE

		@		MYLAN LABS LTD	EQ 150MG BASE/ML	A204748	001	Oct 10, 2017	Jan	DISC
--	--	---	--	----------------	------------------	---------	-----	--------------	-----	------

LOTION;TOPICAL

CLEOCIN T

>A>	AB	+	!	PFIZER	EQ 1% BASE	N050600	001	May 31, 1989	Feb	CAHN
>D>	AB	+	!	PHARMACIA AND UPJOHN	EQ 1% BASE	N050600	001	May 31, 1989	Feb	CAHN

CLINDAMYCIN PHOSPHATE

>A>	AB			GAGE DEVELOPMENT	EQ 1% BASE	A214604	001	Mar 08, 2021	Feb	NEWA
-----	----	--	--	------------------	------------	---------	-----	--------------	-----	------

SOLUTION;TOPICAL

CLEOCIN T

>A>		+	@	PFIZER	EQ 1% BASE	N050537	001		Feb	CAHN
>D>		+	@	PHARMACIA AND UPJOHN	EQ 1% BASE	N050537	001		Feb	CAHN
		+	@		EQ 1% BASE	N050537	001		Jan	DISC

CLINDAMYCIN PHOSPHATE

	AT	!		PERRIGO NEW YORK	EQ 1% BASE	A064050	001	Nov 30, 1995	Jan	CHRS
--	----	---	--	------------------	------------	---------	-----	--------------	-----	------

SUPPOSITORY;VAGINAL

CLEOCIN

>A>		+	!	PFIZER	100MG	N050767	001	Aug 13, 1999	Feb	CAHN
>D>		+	!	PHARMACIA AND UPJOHN	100MG	N050767	001	Aug 13, 1999	Feb	CAHN

SWAB;TOPICAL

CLEOCIN

>A>	AT	+	!	PFIZER	EQ 1% BASE	N050537	002	Feb 22, 1994	Feb	CAHN
>D>	AT	+	!	PHARMACIA AND UPJOHN	EQ 1% BASE	N050537	002	Feb 22, 1994	Feb	CAHN

CLOBETASOL PROPIONATE

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

		@		TORRENT	0.05%	A212926	001	Oct 25, 2019	Jan	DISC
--	--	---	--	---------	-------	---------	-----	--------------	-----	------

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

	AT			PRINSTON INC	0.05%	A213139	001	Feb 08, 2021	Jan	NEWA
--	----	--	--	--------------	-------	---------	-----	--------------	-----	------

CLOFARABINE

SOLUTION; INTRAVENOUS  
CLOFARABINE

AP	MEITHEAL	20MG/20ML (1MG/ML)	A213461	001	Oct 23, 2020	Jan	CAHN
----	----------	--------------------	---------	-----	--------------	-----	------

CLONIDINE

SYSTEM; TRANSDERMAL  
CATAPRES-TTS-1

AB	+	LAVIPHARM	0.1MG/24HR	N018891	001	Oct 10, 1984	Jan	CAHN
AB	+	TECHNOMED	0.1MG/24HR	N018891	001	Oct 10, 1984	Jan	CAHN
CATAPRES-TTS-2								
AB	+	LAVIPHARM	0.2MG/24HR	N018891	002	Oct 10, 1984	Jan	CAHN
AB	+	TECHNOMED	0.2MG/24HR	N018891	002	Oct 10, 1984	Jan	CAHN
CATAPRES-TTS-3								
AB	+	LAVIPHARM	0.3MG/24HR	N018891	003	Oct 10, 1984	Jan	CAHN
AB	+	TECHNOMED	0.3MG/24HR	N018891	003	Oct 10, 1984	Jan	CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL  
CLOPIDOGREL BISULFATE

>D>	@	POLYGEN PHARMS	EQ 75MG BASE	A213351	001	Jul 17, 2020	Feb	CMFD
>A>	AB		EQ 75MG BASE	A213351	001	Jul 17, 2020	Feb	CMFD
>D>	@		EQ 300MG BASE	A213351	002	Jul 17, 2020	Feb	CMFD
>A>	AB		EQ 300MG BASE	A213351	002	Jul 17, 2020	Feb	CMFD

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL  
CLORAZEPATE DIPOTASSIUM

AB		AUROLIFE PHARMA LLC	3.75MG	A071858	002	Jul 17, 1987	Jan	CAHN
AB			7.5MG	A071858	003	Jul 17, 1987	Jan	CAHN
AB	!		15MG	A071858	001	Jul 17, 1987	Jan	CAHN

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL  
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

>A>	AA	AKORN	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A040674	001	Dec 23, 2014	Feb	CAHN
>D>	AA	HI-TECH PHARMA CO	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A040674	001	Dec 23, 2014	Feb	CAHN

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION; ORAL  
COLESEVELAM HYDROCHLORIDE

>D>	AB	GLENMARK PHARMS LTD	1.875GM/PACKET	A202190	001	Jul 16, 2018	Feb	CTEC
>A>			1.875GM/PACKET	A202190	001	Jul 16, 2018	Feb	CTEC
>D>	AB	WATSON LABS INC	1.875GM/PACKET	A202178	001	Sep 01, 2020	Feb	DISC
>A>		@	1.875GM/PACKET	A202178	001	Sep 01, 2020	Feb	DISC
>D>	AB		3.75GM/PACKET	A202178	002	Sep 01, 2020	Feb	DISC
>A>		@	3.75GM/PACKET	A202178	002	Sep 01, 2020	Feb	DISC

TABLET; ORAL  
COLESEVELAM HYDROCHLORIDE

>D>	AB	WATSON LABS INC	625MG	A200830	001	Sep 02, 2020	Feb	DISC
>A>		@	625MG	A200830	001	Sep 02, 2020	Feb	DISC

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL  
COLESTID

>A>	AB	+	PFIZER	5GM/SCOOPFUL	N017563	003	Sep 22, 1995	Feb	CAHN
>A>	AB	+	!	5GM/PACKET	N017563	004	Sep 22, 1995	Feb	CAHN
>D>	AB	+	PHARMACIA UPJOHN	5GM/SCOOPFUL	N017563	003	Sep 22, 1995	Feb	CAHN
>D>	AB	+	!	5GM/PACKET	N017563	004	Sep 22, 1995	Feb	CAHN
FLAVORED COLESTID									
>A>		+	PFIZER	5GM/PACKET	N017563	001		Feb	CAHN
>A>		+		5GM/SCOOPFUL	N017563	002		Feb	CAHN
>D>		+	PHARMACIA UPJOHN	5GM/PACKET	N017563	001		Feb	CAHN
>D>		+		5GM/SCOOPFUL	N017563	002		Feb	CAHN

TABLET; ORAL  
COLESTID

>A>	AB	+	PFIZER	1GM	N020222	001	Jul 19, 1994	Feb	CAHN
>D>	AB	+	PHARMACIA UPJOHN	1GM	N020222	001	Jul 19, 1994	Feb	CAHN

CROTAMITON

	CREAM; TOPICAL						
	EURAX						
	+ @ JOURNEY	10%		N006927	001		Jan CAHN
	LOTION; TOPICAL						
	EURAX						
AT	+! JOURNEY	10%		N009112	003		Jan CAHN

CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE

SOLUTION; INTRAVENOUS  
TRALEMENT

+!	AM REGENT	(1ML) EQ 0.3MG COPPER/ML; EQ 55MCG BASE/ML; EQ 60MCG BASE/ML; EQ 3MG BASE/ML		N209376	001	Jul 02, 2020	Jan CPOT
+!		(5ML) EQ 0.3MG COPPER/ML; EQ 55MCG BASE/ML; EQ 60MCG BASE/ML; EQ 3MG BASE/ML		N209376	002	Dec 02, 2020	Jan NEWA

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL  
CYPROHEPTADINE HYDROCHLORIDE

>A>	AA	QUAGEN	4MG		A212491	001	Feb 24, 2021	Feb NEWA
-----	----	--------	-----	--	---------	-----	--------------	----------

DACTINOMYCIN

INJECTABLE; INJECTION  
DACTINOMYCIN

AP	AUROMEDICS PHARMA	0.5MG/VIAL		A203385	001	Nov 09, 2017	Jan CAHN
>D>	AP	HONG KONG	0.5MG/VIAL	A213463	001	Nov 13, 2020	Feb CAHN
>A>	AP	MEITHEAL	0.5MG/VIAL	A213463	001	Nov 13, 2020	Feb CAHN

DEFERASIROX

GRANULE; ORAL  
DEFERASIROX

AB	AMNEAL	180MG		A214194	001	Feb 09, 2021	Jan NEWA
AB		360MG		A214194	002	Feb 09, 2021	Jan NEWA
>A>	AB	AUCTA	90MG	A214559	001	Mar 09, 2021	Feb NEWA
>A>	AB		180MG	A214559	002	Mar 09, 2021	Feb NEWA
>A>	AB		360MG	A214559	003	Mar 09, 2021	Feb NEWA

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL  
NORPRAMIN

>D>	AB	+ US PHARM HOLDINGS	10MG		N014399	007	Feb 11, 1982	Feb CAHN
>D>	AB		25MG		N014399	001		Feb CAHN
>D>	AB		50MG		N014399	003		Feb CAHN
>D>	AB		75MG		N014399	004		Feb CAHN
>D>	AB	+!	100MG		N014399	005		Feb CAHN
>D>	AB		150MG		N014399	006		Feb CAHN
>A>	AB	+ VALIDUS PHARMS	10MG		N014399	007	Feb 11, 1982	Feb CAHN
>A>	AB		25MG		N014399	001		Feb CAHN
>A>	AB		50MG		N014399	003		Feb CAHN
>A>	AB		75MG		N014399	004		Feb CAHN
>A>	AB	+!	100MG		N014399	005		Feb CAHN
>A>	AB		150MG		N014399	006		Feb CAHN

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL  
NOCTIVA

>D>		+ @ ALYVANT	0.00083MG/SPRAY		N201656	001	Mar 03, 2017	Feb CAHN
>D>		+ @	0.00166MG/SPRAY		N201656	002	Mar 03, 2017	Feb CAHN
>A>		+ @ ROIVANT	0.00083MG/SPRAY		N201656	001	Mar 03, 2017	Feb CAHN
>A>		+ @	0.00166MG/SPRAY		N201656	002	Mar 03, 2017	Feb CAHN

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION  
DEXRAZOXANE HYDROCHLORIDE

AP	AUROMEDICS PHARMA	EQ 250MG BASE/VIAL		A200752	001	Oct 19, 2011	Jan CAHN
AP		EQ 500MG BASE/VIAL		A200752	002	Oct 19, 2011	Jan CAHN

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

		POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
>A>	AP	FRESENIUS KABI USA 5GM/100ML;74.5MG/100ML;450MG/100ML	A213523	001	Mar 09, 2021	Feb	NEWA	
		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
>A>	AP	FRESENIUS KABI USA 5GM/100ML;149MG/100ML;450MG/100ML	A213523	002	Mar 09, 2021	Feb	NEWA	
		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%						
>A>	AP	FRESENIUS KABI USA 5GM/100ML;149MG/100ML;900MG/100ML	A213445	001	Mar 09, 2021	Feb	NFTG	
		POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
>A>	AP	FRESENIUS KABI USA 5GM/100ML;224MG/100ML;450MG/100ML	A213523	003	Mar 09, 2021	Feb	NEWA	
		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%						
>A>	AP	FRESENIUS KABI USA 5GM/100ML;298MG/100ML;450MG/100ML	A213523	004	Mar 09, 2021	Feb	NEWA	
		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%						
>A>	AP	FRESENIUS KABI USA 5GM/100ML;298MG/100ML;900MG/100ML	A213445	002	Mar 09, 2021	Feb	NFTG	

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

>D>	AP	FRESENIUS KABI USA 5GM/100ML;300MG/100ML	A211194	001	Aug 26, 2020	Feb	DISC	
>A>		@ 5GM/100ML;300MG/100ML	A211194	001	Aug 26, 2020	Feb	DISC	
>D>	AP	+! ICU MEDICAL INC 5GM/100ML;300MG/100ML	N017799	001		Feb	CTEC	
>A>		+! 5GM/100ML;300MG/100ML	N017799	001		Feb	CTEC	

DICLOFENAC SODIUM

SOLUTION; TOPICAL

DICLOFENAC SODIUM

AT		AKORN 1.5%	A206655	001	Jan 28, 2021	Jan	NEWA	
		TABLET, DELAYED RELEASE; ORAL						
		DICLOFENAC SODIUM						
>A>		@ MICRO LABS 50MG	A074986	001	Feb 26, 1999	Feb	CAHN	
>A>		@ 75MG	A074986	002	Feb 26, 1999	Feb	CAHN	
>D>		@ MICRO LABS USA 50MG	A074986	001	Feb 26, 1999	Feb	CAHN	
>D>		@ 75MG	A074986	002	Feb 26, 1999	Feb	CAHN	

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DICLOXACILLIN SODIUM

		@ SANDOZ EQ 125MG BASE	A061454	002		Jan	DISC	
		@ EQ 250MG BASE	A061454	001		Jan	DISC	
		@ EQ 500MG BASE	A061454	003		Jan	DISC	
		TEVA EQ 250MG BASE	A062286	001	Jun 03, 1982	Jan	CTEC	
		! EQ 500MG BASE	A062286	002	Jun 03, 1982	Jan	CTEC	
AB		! EQ 500MG BASE	A062286	002	Jun 03, 1982	Jan	CHRS	

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

DIDANOSINE

		@ AUROBINDO PHARMA 125MG	A090094	001	Sep 24, 2008	Jan	DISC	
		@ 200MG	A090094	002	Sep 24, 2008	Jan	DISC	
		@ 250MG	A090094	003	Sep 24, 2008	Jan	DISC	
		@ 400MG	A090094	004	Sep 24, 2008	Jan	DISC	

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

DIHYDROERGOTAMINE MESYLATE

AP		PROVEPHARM SAS 1MG/ML	A212046	001	Jan 07, 2020	Jan	CAHN	
----	--	-----------------------	---------	-----	--------------	-----	------	--

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

		@ INTL MEDICATION 5MG/ML	A075749	001	Nov 21, 2001	Jan	DISC	
--	--	--------------------------	---------	-----	--------------	-----	------	--

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL

DIMETHYL FUMARATE

>D>	AB	ZYDUS PHARMS 120MG	A210538	001	Sep 24, 2020	Feb	DISC	
>A>		@ 120MG	A210538	001	Sep 24, 2020	Feb	DISC	
>D>	AB	240MG	A210538	002	Sep 24, 2020	Feb	DISC	
>A>		@ 240MG	A210538	002	Sep 24, 2020	Feb	DISC	



DINOPROSTONE

GEL; ENDOCERVICAL  
PREPIDIL

+! PFIZER 0.5MG/3GM N019617 001 Dec 09, 1992 Jan CAHN

SUPPOSITORY; VAGINAL  
PROSTIN E2

+! PFIZER 20MG N017810 001 Jan CAHN

DIPYRIDAMOLE

TABLET; ORAL  
DIPYRIDAMOLE

AB OXFORD PHARMS 25MG A040542 001 Apr 21, 2006 Jan CMFD

AB 50MG A040542 002 Apr 21, 2006 Jan CMFD

AB 75MG A040542 003 Apr 21, 2006 Jan CMFD

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL  
DISOPYRAMIDE PHOSPHATE

>D> AB MAYNE PHARMA EQ 100MG BASE A070173 001 May 31, 1985 Feb DISC

>A> @ EQ 100MG BASE A070173 001 May 31, 1985 Feb DISC

>D> AB EQ 150MG BASE A070173 002 May 31, 1985 Feb DISC

>A> @ EQ 150MG BASE A070173 002 May 31, 1985 Feb DISC

DOCETAXEL

INJECTABLE; INJECTION  
DOCETAXEL

AP HIKMA 20MG/ML (20MG/ML) A204490 001 Jan 14, 2021 Jan NEWA

AP 80MG/4ML (20MG/ML) A204490 002 Jan 14, 2021 Jan NEWA

AP SHILPA 20MG/ML (20MG/ML) N205934 001 Dec 22, 2015 Jan CAHN

AP 80MG/4ML (20MG/ML) N205934 002 Dec 22, 2015 Jan CAHN

AP 160MG/8ML (20MG/ML) N205934 003 Dec 22, 2015 Jan CAHN

DOFETILIDE

CAPSULE; ORAL  
DOFETILIDE

>D> AB RICONPHARMA LLC 0.125MG A212410 001 Dec 27, 2019 Feb DISC

>A> @ 0.125MG A212410 001 Dec 27, 2019 Feb DISC

>D> AB 0.25MG A212410 002 Dec 27, 2019 Feb DISC

>A> @ 0.25MG A212410 002 Dec 27, 2019 Feb DISC

>D> AB 0.5MG A212410 003 Dec 27, 2019 Feb DISC

>A> @ 0.5MG A212410 003 Dec 27, 2019 Feb DISC

DOLASETRON MESYLATE

INJECTABLE; INJECTION  
ANZEMET

>D> + @ US PHARM HOLDINGS 12.5MG/0.625ML (20MG/ML) N020624 002 Sep 11, 1997 Feb CAHN

>D> + @ 100MG/5ML (20MG/ML) N020624 001 Sep 11, 1997 Feb CAHN

>D> @ 500MG/25ML (20MG/ML) N020624 003 Dec 11, 2001 Feb CAHN

>A> + @ VALIDUS PHARMS 12.5MG/0.625ML (20MG/ML) N020624 002 Sep 11, 1997 Feb CAHN

>A> + @ 100MG/5ML (20MG/ML) N020624 001 Sep 11, 1997 Feb CAHN

>A> @ 500MG/25ML (20MG/ML) N020624 003 Dec 11, 2001 Feb CAHN

TABLET; ORAL  
ANZEMET

>D> + @ US PHARM HOLDINGS 50MG N020623 001 Sep 11, 1997 Feb CAHN

>D> + @ 100MG N020623 002 Sep 11, 1997 Feb CAHN

>A> + @ VALIDUS PHARMS 50MG N020623 001 Sep 11, 1997 Feb CAHN

>A> + @ 100MG N020623 002 Sep 11, 1997 Feb CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC  
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

>D> @ FDC LTD EQ 2% BASE; EQ 0.5% BASE A205295 001 Jun 13, 2019 Feb CMFD

>A> AT EQ 2% BASE; EQ 0.5% BASE A205295 001 Jun 13, 2019 Feb CMFD

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL  
DOXEPIN HYDROCHLORIDE

>A> AB LEADING PHARMA LLC EQ 10MG BASE A211619 001 Mar 09, 2021 Feb NEWA

>A> AB EQ 25MG BASE A211619 002 Mar 09, 2021 Feb NEWA

>A> AB EQ 50MG BASE A211619 003 Mar 09, 2021 Feb NEWA

>A> AB EQ 75MG BASE A211619 004 Mar 09, 2021 Feb NEWA

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

>A>	AB		EQ 100MG BASE	A211619	005	Mar 09, 2021	Feb	NEWA
>A>	AB		EQ 150MG BASE	A211618	001	Mar 01, 2021	Feb	NEWA
>D>	AB	UPSHER SMITH LABS	EQ 10MG BASE	A210268	001	Sep 04, 2020	Feb	DISC
>A>		@	EQ 10MG BASE	A210268	001	Sep 04, 2020	Feb	DISC
>D>	AB		EQ 25MG BASE	A210268	002	Sep 04, 2020	Feb	DISC
>A>		@	EQ 25MG BASE	A210268	002	Sep 04, 2020	Feb	DISC
>D>	AB		EQ 50MG BASE	A210268	003	Sep 04, 2020	Feb	DISC
>A>		@	EQ 50MG BASE	A210268	003	Sep 04, 2020	Feb	DISC
>D>	AB		EQ 75MG BASE	A210268	004	Sep 04, 2020	Feb	DISC
>A>		@	EQ 75MG BASE	A210268	004	Sep 04, 2020	Feb	DISC
>D>	AB		EQ 100MG BASE	A210268	005	Sep 04, 2020	Feb	DISC
>A>		@	EQ 100MG BASE	A210268	005	Sep 04, 2020	Feb	DISC

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

		@ PAR PHARM INC	EQ 3MG BASE	A202510	001	Jul 24, 2020	Jan	DISC
		@	EQ 6MG BASE	A202510	002	Jul 24, 2020	Jan	DISC
AB		RK PHARMA	EQ 3MG BASE	A202337	001	Jan 20, 2016	Jan	CAHN
AB			EQ 6MG BASE	A202337	002	Jan 20, 2016	Jan	CAHN

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

		@ MYLAN	EQ 50MG BASE	A208942	001	Jan 21, 2021	Jan	DISC
AB			EQ 50MG BASE	A208942	001	Jan 21, 2021	Jan	NEWA
		@	EQ 75MG BASE	A208942	002	Jan 21, 2021	Jan	DISC
AB			EQ 75MG BASE	A208942	002	Jan 21, 2021	Jan	NEWA
		@	EQ 100MG BASE	A208942	003	Jan 21, 2021	Jan	DISC
AB			EQ 100MG BASE	A208942	003	Jan 21, 2021	Jan	NEWA

DOXYCYCLINE HYCLATE

TABLET;ORAL

DOXYCYCLINE HYCLATE

>A>	AB	ORYZA	EQ 100MG BASE	A213475	001	Mar 10, 2021	Feb	NEWA
-----	----	-------	---------------	---------	-----	--------------	-----	------

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

>A>	AB	AJANTA PHARMA LTD	100MG	A214391	001	Feb 18, 2021	Feb	NFTG
>A>	AB		200MG	A214391	002	Feb 18, 2021	Feb	NFTG
>A>	AB		300MG	A214391	003	Feb 18, 2021	Feb	NFTG
>A>	AB	ALKEM LABS LTD	100MG	A213911	001	Feb 18, 2021	Feb	NFTG
>A>	AB		200MG	A213911	002	Feb 18, 2021	Feb	NFTG
>A>	AB		300MG	A213911	003	Feb 18, 2021	Feb	NFTG
>A>	AB	ANNORA	300MG	A211726	001	Feb 18, 2021	Feb	NFTG
>A>	AB	AUROBINDO PHARMA LTD	100MG	A214387	001	Feb 18, 2021	Feb	NFTG
>A>	AB		200MG	A214387	002	Feb 18, 2021	Feb	NFTG
>A>	AB		300MG	A214387	003	Feb 18, 2021	Feb	NFTG
>A>	AB	HIKMA	100MG	A212835	001	Feb 18, 2021	Feb	NFTG
>A>	AB		200MG	A212835	002	Feb 18, 2021	Feb	NFTG
>A>	AB		300MG	A212835	003	Feb 18, 2021	Feb	NFTG
>A>	AB	LUPIN PHARMS	100MG	A211652	001	Feb 18, 2021	Feb	NFTG
>A>	AB		200MG	A211652	002	Feb 18, 2021	Feb	NFTG
>A>	AB		300MG	A211652	003	Feb 18, 2021	Feb	NFTG
>A>	AB	MSN PHARMS INC	100MG	A211741	001	Feb 18, 2021	Feb	NFTG
>A>	AB		200MG	A211741	002	Feb 18, 2021	Feb	NFTG
>A>	AB		300MG	A211741	003	Feb 18, 2021	Feb	NFTG
>A>	AB	SCIEGEN PHARMS INC	100MG	A214017	001	Feb 18, 2021	Feb	NFTG
>A>	AB		200MG	A214017	002	Feb 18, 2021	Feb	NFTG
>A>	AB		300MG	A214017	003	Feb 18, 2021	Feb	NFTG
>A>	AB	SUN PHARM	100MG	A214384	001	Feb 18, 2021	Feb	NFTG
>A>	AB		200MG	A214384	002	Feb 18, 2021	Feb	NFTG
>A>	AB		300MG	A214384	003	Feb 18, 2021	Feb	NFTG
>A>	AB	TASMAN PHARMA	100MG	A213661	001	Feb 18, 2021	Feb	NFTG
>A>	AB		200MG	A213661	002	Feb 18, 2021	Feb	NFTG
>A>	AB		300MG	A213661	003	Feb 18, 2021	Feb	NFTG
>A>	AB	TEVA PHARMS USA INC	100MG	A213162	001	Feb 18, 2021	Feb	NFTG
>A>	AB		200MG	A213162	002	Feb 18, 2021	Feb	NFTG
>A>	AB		300MG	A213162	003	Feb 18, 2021	Feb	NFTG
>A>	AB	ZYDUS PHARMS	100MG	A211818	001	Feb 18, 2021	Feb	NFTG
>A>	AB		200MG	A211818	002	Feb 18, 2021	Feb	NFTG
>A>	AB		300MG	A211818	003	Feb 18, 2021	Feb	NFTG

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL  
DULOXETINE HYDROCHLORIDE

>A>	AB	SUNSHINE	EQ 20MG BASE	A212328	001	Feb 11, 2021	Feb NEWA
>A>	AB		EQ 30MG BASE	A212328	002	Feb 11, 2021	Feb NEWA
>A>	AB		EQ 60MG BASE	A212328	003	Feb 11, 2021	Feb NEWA

ECONAZOLE NITRATE

AEROSOL, FOAM;TOPICAL  
ECOZA

>D>	+	GLENMARK	1%	N205175	001	Oct 24, 2013	Feb CAHN
>A>	+	RESILIA PHARMS	1%	N205175	001	Oct 24, 2013	Feb CAHN

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL  
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

>D>	+	AUROBINDO PHARMA LTD	600MG;300MG;300MG	N022343	001	Aug 15, 2018	Feb DISC
>A>	+	@	600MG;300MG;300MG	N022343	001	Aug 15, 2018	Feb DISC

EFINACONAZOLE

SOLUTION;TOPICAL  
EFINACONAZOLE

>D>	AT	@ PERRIGO PHARMA INTL	10%	A211851	001	Dec 16, 2020	Jan DISC	
>A>	AB	TEVA PHARMS USA	10%	A211827	001	Dec 16, 2020	Feb CTEC	
>A>	AB		10%	A211827	001	Dec 16, 2020	Feb CTEC	
>D>	AT	JUBLIA						
>D>	AT	+	BAUSCH	10%	N203567	001	Jun 06, 2014	Feb CTEC
>A>	AB	+		10%	N203567	001	Jun 06, 2014	Feb CTEC

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL  
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

	AB	LAURUS LABS LTD	200MG;300MG	A212114	001	Jul 26, 2019	Jan CMFD
>D>		@ MACLEODS PHARMS LTD	200MG;300MG	A203442	001	May 15, 2020	Feb CMFD
>A>	AB		200MG;300MG	A203442	001	May 15, 2020	Feb CMFD
>D>		@ MYLAN	200MG;300MG	A206436	001	Apr 09, 2018	Feb CMFD
>A>	AB		200MG;300MG	A206436	001	Apr 09, 2018	Feb CMFD
	AB	STRIDES PHARMA	200MG;300MG	A091055	001	Jan 13, 2021	Jan NEWA

EPLERENONE

TABLET;ORAL  
EPLERENONE

>D>	AB	PIRAMAL HLTHCARE UK	25MG	A212765	001	Aug 10, 2020	Feb DISC
>A>		@	25MG	A212765	001	Aug 10, 2020	Feb DISC
>D>	AB		50MG	A212765	002	Aug 10, 2020	Feb DISC
>A>		@	50MG	A212765	002	Aug 10, 2020	Feb DISC

EPOPROSTENOL SODIUM

INJECTABLE;INJECTION  
EPOPROSTENOL SODIUM

>D>	AP	SUN PHARM	EQ 0.5MG BASE/VIAL	A210473	001	Jan 15, 2021	Feb CTEC	
>A>	AP2		EQ 0.5MG BASE/VIAL	A210473	001	Jan 15, 2021	Feb CTEC	
	AP		EQ 0.5MG BASE/VIAL	A210473	001	Jan 15, 2021	Jan NFTG	
>D>	AP		EQ 1.5MG BASE/VIAL	A210473	002	Jan 15, 2021	Feb CTEC	
>A>	AP2		EQ 1.5MG BASE/VIAL	A210473	002	Jan 15, 2021	Feb CTEC	
	AP		EQ 1.5MG BASE/VIAL	A210473	002	Jan 15, 2021	Jan NFTG	
>D>	AP	TEVA PHARMS USA	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Feb CTEC	
>A>	AP1		EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Feb CTEC	
>D>	AP		EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Feb CTEC	
>A>	AP1		EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Feb CTEC	
		FLOLAN						
>D>	AP	+	GLAXOSMITHKLINE LLC	EQ 0.5MG BASE/VIAL	N020444	001	Sep 20, 1995	Feb CTEC
>A>	AP1	+		EQ 0.5MG BASE/VIAL	N020444	001	Sep 20, 1995	Feb CTEC
>D>	AP	+		EQ 1.5MG BASE/VIAL	N020444	002	Sep 20, 1995	Feb CTEC
>A>	AP1	+		EQ 1.5MG BASE/VIAL	N020444	002	Sep 20, 1995	Feb CTEC
		VELETRI						
>A>	AP2	+	ACTELION	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Feb CAHN
>A>	AP2	+		EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008	Feb CAHN
>D>	AP	+	ACTELION PHARMS LTD	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Feb CAHN
>D>	AP	+		EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008	Feb CAHN

ERGOCALCIFEROLCAPSULE;ORAL  
DRISDOL

>D>	AA	+	US PHARM HOLDINGS	50,000 IU	N003444	001		Feb	CAHN
>A>	AA	+	VALIDUS PHARMS	50,000 IU	N003444	001		Feb	CAHN

ERYTHROMYCINTABLET;ORAL  
ERYTHROMYCIN

>A>	AB		TEVA PHARMS USA INC	250MG	A214549	001	Feb 11, 2021	Feb	NEWA
>A>	AB			500MG	A214549	002	Feb 11, 2021	Feb	NEWA

ESOMEPRAZOLE MAGNESIUMCAPSULE, DELAYED REL PELLETS;ORAL  
ESOMEPRAZOLE MAGNESIUM

>A>	AB		INDCHEMIE HEALTH	EQ 20MG BASE	A210559	001	Feb 26, 2021	Feb	NEWA
>A>	AB			EQ 40MG BASE	A210559	002	Feb 26, 2021	Feb	NEWA

ESTRADIOLINSERT, EXTENDED RELEASE;VAGINAL  
ESTRING

		+	PFIZER	0.0075MG/24HR	N020472	001	Apr 26, 1996	Jan	CAHN
--	--	---	--------	---------------	---------	-----	--------------	-----	------

ESTROPIPATETABLET;ORAL  
OGEN .625

		@	PFIZER	0.75MG	A083220	001		Jan	CAHN
--	--	---	--------	--------	---------	-----	--	-----	------

OGEN 1.25

		@	PFIZER	1.5MG	A083220	002		Jan	CAHN
--	--	---	--------	-------	---------	-----	--	-----	------

OGEN 2.5

		@	PFIZER	3MG	A083220	003		Jan	CAHN
--	--	---	--------	-----	---------	-----	--	-----	------

OGEN 5

			PFIZER	6MG	A083220	004		Jan	CAHN
--	--	--	--------	-----	---------	-----	--	-----	------

ESZOPICLONETABLET;ORAL  
ESZOPICLONE

		@	NOSTRUM LABS INC	1MG	A203087	001	May 08, 2019	Jan	CAHN
--	--	---	------------------	-----	---------	-----	--------------	-----	------

		@		2MG	A203087	002	May 08, 2019	Jan	CAHN
--	--	---	--	-----	---------	-----	--------------	-----	------

		@		3MG	A203087	003	May 08, 2019	Jan	CAHN
--	--	---	--	-----	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; ETONOGESTREL

RING;VAGINAL

ETHINYL ESTRADIOL; ETONOGESTREL

AB			TEVA PHARMS USA INC	0.015MG/24HR;0.12MG/24HR	A204305	001	Jan 13, 2021	Jan	NEWA
----	--	--	---------------------	--------------------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

ETHINYL ESTRADIOL AND NORELGESTROMIN

>A>	AB		AMNEAL	0.035MG/24HR;0.15MG/24HR	A213950	001	Feb 25, 2021	Feb	NEWA
-----	----	--	--------	--------------------------	---------	-----	--------------	-----	------

XULANE

>D>		!	MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Feb	CTEC
-----	--	---	--------------------	--------------------------	---------	-----	--------------	-----	------

>A>	AB		!	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Feb	CTEC
-----	----	--	---	--------------------------	---------	-----	--------------	-----	------

EVEROLIMUSTABLET;ORAL  
AFINITOR

>D>		+	NOVARTIS	10MG	N022334	002	Mar 30, 2009	Feb	CTEC
-----	--	---	----------	------	---------	-----	--------------	-----	------

>A>	AB		+	10MG	N022334	002	Mar 30, 2009	Feb	CTEC
-----	----	--	---	------	---------	-----	--------------	-----	------

EVEROLIMUS

>A>		@	BIOCON PHARMA	2.5MG	A214182	001	Feb 11, 2021	Feb	DISC
-----	--	---	---------------	-------	---------	-----	--------------	-----	------

>A>		@		5MG	A214182	002	Feb 11, 2021	Feb	DISC
-----	--	---	--	-----	---------	-----	--------------	-----	------

>A>		@		7.5MG	A214182	003	Feb 11, 2021	Feb	DISC
-----	--	---	--	-------	---------	-----	--------------	-----	------

>A>		@		10MG	A214182	004	Feb 11, 2021	Feb	DISC
-----	--	---	--	------	---------	-----	--------------	-----	------

>A>	AB		BRECKENRIDGE	2.5MG	A205426	001	Mar 05, 2021	Feb	NEWA
-----	----	--	--------------	-------	---------	-----	--------------	-----	------

>A>	AB			5MG	A205426	002	Mar 05, 2021	Feb	NEWA
-----	----	--	--	-----	---------	-----	--------------	-----	------

>A>	AB			7.5MG	A205426	003	Mar 05, 2021	Feb	NEWA
-----	----	--	--	-------	---------	-----	--------------	-----	------

>A>	AB			10MG	A205426	004	Mar 05, 2021	Feb	NEWA
-----	----	--	--	------	---------	-----	--------------	-----	------

EXENATIDE SYNTHETIC

>D>	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS							
>D>	BYDUREON							
>D>	+! ASTRAZENECA AB	2MG/VIAL	N022200	001	Jan 27, 2012	Feb	DISC	
>A>	+ @	2MG/VIAL	N022200	001	Jan 27, 2012	Feb	DISC	
>D>	BYDUREON PEN							
>D>	+! ASTRAZENECA AB	2MG	N022200	002	Feb 28, 2014	Feb	DISC	
>A>	+ @	2MG	N022200	002	Feb 28, 2014	Feb	DISC	

EZETIMIBE

TABLET;ORAL  
ZETIA

>D>	AB	+! MSD INTL GMBH	10MG	N021445	001	Oct 25, 2002	Feb	CAHN
>A>	AB	+! ORGANON	10MG	N021445	001	Oct 25, 2002	Feb	CAHN

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

		@ MYLAN	10MG;10MG	A200082	001	Dec 17, 2020	Jan	DISC
		@	10MG;20MG	A200082	002	Dec 17, 2020	Jan	DISC
		@	10MG;40MG	A200082	003	Dec 17, 2020	Jan	DISC
		@	10MG;80MG	A200082	004	Dec 17, 2020	Jan	DISC
		VYTORIN						
>D>	AB	+ MSD INTL	10MG;10MG	N021687	001	Jul 23, 2004	Feb	CAHN
>D>	AB	+	10MG;20MG	N021687	002	Jul 23, 2004	Feb	CAHN
>D>	AB	+	10MG;40MG	N021687	003	Jul 23, 2004	Feb	CAHN
>D>	AB	+!	10MG;80MG	N021687	004	Jul 23, 2004	Feb	CAHN
>A>	AB	+ ORGANON	10MG;10MG	N021687	001	Jul 23, 2004	Feb	CAHN
>A>	AB	+	10MG;20MG	N021687	002	Jul 23, 2004	Feb	CAHN
>A>	AB	+	10MG;40MG	N021687	003	Jul 23, 2004	Feb	CAHN
>A>	AB	+!	10MG;80MG	N021687	004	Jul 23, 2004	Feb	CAHN

FAMOTIDINE

FOR SUSPENSION;ORAL  
FAMOTIDINE

>A>	AB	AKORN	40MG/5ML	A201995	001	May 30, 2014	Feb	CAHN
>D>	AB	HI-TECH PHARMA CO	40MG/5ML	A201995	001	May 30, 2014	Feb	CAHN

FENOFIBRATE

TABLET;ORAL

FENOFIBRATE

AB	AUSTARPHARMA	48MG	A208476	001	Feb 10, 2021	Jan	NEWA
AB		145MG	A208476	002	Feb 10, 2021	Jan	NEWA

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

	@ RISING	EQ 200MG BASE	A072394	001	Oct 17, 1988	Jan	CAHN
	@	EQ 300MG BASE	A072395	001	Oct 17, 1988	Jan	CAHN

FERUMOXYTOL

SOLUTION;INTRAVENOUS

FERUMOXYTOL

AB	SANDOZ INC	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	A206604	001	Jan 15, 2021	Jan	NFTG
----	------------	--------------------------------------	---------	-----	--------------	-----	------

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL

FINGOLIMOD HYDROCHLORIDE

>A>	AB	DR REDDYS	EQ 0.5MG BASE	A208000	001	Mar 05, 2021	Feb	NEWA
		@ MYLAN	EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Jan	DISC
	AB		EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Jan	NEWA

FLECAINIDE ACETATE

TABLET;ORAL

TAMBOCOR

	+ @ CNTY LINE PHARMS	50MG	N018830	004	Aug 23, 1988	Jan	DISC
	+ @	100MG	N018830	001	Oct 31, 1985	Jan	DISC
	+ @	150MG	N018830	003	Jun 03, 1988	Jan	DISC

FLUDEOXYGLUCOSE F-18

	INJECTABLE; INTRAVENOUS						
	FLUDEOXYGLUCOSE F18						
	NUKEMED	4-500mCi/ML	A203911	001	Apr 22, 2015	Jan	CAHN
AP	PHARMALOGIC HLDGS	20-200mCi/ML	A203664	001	Feb 04, 2014	Jan	CAHN

FLUOCINOLONE ACETONIDE

	OIL/DROPS; OTIC						
	FLUOCINOLONE ACETONIDE						
AT	TASMAN PHARMA	0.01%	A213264	001	Feb 05, 2021	Jan	NEWA

FLUOXETINE HYDROCHLORIDE

	CAPSULE; ORAL						
	FLUOXETINE HYDROCHLORIDE						
>D>	AB1 ACCORD HLTHCARE	EQ 10MG BASE	A202729	001	Aug 27, 2020	Feb	DISC
>A>	@	EQ 10MG BASE	A202729	001	Aug 27, 2020	Feb	DISC
>D>	AB1	EQ 20MG BASE	A202729	002	Aug 27, 2020	Feb	DISC
>A>	@	EQ 20MG BASE	A202729	002	Aug 27, 2020	Feb	DISC
>D>	AB	EQ 40MG BASE	A202729	003	Aug 27, 2020	Feb	DISC
>A>	@	EQ 40MG BASE	A202729	003	Aug 27, 2020	Feb	DISC

FLUOXYMESTERONE

	TABLET; ORAL						
	FLUOXYMESTERONE						
	@ UPSHER SMITH LABS	10MG	A088342	001	Oct 21, 1983	Jan	DISC

FLUPHENAZINE HYDROCHLORIDE

	TABLET; ORAL						
	FLUPHENAZINE HYDROCHLORIDE						
AB	CEROVENE INC	1MG	A214534	001	Jan 07, 2021	Jan	NEWA
AB		2.5MG	A214534	002	Jan 07, 2021	Jan	NEWA
AB		5MG	A214534	003	Jan 07, 2021	Jan	NEWA
AB		10MG	A214534	004	Jan 07, 2021	Jan	NEWA
>A>	AB NOVITIUM PHARMA	1MG	A214674	001	Mar 01, 2021	Feb	NEWA
>A>	AB	2.5MG	A214674	002	Mar 01, 2021	Feb	NEWA
>A>	AB	5MG	A214674	003	Mar 01, 2021	Feb	NEWA
>A>	AB	10MG	A214674	004	Mar 01, 2021	Feb	NEWA

FLURBIPROFEN SODIUM

	SOLUTION/DROPS; OPHTHALMIC						
	FLURBIPROFEN SODIUM						
!	BAUSCH AND LOMB	0.03%	A074447	001	Jan 04, 1995	Jan	CHRS
		0.03%	A074447	001	Jan 04, 1995	Jan	CTEC
	OCUFEN						
+	@ ALLERGAN	0.03%	N019404	001	Dec 31, 1986	Jan	DISC

FLUVOXAMINE MALEATE

	CAPSULE, EXTENDED RELEASE; ORAL						
	FLUVOXAMINE MALEATE						
>D>	AB BIONPHARMA INC	100MG	A212182	002	Sep 16, 2020	Feb	DISC
>A>	@	100MG	A212182	002	Sep 16, 2020	Feb	DISC

FOSAPREPITANT DIMEGLUMINE

	POWDER; INTRAVENOUS						
	FOSAPREPITANT DIMEGLUMINE						
AP	AUROBINDO PHARMA LTD	EQ 150MG BASE/VIAL	A210625	001	Jan 12, 2021	Jan	NEWA
>A>	AP CHIA TAI TIANQING	EQ 150MG BASE/VIAL	A212143	001	Mar 03, 2021	Feb	NEWA

FOSCARNET SODIUM

	INJECTABLE; INJECTION						
	FOSCARNET SODIUM						
AP	FRESENIUS KABI USA	2.4GM/100ML	A212483	001	Jan 29, 2021	Jan	NEWA
AP	+! FOSCAVIR						
AP	+! CLINIGEN HLTHCARE	2.4GM/100ML	N020068	001	Sep 27, 1991	Jan	CTEC

>A>	<u>FOSDENOPTERIN HYDROBROMIDE</u>						
>A>	POWDER; INTRAVENOUS						
>A>	NULIBRY						
>A>	+! ORIGIN	EQ 9.5MG BASE/VIAL	N214018	001	Feb 26, 2021	Feb	NEWA

FULVESTRANT

INJECTABLE; INTRAMUSCULAR  
FULVESTRANT

AO	AUROMEDICS PHARMA	50MG/ML	A208811	001	Jul 23, 2019	Jan CAHN
----	-------------------	---------	---------	-----	--------------	----------

FUROSEMIDE

INJECTABLE; INJECTION  
FUROSEMIDE

AP	ATHENEX INC	10MG/ML	A214766	001	Jan 27, 2021	Jan NEWA
----	-------------	---------	---------	-----	--------------	----------

TABLET; ORAL  
LASIX

>D>	AB	+	US PHARM HOLDINGS	20MG	N016273	002	Feb CAHN
>D>	AB	+		40MG	N016273	001	Feb CAHN
>D>	AB	+	!	80MG	N016273	003	Feb CAHN
>A>	AB	+	VALIDUS PHARMS	20MG	N016273	002	Feb CAHN
>A>	AB	+		40MG	N016273	001	Feb CAHN
>A>	AB	+	!	80MG	N016273	003	Feb CAHN

GABAPENTIN

CAPSULE; ORAL  
GABAPENTIN

>D>	AB		ZHEJIANG YONGTAI	100MG	A213603	001	Aug 17, 2020	Feb DISC
>A>		@		100MG	A213603	001	Aug 17, 2020	Feb DISC
>D>	AB			300MG	A213603	002	Aug 17, 2020	Feb DISC
>A>		@		300MG	A213603	002	Aug 17, 2020	Feb DISC
>D>	AB			400MG	A213603	003	Aug 17, 2020	Feb DISC
>A>		@		400MG	A213603	003	Aug 17, 2020	Feb DISC

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC  
GATIFLOXACIN

>A>	AT		AKORN	0.5%	A203189	001	Sep 03, 2014	Feb CAHN
>D>	AT		HI-TECH PHARMA CO	0.5%	A203189	001	Sep 03, 2014	Feb CAHN

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION  
GEMCITABINE HYDROCHLORIDE

>D>	AP		JIANGSU HANSOH PHARM	EQ 200MG BASE/VIAL	A202485	001	May 07, 2013	Feb CHRS
>A>	AP	!		EQ 200MG BASE/VIAL	A202485	001	May 07, 2013	Feb CHRS
>D>	AP			EQ 1GM BASE/VIAL	A202485	002	May 07, 2013	Feb CHRS
>A>	AP	!		EQ 1GM BASE/VIAL	A202485	002	May 07, 2013	Feb CHRS
	AP		MEITHEAL	200MG/5.26ML (38MG/ML)	A212129	001	Dec 11, 2020	Jan CAHN
	AP			1GM/26.3ML (38MG/ML)	A212129	002	Dec 11, 2020	Jan CAHN
	AP			2GM/52.6ML (38MG/ML)	A212129	003	Dec 11, 2020	Jan CAHN
>D>			GEMZAR					
>D>	AP	+	LILLY	EQ 200MG BASE/VIAL	N020509	001	May 15, 1996	Feb DISC
>A>		+	@	EQ 200MG BASE/VIAL	N020509	001	May 15, 1996	Feb DISC
>D>	AP	+	!	EQ 1GM BASE/VIAL	N020509	002	May 15, 1996	Feb DISC
>A>		+	@	EQ 1GM BASE/VIAL	N020509	002	May 15, 1996	Feb DISC

GEMFIBROZIL

TABLET; ORAL  
GEMFIBROZIL

AB	ASCENT PHARMS INC	600MG	A214603	001	Jan 13, 2021	Jan NEWA
----	-------------------	-------	---------	-----	--------------	----------

GLYBURIDE

TABLET; ORAL  
GLYNASE

>A>	AB	+	PFIZER	1.5MG	N020051	001	Mar 04, 1992	Feb CAHN	
>A>	AB	+		3MG	N020051	002	Mar 04, 1992	Feb CAHN	
>A>		+	@	4.5MG	N020051	003	Sep 24, 1993	Feb CAHN	
>A>	AB	+	!	6MG	N020051	004	Sep 24, 1993	Feb CAHN	
>D>	AB	+	PHARMACIA AND UPJOHN	1.5MG	N020051	001	Mar 04, 1992	Feb CAHN	
>D>	AB	+		3MG	N020051	002	Mar 04, 1992	Feb CAHN	
>D>		+	@	4.5MG	N020051	003	Sep 24, 1993	Feb CAHN	
>D>	AB	+	!	6MG	N020051	004	Sep 24, 1993	Feb CAHN	
			MICRONASE						
>A>		+	@	PFIZER	1.25MG	N017498	001	May 01, 1984	Feb CAHN
>A>			@		2.5MG	N017498	002	May 01, 1984	Feb CAHN
>A>		+	@		5MG	N017498	003	May 01, 1984	Feb CAHN
>D>		+	@	PHARMACIA AND UPJOHN	1.25MG	N017498	001	May 01, 1984	Feb CAHN

TABLET;ORAL  
MICRONASE

>D> @ 2.5MG N017498 002 May 01, 1984 Feb CAHN  
>D> + @ 5MG N017498 003 May 01, 1984 Feb CAHN

GLYCOPYRROLATE

INJECTABLE; INJECTION  
GLYCOPYRROLATE

AP ATHENEX INC 0.2MG/ML A210083 001 Feb 21, 2020 Jan CAHN  
>A> AP XIROMED 0.2MG/ML A212227 001 Mar 04, 2021 Feb NEWA

GRANISETRON HYDROCHLORIDE

SOLUTION;ORAL  
GRANISOL

@ INTRA SANA LABS EQ 2MG BASE/10ML A078334 001 Feb 28, 2008 Jan CAHN

GUANFACINE HYDROCHLORIDE

TABLET;ORAL  
GUANFACINE HYDROCHLORIDE

AB ! AMNEAL PHARM EQ 2MG BASE A075109 002 Nov 25, 1998 Jan CHRS  
@ MYLAN EQ 1MG BASE A074796 001 Jan 27, 1997 Jan DISC  
@ EQ 2MG BASE A074796 002 Jan 27, 1997 Jan DISC  
>A> AB UNICHEM EQ 1MG BASE A214689 001 Mar 03, 2021 Feb NEWA  
>A> AB EQ 2MG BASE A214689 002 Mar 03, 2021 Feb NEWA

HEPARIN SODIUM

INJECTABLE; INJECTION  
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ FRESENIUS KABI USA 200 UNITS/100ML A212441 001 Jul 24, 2020 Jan DISC

HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ FRESENIUS KABI USA 200 UNITS/100ML A212441 002 Jul 24, 2020 Jan DISC

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL  
ZESTORETIC

AB + ALMATICA 12.5MG;10MG N019888 003 Nov 18, 1993 Jan CAHN  
AB +! 12.5MG;20MG N019888 001 Sep 20, 1990 Jan CAHN  
AB +! 25MG;20MG N019888 002 Jul 20, 1989 Jan CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL  
LOPRESSOR HCT

>D> AB + US PHARMS HOLDINGS I 25MG;50MG N018303 001 Dec 31, 1984 Feb CAHN  
>D> + @ 25MG;100MG N018303 002 Dec 31, 1984 Feb CAHN  
>D> + @ 50MG;100MG N018303 003 Dec 31, 1984 Feb CAHN  
>A> AB + VALIDUS PHARMS 25MG;50MG N018303 001 Dec 31, 1984 Feb CAHN  
>A> + @ 25MG;100MG N018303 002 Dec 31, 1984 Feb CAHN  
>A> + @ 50MG;100MG N018303 003 Dec 31, 1984 Feb CAHN

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE;ORAL  
HYDROCODONE BITARTRATE

>A> ALVOGEN PINE BROOK 20MG A208269 001 Mar 01, 2021 Feb NFTG  
>A> AB 30MG A208269 002 Mar 01, 2021 Feb NFTG  
>A> AB 40MG A208269 003 Mar 01, 2021 Feb NFTG  
>A> AB 60MG A208269 004 Mar 01, 2021 Feb NFTG  
>A> AB 80MG A208269 005 Mar 01, 2021 Feb NFTG  
>A> AB 100MG A208269 006 Mar 01, 2021 Feb NFTG  
>A> AB 120MG A208269 007 Mar 01, 2021 Feb NFTG

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL  
HYDROCODONE BITARTRATE AND IBUPROFEN

AB NOSTRUM LABS INC 5MG;200MG A077727 001 Nov 06, 2006 Jan CAHN  
AB 7.5MG;200MG A077723 001 Nov 06, 2006 Jan CAHN  
AB 10MG;200MG A077723 002 Nov 06, 2006 Jan CAHN



HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION  
HYDROCORTONE

>D> @ MERCK EQ 50MG BASE/ML N012052 001 Feb CRLD  
>A> + @ EQ 50MG BASE/ML N012052 001 Feb CRLD

HYDROCORTISONE VALERATE

CREAM; TOPICAL  
HYDROCORTISONE VALERATE

>A> AB COSETTE 0.2% A213724 001 Feb 11, 2021 Feb NEWA

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL  
HYDROXYZINE HYDROCHLORIDE

>A> AB PRINSTON INC 10MG A040580 003 May 27, 2005 Feb CMS1  
>A> AB 25MG A040580 002 May 27, 2005 Feb CMS1

IBUPROFEN

TABLET; ORAL  
IBUPROFEN

>D> AB VINTAGE PHARMS 400MG A071644 001 Feb 01, 1988 Feb DISC  
>A> @ 400MG A071644 001 Feb 01, 1988 Feb DISC

IBUTILIDE FUMARATE

INJECTABLE; INJECTION  
CORVERT

>A> AP +! PFIZER 0.1MG/ML N020491 001 Dec 28, 1995 Feb CAHN  
>D> AP +! PHARMACIA AND UPJOHN 0.1MG/ML N020491 001 Dec 28, 1995 Feb CAHN

ILOPROST

SOLUTION; INHALATION  
VENTAVIS

>A> +! ACTELION 10MCG/ML (10MCG/ML) N021779 002 Dec 08, 2005 Feb CAHN  
>A> @ 20MCG/2ML (10MCG/ML) N021779 001 Dec 29, 2004 Feb CAHN  
>A> +! 20MCG/ML (20MCG/ML) N021779 003 Aug 07, 2009 Feb CAHN  
>D> +! ACTELION PHARMS LTD 10MCG/ML (10MCG/ML) N021779 002 Dec 08, 2005 Feb CAHN  
>D> @ 20MCG/2ML (10MCG/ML) N021779 001 Dec 29, 2004 Feb CAHN  
>D> +! 20MCG/ML (20MCG/ML) N021779 003 Aug 07, 2009 Feb CAHN

IMIQUIMOD

CREAM; TOPICAL  
IMIQUIMOD

AB TARO 3.75% A205971 001 Jan 26, 2021 Jan NFTG

INDOMETHACIN

CAPSULE; ORAL  
INDOMETHACIN

@ JUBILANT GENERICS 25MG A205215 001 Aug 25, 2017 Jan DISC  
@ 50MG A205215 002 Aug 25, 2017 Jan DISC

CAPSULE, EXTENDED RELEASE; ORAL  
INDOMETHACIN

@ AUROBINDO PHARMA LTD 75MG A204243 001 Dec 27, 2016 Jan DISC

IOPAMIDOL

INJECTABLE; INJECTION  
ISOVUE-300

+! BRACCO 61% N018735 002 Dec 31, 1985 Jan CTEC  
ISOVUE-370

+! BRACCO 76% N018735 003 Dec 31, 1985 Jan CTEC  
SCANLUX-300

@ SANOCHEMIA CORP USA 61% A090394 001 Jun 18, 2010 Jan DISC  
SCANLUX-370

@ SANOCHEMIA CORP USA 76% A090394 002 Jun 18, 2010 Jan DISC

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION  
ISOPROTERENOL HYDROCHLORIDE

AP AUROBINDO PHARMA LTD 0.2MG/ML A211864 001 Feb 09, 2021 Jan NEWA  
>A> AP MICRO LABS 0.2MG/ML A210845 001 Feb 16, 2021 Feb NEWA

IVERMECTIN

TABLET;ORAL  
STROMEKTOL

>D>	@	MERCK SHARP DOHME	6MG	N050742	001	Nov 22, 1996	Feb	CRLD
>A>	+	@	6MG	N050742	001	Nov 22, 1996	Feb	CRLD

KETAMINE HYDROCHLORIDE

INJECTABLE;INJECTION  
KETAMINE HYDROCHLORIDE

AP	AUROMEDICS PHARMA	EQ 10MG BASE/ML	A076092	001	Sep 30, 2008	Jan	CAHN
AP		EQ 50MG BASE/ML	A076092	002	Dec 28, 2001	Jan	CAHN
AP		EQ 100MG BASE/ML	A076092	003	Oct 25, 2002	Jan	CAHN

KETOPROFEN

CAPSULE;ORAL  
KETOPROFEN

@	RISING	50MG	A074024	001	Dec 29, 1995	Jan	CAHN
@		75MG	A074024	002	Dec 29, 1995	Jan	CAHN

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL  
LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

>D>	+	AUROBINDO PHARMA LTD	300MG;300MG	N022344	001	May 15, 2018	Feb	DISC
>A>	+	@	300MG;300MG	N022344	001	May 15, 2018	Feb	DISC

LAMOTRIGINE

TABLET, ORALLY DISINTEGRATING;ORAL  
LAMOTRIGINE

AB	AJANTA PHARMA LTD	25MG	A213271	001	Jan 19, 2021	Jan	NEWA
AB		50MG	A213271	002	Jan 19, 2021	Jan	NEWA
AB		100MG	A213271	003	Jan 19, 2021	Jan	NEWA
AB		200MG	A213271	004	Jan 19, 2021	Jan	NEWA

LANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL  
LANSOPRAZOLE

AB	DR REDDYS LABS LTD	15MG	A210465	001	Feb 01, 2021	Jan	NEWA
AB		30MG	A210465	002	Feb 01, 2021	Jan	NEWA

LETROZOLE

TABLET;ORAL  
LETROZOLE

@	APOTEX INC	2.5MG	A091303	001	Apr 19, 2012	Jan	DISC
---	------------	-------	---------	-----	--------------	-----	------

LEVETIRACETAM

INJECTABLE;INTRAVENOUS  
LEVETIRACETAM IN SODIUM CHLORIDE

>D>	AP	AUROBINDO PHARMA LTD	1000MG/100ML (10MG/ML)	A207160	002	Jan 04, 2017	Feb	CPOT
>A>	AP		1GM/100ML (10MG/ML)	A207160	002	Jan 04, 2017	Feb	CPOT
>D>	AP		1500MG/100ML (15MG/ML)	A207160	003	Jan 04, 2017	Feb	CPOT
>A>	AP		1.5GM/100ML (15MG/ML)	A207160	003	Jan 04, 2017	Feb	CPOT
>D>	AP	GLAND PHARMA LTD	1000MG/100ML (10MG/ML)	A206880	002	Oct 25, 2017	Feb	CPOT
>A>	AP		1GM/100ML (10MG/ML)	A206880	002	Oct 25, 2017	Feb	CPOT
>D>	AP		1500MG/100ML (15MG/ML)	A206880	003	Oct 25, 2017	Feb	CDFR
>A>	AP		1.5GM/100ML (15MG/ML)	A206880	003	Oct 25, 2017	Feb	CDFR
>D>	AP	+	HQ SPECIALITY PHARMA	N202543	002	Nov 09, 2011	Feb	CPOT
>A>	AP	+		N202543	002	Nov 09, 2011	Feb	CPOT
>D>	AP	+		N202543	003	Nov 09, 2011	Feb	CPOT
>A>	AP	+		N202543	003	Nov 09, 2011	Feb	CPOT
>D>	AP	NEXUS PHARMS	1000MG/100ML (10MG/ML)	A213532	002	Jul 06, 2020	Feb	CPOT
>A>	AP		1GM/100ML (10MG/ML)	A213532	002	Jul 06, 2020	Feb	CPOT
>D>	AP		1500MG/100ML (15MG/ML)	A213532	003	Jul 06, 2020	Feb	CPOT
>A>	AP		1.5GM/100ML (15MG/ML)	A213532	003	Jul 06, 2020	Feb	CPOT

SOLUTION;ORAL

LEVETIRACETAM

>A>	AA	AKORN	100MG/ML	A090601	001	Feb 28, 2012	Feb	CAHN
>D>	AA	HI-TECH PHARMACAL	100MG/ML	A090601	001	Feb 28, 2012	Feb	CAHN

TABLET;ORAL

LEVETIRACETAM

AB	NOSTRUM LABS INC	250MG	A090511	001	Aug 18, 2011	Jan	CAHN
AB		500MG	A090511	002	Aug 18, 2011	Jan	CAHN

TABLET;ORAL									
LEVETIRACETAM									
AB		750MG		A090511	003	Aug 18, 2011	Jan	CAHN	
AB		1GM		A090511	004	Aug 18, 2011	Jan	CAHN	
TABLET, EXTENDED RELEASE;ORAL									
ELEPSIA XR									
+	TRIPOINT	1GM		N204417	001	Dec 20, 2018	Jan	CAHN	
+	!	1.5GM		N204417	002	Dec 20, 2018	Jan	CAHN	
<u>LEVORPHANOL TARTRATE</u>									
TABLET;ORAL									
LEVORPHANOL TARTRATE									
AB	NOVITIUM PHARMA	3MG		A213479	002	Jan 12, 2021	Jan	NEWA	
AB	! SENTRYNL THERAPS INC	3MG		A074278	003	Jun 18, 2018	Jan	CTEC	
<u>LEVOTHYROXINE SODIUM</u>									
POWDER;INTRAVENOUS									
LEVOTHYROXINE SODIUM									
>D>	AP	DR REDDYS	100MCG/VIAL	A208837	001	Mar 27, 2020	Feb	DISC	
>A>		@	100MCG/VIAL	A208837	001	Mar 27, 2020	Feb	DISC	
SOLUTION;ORAL									
TIROSINT-SOL									
+	INSTITUT BIOCHIMIQUE	37.5MCG/ML		N206977	013	Jan 13, 2021	Jan	NEWA	
+		44MCG/ML		N206977	014	Jan 13, 2021	Jan	NEWA	
+		62.5MCG/ML		N206977	015	Jan 13, 2021	Jan	NEWA	
<u>LIDOCAINE HYDROCHLORIDE</u>									
JELLY;TOPICAL									
XYLOCAINE									
+	@ AKORN	2%		N008816	001		Jan	DISC	
SOLUTION;ORAL									
LIDOCAINE HYDROCHLORIDE VISCOUS									
AT	LANNETT CO INC	2%		A040708	001	Feb 27, 2007	Jan	CMFD	
<u>LINACLOTIDE</u>									
CAPSULE;ORAL									
LINACLOTIDE									
>D>	AB	MYLAN	145MCG	A209564	001	Feb 09, 2021	Feb	DISC	
>A>		@	145MCG	A209564	001	Feb 09, 2021	Feb	DISC	
	AB		145MCG	A209564	001	Feb 09, 2021	Jan	NFTG	
>D>	AB		290MCG	A209564	002	Feb 09, 2021	Feb	DISC	
>A>		@	290MCG	A209564	002	Feb 09, 2021	Feb	DISC	
	AB		290MCG	A209564	002	Feb 09, 2021	Jan	NFTG	
LINZESS									
>D>	AB	! ALLERGAN	145MCG	N202811	001	Aug 30, 2012	Feb	CTEC	
>A>		!	145MCG	N202811	001	Aug 30, 2012	Feb	CTEC	
>D>	AB	+	290MCG	N202811	002	Aug 30, 2012	Feb	CTEC	
>A>		+	290MCG	N202811	002	Aug 30, 2012	Feb	CTEC	
<u>LINCOMYCIN HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
LINCOCIN									
>A>	AP	! PFIZER	EQ 300MG BASE/ML	N050317	001		Feb	CAHN	
>D>	AP	! PHARMACIA AND UPJOHN	EQ 300MG BASE/ML	N050317	001		Feb	CAHN	
<u>LIOTHYRONINE SODIUM</u>									
TABLET;ORAL									
LIOTHYRONINE SODIUM									
AB	ZYDUS	EQ 0.005MG BASE		A214803	001	Jan 22, 2021	Jan	NEWA	
AB		EQ 0.025MG BASE		A214803	002	Jan 22, 2021	Jan	NEWA	
AB		EQ 0.05MG BASE		A214803	003	Jan 22, 2021	Jan	NEWA	
<u>LISINOPRIL</u>									
TABLET;ORAL									
LISINOPRIL									
>A>	AB	YILING	20MG	A208920	001	Mar 04, 2021	Feb	NEWA	
>A>	AB		30MG	A208920	002	Mar 04, 2021	Feb	NEWA	
>A>	AB		40MG	A208920	003	Mar 04, 2021	Feb	NEWA	

LORAZEPAM

CONCENTRATE;ORAL

LORAZEPAM

>A>	AA	AKORN	2MG/ML	A200169	001	Jan 30, 2012	Feb CAHN
>D>	AA	HI-TECH PHARMA CO	2MG/ML	A200169	001	Jan 30, 2012	Feb CAHN

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC

LOTEPREDNOL ETABONATE

AB	AKORN	0.5%	A212080	001	Feb 10, 2021	Jan NFTG
----	-------	------	---------	-----	--------------	----------

SUSPENSION/DROPS;OPHTHALMIC

LOTEPREDNOL ETABONATE

>A>	AB	SUN PHARM	0.5%	A212450	001	Feb 26, 2021	Feb NEWA
-----	----	-----------	------	---------	-----	--------------	----------

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

AB	WATSON LABS TEVA	20MG	A208016	001	Feb 02, 2021	Jan NEWA
----	------------------	------	---------	-----	--------------	----------

AB		40MG	A208016	002	Feb 02, 2021	Jan NEWA
----	--	------	---------	-----	--------------	----------

AB		60MG	A208016	003	Feb 02, 2021	Jan NEWA
----	--	------	---------	-----	--------------	----------

AB		80MG	A208016	004	Feb 02, 2021	Jan NEWA
----	--	------	---------	-----	--------------	----------

AB		120MG	A208016	005	Feb 02, 2021	Jan NEWA
----	--	-------	---------	-----	--------------	----------

MACITENTAN

TABLET;ORAL

OPSUMIT

>A>	+	ACTELION	10MG	N204410	001	Oct 18, 2013	Feb CAHN
-----	---	----------	------	---------	-----	--------------	----------

>D>	+	ACTELION PHARMS LTD	10MG	N204410	001	Oct 18, 2013	Feb CAHN
-----	---	---------------------	------	---------	-----	--------------	----------

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>	@	BAXTER HLTHCARE CORP	1GM/100ML	A211965	001	Aug 11, 2020	Feb CMFD
-----	---	----------------------	-----------	---------	-----	--------------	----------

>A>	AP		1GM/100ML	A211965	001	Aug 11, 2020	Feb CMFD
-----	----	--	-----------	---------	-----	--------------	----------

MAGNESIUM SULFATE IN PLASTIC CONTAINER

>D>	@	BAXTER HLTHCARE CORP	2GM/50ML (40MG/ML)	A211966	001	Jun 01, 2020	Feb CMFD
-----	---	----------------------	--------------------	---------	-----	--------------	----------

>A>	AP		2GM/50ML (40MG/ML)	A211966	001	Jun 01, 2020	Feb CMFD
-----	----	--	--------------------	---------	-----	--------------	----------

>D>	@		4GM/50ML (80MG/ML)	A211966	002	Jun 01, 2020	Feb CMFD
-----	---	--	--------------------	---------	-----	--------------	----------

>A>	AP		4GM/50ML (80MG/ML)	A211966	002	Jun 01, 2020	Feb CMFD
-----	----	--	--------------------	---------	-----	--------------	----------

>D>	@		4GM/100ML (40MG/ML)	A211966	003	Jun 01, 2020	Feb CMFD
-----	---	--	---------------------	---------	-----	--------------	----------

>A>	AP		4GM/100ML (40MG/ML)	A211966	003	Jun 01, 2020	Feb CMFD
-----	----	--	---------------------	---------	-----	--------------	----------

MELOXICAM

CAPSULE;ORAL

MELOXICAM

>D>		LUPIN LTD	5MG	A209487	001	Jun 01, 2020	Feb CTEC
-----	--	-----------	-----	---------	-----	--------------	----------

>A>	AB		5MG	A209487	001	Jun 01, 2020	Feb CTEC
-----	----	--	-----	---------	-----	--------------	----------

>D>	!		10MG	A209487	002	Jun 01, 2020	Feb CTEC
-----	---	--	------	---------	-----	--------------	----------

>A>	AB	!	10MG	A209487	002	Jun 01, 2020	Feb CTEC
-----	----	---	------	---------	-----	--------------	----------

>A>	AB	NOVITIUM PHARMA	5MG	A211398	001	Mar 09, 2021	Feb NEWA
-----	----	-----------------	-----	---------	-----	--------------	----------

>A>	AB		10MG	A211398	002	Mar 09, 2021	Feb NEWA
-----	----	--	------	---------	-----	--------------	----------

MELPHALAN

TABLET;ORAL

MELPHALAN

!	ALVOGEN	2MG	A207809	001	Mar 22, 2017	Jan CAHN
---	---------	-----	---------	-----	--------------	----------

MELPHALAN FLUFENAMIDE

>A>		POWDER;INTRAVENOUS				
-----	--	--------------------	--	--	--	--

>A>		PEPAXTO				
-----	--	---------	--	--	--	--

>A>	+	ONCOPEPTIDES AB	20MG/VIAL	N214383	001	Feb 26, 2021	Feb NEWA
-----	---	-----------------	-----------	---------	-----	--------------	----------

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

ALKERAN

+	@	APOTEX	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992	Jan DISC
---	---	--------	-------------------	---------	-----	--------------	----------

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION  
 DEMEROL

>D>	@	US PHARM HOLDINGS	25MG/ML	N005010	007		Feb	CAHN
>D>	@		50MG/ML	N005010	002		Feb	CAHN
>D>	@		75MG/ML	N005010	009		Feb	CAHN
>D>	@		100MG/ML	N005010	003		Feb	CAHN
>A>	@	VALIDUS PHARMS	25MG/ML	N005010	007		Feb	CAHN
>A>	@		50MG/ML	N005010	002		Feb	CAHN
>A>	@		75MG/ML	N005010	009		Feb	CAHN
>A>	@		100MG/ML	N005010	003		Feb	CAHN

SYRUP; ORAL  
 DEMEROL

>D>	@	US PHARM HOLDINGS	50MG/5ML	N005010	005		Feb	CAHN
>A>	@	VALIDUS PHARMS	50MG/5ML	N005010	005		Feb	CAHN

TABLET; ORAL  
 DEMEROL

>D>	+ @	US PHARM HOLDINGS	50MG	N005010	001		Feb	CAHN
>D>	+ @		100MG	N005010	004		Feb	CAHN
>A>	+ @	VALIDUS PHARMS	50MG	N005010	001		Feb	CAHN
>A>	+ @		100MG	N005010	004		Feb	CAHN

MEROPENEM; VABORBACTAM

POWDER; INTRAVENOUS  
 VABOMERE

>A>	+	REMPEX	1GM/VIAL; 1GM/VIAL	N209776	001	Aug 29, 2017	Feb	CAHN
>D>	+	REMPEX PHARMS	1GM/VIAL; 1GM/VIAL	N209776	001	Aug 29, 2017	Feb	CAHN

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL  
 METFORMIN HYDROCHLORIDE

>A>	AB3	AJANTA PHARMA LTD	500MG	A213962	001	Mar 09, 2021	Feb	NEWA
>A>	AB3		1GM	A213962	002	Mar 09, 2021	Feb	NEWA
	AB3	GRANULES	500MG	A213344	001	Jan 12, 2021	Jan	NEWA
	AB3		1GM	A213344	002	Jan 12, 2021	Jan	NEWA

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL  
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

	@	TORRENT PHARMS LTD	500MG; EQ 15MG BASE	A202001	001	Feb 13, 2013	Jan	DISC
	@		850MG; EQ 15MG BASE	A202001	002	Feb 13, 2013	Jan	DISC

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL  
 METHADONE HYDROCHLORIDE

>A>	AA	LANNETT CO INC	10MG/ML	A212094	001	Mar 03, 2021	Feb	NEWA
-----	----	----------------	---------	---------	-----	--------------	-----	------

METHENAMINE HIPPURATE

TABLET; ORAL  
 HIPREX

>D>	AB	+	US PHARM HOLDINGS	1GM	N017681	001		Feb	CAHN
>A>	AB	+	VALIDUS PHARMS	1GM	N017681	001		Feb	CAHN

METHOCARBAMOL

TABLET; ORAL  
 METHOCARBAMOL

>D>	AA	AUROBINDO PHARMA LTD	750MG	A213967	001	Aug 12, 2020	Feb	DISC
>A>		@	750MG	A213967	001	Aug 12, 2020	Feb	DISC

METHYLERGONOVINE MALEATE

TABLET; ORAL  
 METHYLERGONOVINE MALEATE

AB		RISING	0.2MG	A211919	001	Jan 15, 2021	Jan	NEWA
----	--	--------	-------	---------	-----	--------------	-----	------

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION; ORAL  
 METHYLPHENIDATE HYDROCHLORIDE

AA		ASCENT PHARMS INC	5MG/5ML	A207417	001	Jan 29, 2021	Jan	NEWA	
AA			10MG/5ML	A207417	002	Jan 29, 2021	Jan	NEWA	
		@	LANNETT CO INC	5MG/5ML	A207414	001	Dec 16, 2020	Jan	DISC
		@		10MG/5ML	A207414	002	Dec 16, 2020	Jan	DISC

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

>A>	AB	PRAXGEN	4MG	A212262	001	Jun 27, 2019	Feb CAHN
>D>	AB	SUNGEN PHARMA	4MG	A212262	001	Jun 27, 2019	Feb CAHN

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

>A>	AB	YICHANG HUMANWELL	EQ 100MG TARTRATE	A213854	001	Feb 12, 2021	Feb NEWA
>A>	AB		EQ 200MG TARTRATE	A213854	002	Feb 12, 2021	Feb NEWA

METOPROLOL TARTRATE

TABLET;ORAL

LOPRESSOR

>D>	AB	+ US PHARMS HOLDINGS I	50MG	N017963	001		Feb CAHN
>D>	AB	+	100MG	N017963	002		Feb CAHN
>A>	AB	+ VALIDUS PHARMS	50MG	N017963	001		Feb CAHN
>A>	AB	+	100MG	N017963	002		Feb CAHN

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL

MEXILETINE HYDROCHLORIDE

AB		RICONPHARMA LLC	150MG	A214352	001	Jan 25, 2021	Jan NEWA
AB			200MG	A214352	002	Jan 25, 2021	Jan NEWA
AB			250MG	A214352	003	Jan 25, 2021	Jan NEWA

MIDODRINE HYDROCHLORIDE

TABLET;ORAL

MIDODRINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	2.5MG	A214734	001	Jan 21, 2021	Jan NEWA
AB			5MG	A214734	002	Jan 21, 2021	Jan NEWA
AB			10MG	A214734	003	Jan 21, 2021	Jan NEWA

MIGLITOL

TABLET;ORAL

GLYSET

>A>	AB	+! PFIZER	25MG	N020682	001	Dec 18, 1996	Feb CAHN
>A>	AB	+	50MG	N020682	002	Dec 18, 1996	Feb CAHN
>A>	AB	+	100MG	N020682	003	Dec 18, 1996	Feb CAHN
>D>	AB	+! PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996	Feb CAHN
>D>	AB	+	50MG	N020682	002	Dec 18, 1996	Feb CAHN
>D>	AB	+	100MG	N020682	003	Dec 18, 1996	Feb CAHN

MINOXIDIL

TABLET;ORAL

LONITEN

>A>		+ @ PFIZER	2.5MG	N018154	001		Feb CAHN
>A>		+ @	10MG	N018154	003		Feb CAHN
>D>		+ @ PHARMACIA AND UPJOHN	2.5MG	N018154	001		Feb CAHN
>D>		+ @	10MG	N018154	003		Feb CAHN

MOMETASONE FUROATE

OINTMENT;TOPICAL

MOMETASONE FUROATE

@ TORRENT

0.1%

A207899	001	Jul 13, 2018	Jan DISC
---------	-----	--------------	----------

SPRAY, METERED;NASAL

NASONEX

>D>	AB	+! MERCK SHARP DOHME	0.05MG/SPRAY	N020762	001	Oct 01, 1997	Feb CAHN
>A>	AB	+! ORGANON	0.05MG/SPRAY	N020762	001	Oct 01, 1997	Feb CAHN

MORPHINE SULFATE

SOLUTION;ORAL

MORPHINE SULFATE

@ ANI PHARMS INC

10MG/5ML

A205509	001	Apr 17, 2018	Jan DISC
---------	-----	--------------	----------

@

20MG/5ML

A205509	002	Apr 17, 2018	Jan DISC
---------	-----	--------------	----------

@

100MG/5ML

A205509	003	Apr 17, 2018	Jan DISC
---------	-----	--------------	----------

>A>	AA	WINDER LABS LLC	10MG/5ML	A211454	001	Feb 12, 2021	Feb NEWA
>A>	AA		20MG/5ML	A211454	002	Feb 12, 2021	Feb NEWA
>A>	AA		100MG/5ML	A211454	003	Feb 12, 2021	Feb NEWA

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
MOXIFLOXACIN HYDROCHLORIDE

AT1 UPSHER SMITH LABS EQ 0.5% BASE A212616 001 Feb 10, 2021 Jan NEWA

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION  
MYCOPHENOLATE MOFETIL HYDROCHLORIDE

>A> AP AMNEAL 500MG/VIAL A211374 001 Mar 05, 2021 Feb NEWA  
 AP MEITHEAL 500MG/VIAL A212130 001 Jan 15, 2021 Jan CAHN  
 AP NANJING KING-FRIEND 500MG/VIAL A212130 001 Jan 15, 2021 Jan NEWA

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE; ORAL  
MYCOPHENOLIC ACID

AB AMTA 180MG A214376 001 Feb 10, 2021 Jan NEWA  
 AB 360MG A214376 002 Feb 10, 2021 Jan NEWA

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION  
NALOXONE HYDROCHLORIDE

AP AUROBINDO PHARMA LTD 1MG/ML A213279 001 Jan 14, 2021 Jan NEWA  
 AP BAXTER HLTHCARE CORP 0.4MG/ML A214785 001 Jan 29, 2021 Jan NEWA

NAPROXEN

SUSPENSION; ORAL  
NAPROXEN

>A> AB NOVITIUM PHARMA 25MG/ML A211910 001 Mar 10, 2021 Feb NEWA  
 TABLET; ORAL  
 NAPROXEN  
 >D> @ GRANULES 250MG A074140 001 Dec 21, 1993 Feb CMFD  
 >A> AB 250MG A074140 001 Dec 21, 1993 Feb CMFD  
 >D> @ 375MG A074140 002 Dec 21, 1993 Feb CMFD  
 >A> AB 375MG A074140 002 Dec 21, 1993 Feb CMFD  
 >D> @ 500MG A074140 003 Dec 21, 1993 Feb CMFD  
 >A> AB 500MG A074140 003 Dec 21, 1993 Feb CMFD

NICARDIPINE HYDROCHLORIDE

INJECTABLE; INJECTION  
NICARDIPINE HYDROCHLORIDE

>D> AM REGENT 25MG/10ML (2.5MG/ML) A090534 001 Nov 17, 2009 Feb CHRS  
 >A> ! 25MG/10ML (2.5MG/ML) A090534 001 Nov 17, 2009 Feb CHRS

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL  
NISOLDIPINE

! MYLAN 20MG A079051 001 Jul 25, 2008 Jan CHRS  
 30MG A079051 002 Jul 25, 2008 Jan CHRS

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION  
NOREPINEPHRINE BITARTRATE

AP SUN PHARM EQ 1MG BASE/ML A211980 001 Jan 29, 2021 Jan NEWA  
 SOLUTION; INTRAVENOUS  
 NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE  
 +! BAXTER HLTHCARE CORP EQ 4MG BASE/250ML (EQ 16MCG  
 BASE/ML) N214313 001 Jan 15, 2021 Jan NEWA  
 +! EQ 8MG BASE/250ML (EQ 32MCG  
 BASE/ML) N214313 002 Jan 15, 2021 Jan NEWA

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL  
NORTRIPTYLINE HYDROCHLORIDE

>A> AB ZYDUS EQ 10MG BASE A213441 001 Feb 24, 2021 Feb NEWA  
 >A> AB EQ 25MG BASE A213441 002 Feb 24, 2021 Feb NEWA  
 >A> AB EQ 50MG BASE A213441 003 Feb 24, 2021 Feb NEWA  
 >A> AB EQ 75MG BASE A213441 004 Feb 24, 2021 Feb NEWA

NYSTATIN

OINTMENT;TOPICAL  
 NYSTATIN  
 AT MACLEODS PHARMS LTD 100,000 UNITS/GM A213826 001 Jan 14, 2021 Jan NEWA

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC  
 OFLOXACIN  
 @ ALVOGEN 0.3% A076830 001 Aug 31, 2004 Jan DISC  
 TABLET;ORAL  
 FLOXIN  
 + @ JANSSEN PHARMS 200MG N019735 001 Dec 28, 1990 Jan CRLD  
 + @ 300MG N019735 002 Dec 28, 1990 Jan CRLD  
 + @ 400MG N019735 003 Dec 28, 1990 Jan CRLD

OLANZAPINE

TABLET;ORAL  
 OLANZAPINE  
 >A> AB HISUN PHARM HANGZHOU 2.5MG A206924 001 Dec 31, 2020 Feb CAHN  
 >A> AB 5MG A206924 002 Dec 31, 2020 Feb CAHN  
 >A> AB 7.5MG A206924 003 Dec 31, 2020 Feb CAHN  
 >A> AB 10MG A206924 004 Dec 31, 2020 Feb CAHN  
 >A> AB 15MG A206924 005 Dec 31, 2020 Feb CAHN  
 >A> AB 20MG A206924 006 Dec 31, 2020 Feb CAHN  
 >D> AB PHARMTAK INC 2.5MG A206924 001 Dec 31, 2020 Feb CAHN  
 >D> AB 5MG A206924 002 Dec 31, 2020 Feb CAHN  
 >D> AB 7.5MG A206924 003 Dec 31, 2020 Feb CAHN  
 >D> AB 10MG A206924 004 Dec 31, 2020 Feb CAHN  
 >D> AB 15MG A206924 005 Dec 31, 2020 Feb CAHN  
 >D> AB 20MG A206924 006 Dec 31, 2020 Feb CAHN

TABLET, ORALLY DISINTEGRATING;ORAL  
 OLANZAPINE

>A> AB HISUN PHARM HANGZHOU 5MG A206892 001 Dec 31, 2020 Feb CAHN  
 >A> AB 10MG A206892 002 Dec 31, 2020 Feb CAHN  
 >A> AB 15MG A206892 003 Dec 31, 2020 Feb CAHN  
 >A> AB 20MG A206892 004 Dec 31, 2020 Feb CAHN  
 >D> AB PHARMTAK INC 5MG A206892 001 Dec 31, 2020 Feb CAHN  
 >D> AB 10MG A206892 002 Dec 31, 2020 Feb CAHN  
 >D> AB 15MG A206892 003 Dec 31, 2020 Feb CAHN  
 >D> AB 20MG A206892 004 Dec 31, 2020 Feb CAHN

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
 OLOPATADINE HYDROCHLORIDE  
 >D> AT ALEMBIC PHARMS LTD EQ 0.1% BASE A209919 001 Dec 07, 2018 Feb CMKT  
 >D> AT BARR LABS INC EQ 0.2% BASE A090848 001 Jul 13, 2015 Feb CMKT  
 >D> AT FDC LTD EQ 0.1% BASE A209282 001 Sep 26, 2019 Feb CMKT  
 >D> AT MYLAN EQ 0.1% BASE A204392 001 Mar 21, 2018 Feb CMKT  
 SPRAY, METERED;NASAL  
 OLOPATADINE HYDROCHLORIDE  
 @ AMNEAL 0.665MG/SPRAY A210901 001 Jan 28, 2020 Jan DISC

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL  
 LOVAZA  
 >D> AB +! SMITHKLINE BEECHAM 1GM CONTAINS AT LEAST 900MG OF THE N021654 001 Nov 10, 2004 Feb CAHN  
 ETHYL ESTERS OF OMEGA-3 FATTY  
 ACIDS  
 >A> AB +! WOODWARD 1GM CONTAINS AT LEAST 900MG OF THE N021654 001 Nov 10, 2004 Feb CAHN  
 ETHYL ESTERS OF OMEGA-3 FATTY  
 ACIDS

ONDANSETRON

FILM;ORAL  
 ZUPLENZ  
 >A> + @ AQUESTIVE 4MG N022524 001 Jul 02, 2010 Feb CAHN  
 >A> + @ 8MG N022524 002 Jul 02, 2010 Feb CAHN  
 >D> + @ FORTOVIA 4MG N022524 001 Jul 02, 2010 Feb CAHN  
 >D> + @ 8MG N022524 002 Jul 02, 2010 Feb CAHN



ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE;ORAL  
ORPHENADRINE CITRATE

@ IMPAX PHARMS 100MG A040368 001 Jun 23, 2000 Jan DISC

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL  
OSELTAMIVIR PHOSPHATE

@ MYLAN EQ 30MG BASE A210157 001 Jan 21, 2021 Jan DISC  
AB EQ 30MG BASE A210157 001 Jan 21, 2021 Jan NEWA  
@ EQ 45MG BASE A210157 002 Jan 21, 2021 Jan DISC  
AB EQ 45MG BASE A210157 002 Jan 21, 2021 Jan NEWA  
@ EQ 75MG BASE A210157 003 Jan 21, 2021 Jan DISC  
AB EQ 75MG BASE A210157 003 Jan 21, 2021 Jan NEWA

OXYBUTYNIN CHLORIDE

TABLET;ORAL  
OXYBUTYNIN CHLORIDE

AB APPCO 5MG A209025 001 Dec 21, 2017 Jan CAHN

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL  
PAROXETINE HYDROCHLORIDE

>A> AB CSPC OUYI EQ 12.5MG BASE A213485 001 Feb 16, 2021 Feb NEWA  
>A> AB EQ 25MG BASE A213485 002 Feb 16, 2021 Feb NEWA  
>A> AB EQ 37.5MG BASE A213485 003 Feb 16, 2021 Feb NEWA

PEMETREXED

SOLUTION;INTRAVENOUS  
PEMETREXED

+ @ ACTAVIS LLC 100MG/4ML (25MG/ML) N208419 001 Aug 21, 2020 Jan DISC  
+ @ 500MG/20ML (25MG/ML) N208419 002 Aug 21, 2020 Jan DISC  
+ @ 1GM/40ML (25MG/ML) N208419 003 Aug 21, 2020 Jan DISC

PENTAMIDINE ISETHIONATE

INJECTABLE;INJECTION  
PENTAMIDINE ISETHIONATE

AP EMCURE PHARMS LTD 300MG/VIAL A213806 001 Jan 07, 2021 Jan NEWA

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL  
TRENAL

>D> + @ US PHARM HOLDINGS 400MG N018631 001 Aug 30, 1984 Feb CAHN  
>A> + @ VALIDUS PHARMS 400MG N018631 001 Aug 30, 1984 Feb CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS  
BIORPHEN

>D> +! ETON PHARMS 0.1MG/ML (0.1MG/ML) N212909 001 Oct 21, 2019 Feb CPOT  
>A> +! 0.5MG/5ML (0.1MG/ML) N212909 001 Oct 21, 2019 Feb CPOT

PHENYLEPHRINE HYDROCHLORIDE

AP2 AUROBINDO PHARMA LTD 10MG/ML (10MG/ML) A210696 001 Jan 07, 2021 Jan NEWA  
AP2 +! HIKMA 10MG/ML (10MG/ML) N203826 001 Dec 20, 2012 Jan CAHN  
AP2 +! 50MG/5ML (10MG/ML) N203826 002 Jun 19, 2019 Jan CAHN  
AP2 +! 100MG/10ML (10MG/ML) N203826 003 Jun 19, 2019 Jan CAHN  
AP1 PROVEPHARM SAS 10MG/ML (10MG/ML) A211081 001 Jul 17, 2020 Jan CAHN  
AP1 50MG/5ML (10MG/ML) A211081 002 Jul 17, 2020 Jan CAHN  
AP1 100MG/10ML (10MG/ML) A211081 003 Jul 17, 2020 Jan CAHN

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL  
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

>A> AA AKORN 5MG/5ML;6.25MG/5ML A040675 001 Dec 23, 2014 Feb CAHN  
>D> AA HI TECH 5MG/5ML;6.25MG/5ML A040675 001 Dec 23, 2014 Feb CAHN

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL  
PIOGLITAZONE HYDROCHLORIDE

AB ANNORA PHARMA EQ 15MG BASE A204133 001 Apr 07, 2014 Jan CAHN  
AB EQ 30MG BASE A204133 002 Apr 07, 2014 Jan CAHN  
AB EQ 45MG BASE A204133 003 Apr 07, 2014 Jan CAHN

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

AB	SHUANGCHENG	EQ 15MG BASE	A210165	001	Jan 22, 2021	Jan NEWA
AB		EQ 30MG BASE	A210165	002	Jan 22, 2021	Jan NEWA
AB		EQ 45MG BASE	A210165	003	Jan 22, 2021	Jan NEWA

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	PROVEPHARM SAS	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A207847	001	Jan 13, 2017	Jan CAHN
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A207847	002	Jan 13, 2017	Jan CAHN
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207848	002	Jan 13, 2017	Jan CAHN
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207847	003	Jan 13, 2017	Jan CAHN
AP		EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A207848	001	May 11, 2018	Jan CAHN
>A>	AP SAGENT PHARMS INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A208674	001	Feb 16, 2021	Feb NEWA
>A>	AP	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A208674	002	Feb 16, 2021	Feb NEWA
>A>	AP	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A208674	003	Feb 16, 2021	Feb NEWA
>A>	AP	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A208675	001	Feb 16, 2021	Feb NEWA
AP	! WOCKHARDT BIO AG	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A206996	001	Mar 22, 2017	Jan CHRS
AP	!	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A206996	002	Mar 22, 2017	Jan CHRS
AP	!	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A206996	003	Mar 22, 2017	Jan CHRS
AP	!	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207146	001	Mar 17, 2017	Jan CHRS
	ZOSYN					
+	@ WYETH PHARMS	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	N050684	001	Oct 22, 1993	Jan DISC
+	@	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	N050684	002	Oct 22, 1993	Jan DISC
+	@	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	N050684	003	Oct 22, 1993	Jan DISC
+	@	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	N050684	004	Oct 22, 1993	Jan DISC

PIROXICAM

CAPSULE;ORAL

PIROXICAM

AB	NOSTRUM LABS INC	10MG	A074118	002	Jun 15, 1993	Jan CMS1
----	------------------	------	---------	-----	--------------	----------

POMALIDOMIDE

CAPSULE;ORAL

POMALIDOMIDE

>D>	AB BRECKENRIDGE	1MG	A210111	001	Oct 30, 2020	Feb DISC
>A>	@	1MG	A210111	001	Oct 30, 2020	Feb DISC
>D>	AB	2MG	A210111	002	Oct 30, 2020	Feb DISC
>A>	@	2MG	A210111	002	Oct 30, 2020	Feb DISC
>D>	AB	3MG	A210111	003	Oct 30, 2020	Feb DISC
>A>	@	3MG	A210111	003	Oct 30, 2020	Feb DISC
>D>	AB	4MG	A210111	004	Oct 30, 2020	Feb DISC
>A>	@	4MG	A210111	004	Oct 30, 2020	Feb DISC

POSACONAZOLE

TABLET, DELAYED RELEASE;ORAL

POSACONAZOLE

AB	AET PHARMA	100MG	A213454	001	Feb 01, 2021	Jan NEWA
----	------------	-------	---------	-----	--------------	----------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

>A>	AB GRANULES	8MEQ	A214686	001	Feb 16, 2021	Feb NEWA
>A>	AB	10MEQ	A214686	002	Feb 16, 2021	Feb NEWA

SOLUTION;ORAL

POTASSIUM CHLORIDE

AA	GRANULES PHARMS	20MEQ/15ML	A213392	001	Jan 29, 2021	Jan NEWA
AA		40MEQ/15ML	A213392	002	Jan 29, 2021	Jan NEWA

TABLET, EXTENDED RELEASE;ORAL  
POTASSIUM CHLORIDE

AB1	AMTA	10MEQ	A214395	001	Jan 28, 2021	Jan NEWA
AB1		20MEQ	A214395	002	Jan 28, 2021	Jan NEWA

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL  
POTASSIUM CITRATE

AB	ASCENT PHARMS INC	5MEQ	A214420	001	Feb 05, 2021	Jan NEWA
AB		10MEQ	A214420	002	Feb 05, 2021	Jan NEWA
AB		15MEQ	A214420	003	Feb 05, 2021	Jan NEWA
>D>	BIONPHARMA INC	10MEQ	A212799	001	Jun 29, 2020	Feb DISC
>A>	@	10MEQ	A212799	001	Jun 29, 2020	Feb DISC
>D>	AB	15MEQ	A212799	002	Jun 29, 2020	Feb DISC
>A>	@	15MEQ	A212799	002	Jun 29, 2020	Feb DISC
>A>	AB	5MEQ	A214426	001	Feb 19, 2021	Feb NEWA
>A>	AB	10MEQ	A214426	002	Feb 19, 2021	Feb NEWA
>A>	AB	15MEQ	A214426	003	Feb 19, 2021	Feb NEWA

PRASUGREL HYDROCHLORIDE

TABLET;ORAL  
PRASUGREL

@	DR REDDYS LABS LTD	EQ 5MG BASE	A205926	001	Jul 07, 2020	Jan DISC
@		EQ 10MG BASE	A205926	002	Jul 07, 2020	Jan DISC

PRAVASTATIN SODIUM

TABLET;ORAL  
PRAVASTATIN SODIUM

AB	BIOCON PHARMA	10MG	A209869	001	Apr 13, 2018	Jan CAHN
AB		20MG	A209869	002	Apr 13, 2018	Jan CAHN
AB		40MG	A209869	003	Apr 13, 2018	Jan CAHN
AB		80MG	A209869	004	Apr 13, 2018	Jan CAHN
@	HISUN PHARM HANGZHOU	20MG	A206061	001	Nov 23, 2018	Jan DISC
@		40MG	A206061	002	Nov 23, 2018	Jan DISC
@		80MG	A206061	003	Nov 23, 2018	Jan DISC

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL  
PRAZOSIN HYDROCHLORIDE

>D>	@ ANI PHARMS INC	EQ 1MG BASE	A072577	002	May 16, 1989	Feb CMFD
>A>	AB	EQ 1MG BASE	A072577	002	May 16, 1989	Feb CMFD
>D>	@	EQ 2MG BASE	A072577	001	May 16, 1989	Feb CMFD
>A>	AB	EQ 2MG BASE	A072577	001	May 16, 1989	Feb CMFD
>D>	@	EQ 5MG BASE	A072577	003	May 16, 1989	Feb CMFD
>A>	AB	EQ 5MG BASE	A072577	003	May 16, 1989	Feb CMFD

PREDNISOLONE

TABLET;ORAL  
PREDNISOLONE  
@ RISING

5MG	A084773	001		Jan CAHN
-----	---------	-----	--	----------

PREDNISON

TABLET;ORAL  
PREDNISON

@	RISING	10MG	A089983	001	Jan 12, 1989	Jan CAHN
@		20MG	A085813	001		Jan CAHN
@		50MG	A089984	001	Jan 12, 1989	Jan CAHN
>A>	AB	STRIDES PHARMA	A208412	001	Feb 11, 2021	Feb NEWA
>A>	AB		A208412	002	Feb 11, 2021	Feb NEWA

PREGABALIN

CAPSULE;ORAL  
PREGABALIN

>A>	AB	ALKEM LABS LTD	A207799	007	Sep 30, 2019	Feb CMS1
>A>	AB		A207799	008	Sep 30, 2019	Feb CMS1

PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL  
PROMETHAZINE HYDROCHLORIDE

>D>	AA	AMNEAL PHARMS	A040882	001	Dec 30, 2009	Feb DISC
>A>	@		A040882	001	Dec 30, 2009	Feb DISC

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL  
QUETIAPINE FUMARATE

>D>	AB	MYLAN	EQ 50MG BASE	A202228	001	Feb 02, 2021	Feb DISC
>A>		@	EQ 50MG BASE	A202228	001	Feb 02, 2021	Feb DISC
	AB		EQ 50MG BASE	A202228	001	Feb 02, 2021	Jan NEWA
>D>	AB		EQ 150MG BASE	A202228	002	Feb 02, 2021	Feb DISC
>A>		@	EQ 150MG BASE	A202228	002	Feb 02, 2021	Feb DISC
	AB		EQ 150MG BASE	A202228	002	Feb 02, 2021	Jan NEWA
>D>	AB		EQ 200MG BASE	A202228	003	Feb 02, 2021	Feb DISC
>A>		@	EQ 200MG BASE	A202228	003	Feb 02, 2021	Feb DISC
	AB		EQ 200MG BASE	A202228	003	Feb 02, 2021	Jan NEWA
>D>	AB		EQ 300MG BASE	A202228	004	Feb 02, 2021	Feb DISC
>A>		@	EQ 300MG BASE	A202228	004	Feb 02, 2021	Feb DISC
	AB		EQ 300MG BASE	A202228	004	Feb 02, 2021	Jan NEWA
>D>	AB		EQ 400MG BASE	A202228	005	Feb 02, 2021	Feb DISC
>A>		@	EQ 400MG BASE	A202228	005	Feb 02, 2021	Feb DISC
	AB		EQ 400MG BASE	A202228	005	Feb 02, 2021	Jan NEWA

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL  
QUINIDINE GLUCONATE  
@ RISING 324MG

A089894	001	Dec 15, 1988	Jan CAHN
---------	-----	--------------	----------

RANITIDINE HYDROCHLORIDE

TABLET;ORAL  
RANITIDINE HYDROCHLORIDE  
@ WOCKHARDT LTD EQ 150MG BASE  
@ EQ 300MG BASE

A075208	001	Dec 17, 1998	Jan DISC
A075208	002	Dec 17, 1998	Jan DISC

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL  
RANOLAZINE

	AB	GRAVITI PHARMS	500MG	A212889	001	Jan 28, 2021	Jan NEWA
	AB		1GM	A212889	002	Jan 28, 2021	Jan NEWA
>A>	AB	PRAXGEN	500MG	A212781	001	Mar 23, 2020	Feb CAHN
>A>	AB		1GM	A212781	002	Mar 23, 2020	Feb CAHN
>D>	AB	SUNGEN PHARMA	500MG	A212781	001	Mar 23, 2020	Feb CAHN
>D>	AB		1GM	A212781	002	Mar 23, 2020	Feb CAHN

RIFAMPIN

INJECTABLE; INJECTION  
RIFAMPIN  
>D> AP WATSON PHARMS TEVA 600MG/VIAL  
>A> @ 600MG/VIAL

A206736	001	Jan 19, 2016	Feb DISC
A206736	001	Jan 19, 2016	Feb DISC

RILUZOLE

FILM;ORAL  
EXSERVAN  
>D> +! AQUESTIVE THERAP 50MG  
>A> +! MITSUBISHI HOLDINGS 50MG

N212640	001	Nov 22, 2019	Feb CAHN
N212640	001	Nov 22, 2019	Feb CAHN

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL  
RISPERDAL

>D>	AB	+	JANSSSEN PHARMS	0.5MG	N021444	001	Apr 02, 2003	Feb DISC
>A>		+	@	0.5MG	N021444	001	Apr 02, 2003	Feb DISC
>D>	AB	+	!	1MG	N021444	002	Apr 02, 2003	Feb DISC
>A>		+	@	1MG	N021444	002	Apr 02, 2003	Feb DISC
>D>	AB	+		2MG	N021444	003	Apr 02, 2003	Feb DISC
>A>		+	@	2MG	N021444	003	Apr 02, 2003	Feb DISC
>D>	AB	+		3MG	N021444	004	Dec 23, 2004	Feb DISC
>A>		+	@	3MG	N021444	004	Dec 23, 2004	Feb DISC
>D>	AB	+		4MG	N021444	005	Dec 23, 2004	Feb DISC
>A>		+	@	4MG	N021444	005	Dec 23, 2004	Feb DISC
RISPERIDONE								
>D>	AB		JUBILANT GENERICS	1MG	A090839	002	Nov 04, 2011	Feb CHRS
>A>	AB	!		1MG	A090839	002	Nov 04, 2011	Feb CHRS

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

ROPIVACAINE HYDROCHLORIDE

@ MYLAN ASI 150MG/30ML (5MG/ML)  
 @ 200MG/20ML (10MG/ML)

A090318 002 Sep 23, 2014 Jan DISC  
 A090318 004 Sep 23, 2014 Jan DISC

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

AB INVENTIA 5MG  
 AB 10MG  
 AB 20MG  
 AB 40MG  
 >D> @ ZHEJIANG YONGTAI 5MG  
 >A> AB 5MG  
 >D> @ 10MG  
 >A> AB 10MG  
 >D> @ 20MG  
 >A> AB 20MG  
 >D> @ 40MG  
 >A> AB 40MG

A207653 001 Feb 05, 2021 Jan NEWA  
 A207653 002 Feb 05, 2021 Jan NEWA  
 A207653 003 Feb 05, 2021 Jan NEWA  
 A207653 004 Feb 05, 2021 Jan NEWA  
 A212059 001 Nov 04, 2019 Feb CMFD  
 A212059 001 Nov 04, 2019 Feb CMFD  
 A212059 002 Nov 04, 2019 Feb CMFD  
 A212059 002 Nov 04, 2019 Feb CMFD  
 A212059 003 Nov 04, 2019 Feb CMFD  
 A212059 003 Nov 04, 2019 Feb CMFD  
 A212059 004 Nov 04, 2019 Feb CMFD  
 A212059 004 Nov 04, 2019 Feb CMFD

RUFINAMIDE

SUSPENSION; ORAL

RUFINAMIDE

>A> AB ALKEM LABS LTD 40MG/ML

A213410 001 Feb 23, 2021 Feb NEWA

SELENIOUS ACID

SOLUTION; INTRAVENOUS

SELENIOUS ACID

+! AM REGENT EQ 60MCG BASE/ML (EQ 60MCG  
 BASE/ML)

N209379 002 Jan 25, 2021 Jan NEWA

SELEXIPAG

TABLET; ORAL

UPTRAVI

>A> + ACTELION 0.2MG  
 >A> +! 0.4MG  
 >A> + 0.6MG  
 >A> + 0.8MG  
 >A> + 1MG  
 >A> + 1.2MG  
 >A> + 1.4MG  
 >A> + 1.6MG  
 >D> + ACTELION PHARMS LTD 0.2MG  
 >D> +! 0.4MG  
 >D> + 0.6MG  
 >D> + 0.8MG  
 >D> + 1MG  
 >D> + 1.2MG  
 >D> + 1.4MG  
 >D> + 1.6MG

N207947 001 Dec 21, 2015 Feb CAHN  
 N207947 002 Dec 21, 2015 Feb CAHN  
 N207947 003 Dec 21, 2015 Feb CAHN  
 N207947 004 Dec 21, 2015 Feb CAHN  
 N207947 005 Dec 21, 2015 Feb CAHN  
 N207947 006 Dec 21, 2015 Feb CAHN  
 N207947 007 Dec 21, 2015 Feb CAHN  
 N207947 008 Dec 21, 2015 Feb CAHN  
 N207947 001 Dec 21, 2015 Feb CAHN  
 N207947 002 Dec 21, 2015 Feb CAHN  
 N207947 003 Dec 21, 2015 Feb CAHN  
 N207947 004 Dec 21, 2015 Feb CAHN  
 N207947 005 Dec 21, 2015 Feb CAHN  
 N207947 006 Dec 21, 2015 Feb CAHN  
 N207947 007 Dec 21, 2015 Feb CAHN  
 N207947 008 Dec 21, 2015 Feb CAHN

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB ACI HEALTHCARE LTD EQ 25MG BASE  
 AB EQ 50MG BASE  
 AB EQ 100MG BASE

A076881 001 Feb 06, 2007 Jan CMFD  
 A076881 002 Feb 06, 2007 Jan CMFD  
 A076881 003 Feb 06, 2007 Jan CMFD

SEVELAMER CARBONATE

TABLET; ORAL

SEVELAMER CARBONATE

AB LUPIN LTD 800MG

A204600 001 Jan 14, 2021 Jan NEWA

SIMVASTATIN

TABLET; ORAL

ZOCOR

>D> AB + MSD MERCK CO 5MG  
 >D> AB + 10MG  
 >D> AB + 20MG  
 >D> AB + 40MG

N019766 001 Dec 23, 1991 Feb CAHN  
 N019766 002 Dec 23, 1991 Feb CAHN  
 N019766 003 Dec 23, 1991 Feb CAHN  
 N019766 004 Dec 23, 1991 Feb CAHN

TABLET;ORAL  
ZOCOR

>D>	AB	+		80MG	N019766	005	Jul 10, 1998	Feb	CAHN
>A>	AB	+	ORGANON	5MG	N019766	001	Dec 23, 1991	Feb	CAHN
>A>	AB	+		10MG	N019766	002	Dec 23, 1991	Feb	CAHN
>A>	AB	+		20MG	N019766	003	Dec 23, 1991	Feb	CAHN
>A>	AB	+		40MG	N019766	004	Dec 23, 1991	Feb	CAHN
>A>	AB	+		80MG	N019766	005	Jul 10, 1998	Feb	CAHN

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS  
SODIUM FLUORIDE F-18

AP			NUKEMED	10-200mCi/ML	A203912	001	Apr 22, 2015	Jan	CAHN
----	--	--	---------	--------------	---------	-----	--------------	-----	------

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

AB			NOVEL LABS INC	0.398GM;1.102GM	A079247	001	Dec 30, 2011	Jan	CMFD
AB	+	!	SALIX PHARMS	0.398GM;1.102GM	N021892	001	Mar 16, 2006	Jan	CTEC

SOTALOL HYDROCHLORIDE

TABLET;ORAL

SOTALOL HYDROCHLORIDE

>D>	AB		MYLAN	80MG	A077616	001	Feb 07, 2007	Feb	DISC
>A>			@	80MG	A077616	001	Feb 07, 2007	Feb	DISC
>D>	AB			120MG	A077616	002	Feb 07, 2007	Feb	DISC
>A>			@	120MG	A077616	002	Feb 07, 2007	Feb	DISC
>D>	AB			160MG	A077616	003	Feb 07, 2007	Feb	DISC
>A>			@	160MG	A077616	003	Feb 07, 2007	Feb	DISC

STERILE WATER FOR INJECTION

LIQUID;N/A

STERILE WATER FOR INJECTION

!			NEPHRON	100% (5ML)	A211222	001	Feb 10, 2021	Jan	NEWA
---	--	--	---------	------------	---------	-----	--------------	-----	------

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

SUCCINYLCHOLINE CHLORIDE

>D>	AP		HIKMA	20MG/ML	A213229	001	Jun 12, 2020	Feb	DISC
>A>			@	20MG/ML	A213229	001	Jun 12, 2020	Feb	DISC

SULFAMETHOXAZOLE

TABLET;ORAL

SULFAMETHOXAZOLE

@			RISING	500MG	A085844	001		Jan	CAHN
---	--	--	--------	-------	---------	-----	--	-----	------

SULFISOXAZOLE

TABLET;ORAL

SULFISOXAZOLE

@			RISING	500MG	A085628	001		Jan	CAHN
---	--	--	--------	-------	---------	-----	--	-----	------

SUMATRIPTAN

SPRAY;NASAL

SUMATRIPTAN

>A>	AB		CIPLA	20MG/SPRAY	A214209	001	Feb 22, 2021	Feb	NEWA
>A>	AB		PHARMASERVE NW	20MG/SPRAY	A208967	001	Feb 17, 2021	Feb	NEWA

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

@			MYLAN ASI	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090641	001	Jul 28, 2010	Jan	DISC
---	--	--	-----------	-------------------------------------	---------	-----	--------------	-----	------

SPRAY;NASAL

SUMATRIPTAN

>A>	AB		PERRIGO UK FINCO	5MG/SPRAY	A213465	002	Sep 21, 2020	Feb	CMS1
-----	----	--	------------------	-----------	---------	-----	--------------	-----	------

TADALAFIL

TABLET;ORAL

CIALIS

>D>	AB	+	LILLY	2.5MG	N021368	004	Jan 07,	2008	Feb	CTEC
>A>	AB1	+		2.5MG	N021368	004	Jan 07,	2008	Feb	CTEC
>D>	AB	+		5MG	N021368	001	Nov 21,	2003	Feb	CTEC
>A>	AB1	+		5MG	N021368	001	Nov 21,	2003	Feb	CTEC
>D>	AB	+		10MG	N021368	002	Nov 21,	2003	Feb	CTEC
>A>	AB1	+		10MG	N021368	002	Nov 21,	2003	Feb	CTEC

TADALAFIL

>D>	AB		ACCORD HLTHCARE	2.5MG	A209167	001	Mar 26,	2019	Feb	CTEC
>A>	AB1			2.5MG	A209167	001	Mar 26,	2019	Feb	CTEC
>D>	AB			5MG	A209167	002	Mar 26,	2019	Feb	CTEC
>A>	AB1			5MG	A209167	002	Mar 26,	2019	Feb	CTEC
>D>	AB			10MG	A209167	003	Oct 23,	2019	Feb	CTEC
>A>	AB1			10MG	A209167	003	Oct 23,	2019	Feb	CTEC
>D>	AB		AJANTA PHARMA LTD	2.5MG	A209654	001	Mar 26,	2019	Feb	CTEC
>A>	AB1			2.5MG	A209654	001	Mar 26,	2019	Feb	CTEC
>D>	AB			5MG	A209654	002	Mar 26,	2019	Feb	CTEC
>A>	AB1			5MG	A209654	002	Mar 26,	2019	Feb	CTEC
>D>	AB			10MG	A209654	003	Mar 26,	2019	Feb	CTEC
>A>	AB1			10MG	A209654	003	Mar 26,	2019	Feb	CTEC
>D>	AB		ALEMBIC PHARMS LTD	2.5MG	A204809	001	Mar 26,	2019	Feb	CTEC
>A>	AB1			2.5MG	A204809	001	Mar 26,	2019	Feb	CTEC
>D>	AB			5MG	A204809	002	Mar 26,	2019	Feb	CTEC
>A>	AB1			5MG	A204809	002	Mar 26,	2019	Feb	CTEC
>D>	AB			10MG	A204809	003	Mar 26,	2019	Feb	CTEC
>A>	AB1			10MG	A204809	003	Mar 26,	2019	Feb	CTEC
>D>	AB		AMNEAL PHARMS CO	2.5MG	A209744	001	Mar 26,	2019	Feb	CTEC
>A>	AB1			2.5MG	A209744	001	Mar 26,	2019	Feb	CTEC
>D>	AB			5MG	A209744	002	Mar 26,	2019	Feb	CTEC
>A>	AB1			5MG	A209744	002	Mar 26,	2019	Feb	CTEC
>D>	AB			10MG	A209744	003	Mar 26,	2019	Feb	CTEC
>A>	AB1			10MG	A209744	003	Mar 26,	2019	Feb	CTEC
>D>	AB		AUROBINDO PHARMA LTD	2.5MG	A206285	001	Mar 26,	2019	Feb	CTEC
>A>	AB1			2.5MG	A206285	001	Mar 26,	2019	Feb	CTEC
>D>	AB			5MG	A206285	002	Mar 26,	2019	Feb	CTEC
>A>	AB1			5MG	A206285	002	Mar 26,	2019	Feb	CTEC
>D>	AB			10MG	A206285	003	Mar 26,	2019	Feb	CTEC
>A>	AB1			10MG	A206285	003	Mar 26,	2019	Feb	CTEC
>D>	AB		CIPLA	2.5MG	A209539	001	Mar 26,	2019	Feb	CTEC
>A>	AB1			2.5MG	A209539	001	Mar 26,	2019	Feb	CTEC
>D>	AB			5MG	A209539	002	Mar 26,	2019	Feb	CTEC
>A>	AB1			5MG	A209539	002	Mar 26,	2019	Feb	CTEC
>D>	AB			10MG	A209539	003	Mar 26,	2019	Feb	CTEC
>A>	AB1			10MG	A209539	003	Mar 26,	2019	Feb	CTEC
>D>	AB		DR REDDYS LABS LTD	2.5MG	A210069	001	Mar 26,	2019	Feb	CTEC
>A>	AB1			2.5MG	A210069	001	Mar 26,	2019	Feb	CTEC
>D>	AB			5MG	A210069	002	Mar 26,	2019	Feb	CTEC
>A>	AB1			5MG	A210069	002	Mar 26,	2019	Feb	CTEC
>D>	AB			10MG	A210069	003	Mar 26,	2019	Feb	CTEC
>A>	AB1			10MG	A210069	003	Mar 26,	2019	Feb	CTEC
>D>	AB		GLENMARK PHARMS LTD	2.5MG	A210716	001	Dec 29,	2020	Feb	DISC
>A>	@			2.5MG	A210716	001	Dec 29,	2020	Feb	DISC
>D>	AB			5MG	A210716	002	Dec 29,	2020	Feb	DISC
>A>	@			5MG	A210716	002	Dec 29,	2020	Feb	DISC
>D>	AB			10MG	A210716	003	Dec 29,	2020	Feb	DISC
>A>	@			10MG	A210716	003	Dec 29,	2020	Feb	DISC
>D>	AB1			20MG	A210716	004	Dec 29,	2020	Feb	DISC
>A>	@			20MG	A210716	004	Dec 29,	2020	Feb	DISC
>D>	AB		HETERO LABS LTD III	2.5MG	A209908	001	Mar 26,	2019	Feb	CTEC
>A>	AB1			2.5MG	A209908	001	Mar 26,	2019	Feb	CTEC
>D>	AB			5MG	A209908	002	Mar 26,	2019	Feb	CTEC
>A>	AB1			5MG	A209908	002	Mar 26,	2019	Feb	CTEC
>D>	AB			10MG	A209908	003	Mar 26,	2019	Feb	CTEC
>A>	AB1			10MG	A209908	003	Mar 26,	2019	Feb	CTEC
>D>	AB		LUPIN LTD	2.5MG	A210567	001	Mar 26,	2019	Feb	CTEC
>A>	AB1			2.5MG	A210567	001	Mar 26,	2019	Feb	CTEC
>D>	AB			5MG	A210567	002	Mar 26,	2019	Feb	CTEC
>A>	AB1			5MG	A210567	002	Mar 26,	2019	Feb	CTEC
>D>	AB			10MG	A210567	003	Mar 26,	2019	Feb	CTEC
>A>	AB1			10MG	A210567	003	Mar 26,	2019	Feb	CTEC
>D>	AB		MACLEODS PHARMS LTD	2.5MG	A207244	001	Oct 07,	2019	Feb	CTEC

TABLET;ORAL  
TADALAFIL

>A>	AB1	2.5MG	A207244	001	Oct 07, 2019	Feb CTEC
>D>	AB	5MG	A207244	002	Oct 07, 2019	Feb CTEC
>A>	AB1	5MG	A207244	002	Oct 07, 2019	Feb CTEC
>D>	AB	10MG	A207244	003	Oct 07, 2019	Feb CTEC
>A>	AB1	10MG	A207244	003	Oct 07, 2019	Feb CTEC
>D>	AB	2.5MG	A206956	001	Apr 29, 2019	Feb CTEC
>A>	AB1	2.5MG	A206956	001	Apr 29, 2019	Feb CTEC
>D>	AB	5MG	A206957	001	Apr 29, 2019	Feb CTEC
>A>	AB1	5MG	A206957	001	Apr 29, 2019	Feb CTEC
>D>	AB	10MG	A206956	002	Apr 29, 2019	Feb CTEC
>A>	AB1	10MG	A206956	002	Apr 29, 2019	Feb CTEC
>D>	AB	2.5MG	A210420	001	Mar 26, 2019	Feb CTEC
>A>	AB1	2.5MG	A210420	001	Mar 26, 2019	Feb CTEC
>D>	AB	5MG	A210420	002	Mar 26, 2019	Feb CTEC
>A>	AB1	5MG	A210420	002	Mar 26, 2019	Feb CTEC
>D>	AB	10MG	A210420	003	Mar 26, 2019	Feb CTEC
>A>	AB1	10MG	A210420	003	Mar 26, 2019	Feb CTEC
>D>	AB	2.5MG	A208934	001	Mar 26, 2019	Feb CTEC
>A>	AB1	2.5MG	A208934	001	Mar 26, 2019	Feb CTEC
>D>	AB	5MG	A208934	002	Mar 26, 2019	Feb CTEC
>A>	AB1	5MG	A208934	002	Mar 26, 2019	Feb CTEC
>D>	AB	10MG	A208934	003	Mar 26, 2019	Feb CTEC
>A>	AB1	10MG	A208934	003	Mar 26, 2019	Feb CTEC
>D>	AB	2.5MG	A211335	001	Mar 26, 2019	Feb CTEC
>A>	AB1	2.5MG	A211335	001	Mar 26, 2019	Feb CTEC
>D>	AB	5MG	A211335	002	Mar 26, 2019	Feb CTEC
>A>	AB1	5MG	A211335	002	Mar 26, 2019	Feb CTEC
>D>	AB	10MG	A211335	003	Mar 26, 2019	Feb CTEC
>A>	AB1	10MG	A211335	003	Mar 26, 2019	Feb CTEC
>D>	AB	2.5MG	A090141	001	May 22, 2018	Feb CTEC
>A>	AB1	2.5MG	A090141	001	May 22, 2018	Feb CTEC
>D>	AB	5MG	A090141	002	May 22, 2018	Feb CTEC
>A>	AB1	5MG	A090141	002	May 22, 2018	Feb CTEC
>D>	AB	10MG	A090141	003	May 22, 2018	Feb CTEC
>A>	AB1	10MG	A090141	003	May 22, 2018	Feb CTEC
>D>	AB	2.5MG	A211839	001	Mar 26, 2019	Feb CTEC
>A>	AB1	2.5MG	A211839	001	Mar 26, 2019	Feb CTEC
>D>	AB	5MG	A211839	002	Mar 26, 2019	Feb CTEC
>A>	AB1	5MG	A211839	002	Mar 26, 2019	Feb CTEC
>D>	AB	10MG	A211839	003	Mar 26, 2019	Feb CTEC
>A>	AB1	10MG	A211839	003	Mar 26, 2019	Feb CTEC
>D>	AB	2.5MG	A211298	001	Oct 23, 2020	Feb CTEC
>A>	AB1	2.5MG	A211298	001	Oct 23, 2020	Feb CTEC
>D>	AB	5MG	A211298	002	Oct 23, 2020	Feb CTEC
>A>	AB1	5MG	A211298	002	Oct 23, 2020	Feb CTEC
>D>	AB	10MG	A211298	003	Oct 23, 2020	Feb CTEC
>A>	AB1	10MG	A211298	003	Oct 23, 2020	Feb CTEC
>D>	AB	2.5MG	A209250	001	Mar 26, 2019	Feb CTEC
>A>	AB1	2.5MG	A209250	001	Mar 26, 2019	Feb CTEC
>D>	AB	5MG	A209250	002	Mar 26, 2019	Feb CTEC
>A>	AB1	5MG	A209250	002	Mar 26, 2019	Feb CTEC
>D>	AB	10MG	A209250	003	Mar 26, 2019	Feb CTEC
>A>	AB1	10MG	A209250	003	Mar 26, 2019	Feb CTEC
>D>	AB	2.5MG	A208824	001	Oct 27, 2020	Feb CTEC
>A>	AB1	2.5MG	A208824	001	Oct 27, 2020	Feb CTEC
>D>	AB	5MG	A208824	002	Oct 27, 2020	Feb CTEC
>A>	AB1	5MG	A208824	002	Oct 27, 2020	Feb CTEC
>D>	AB	10MG	A208824	003	Oct 27, 2020	Feb CTEC
>A>	AB1	10MG	A208824	003	Oct 27, 2020	Feb CTEC
>D>	AB	2.5MG	A206693	001	Mar 26, 2019	Feb CTEC
>A>	AB1	2.5MG	A206693	001	Mar 26, 2019	Feb CTEC
>D>	AB	5MG	A206693	002	Mar 26, 2019	Feb CTEC
>A>	AB1	5MG	A206693	002	Mar 26, 2019	Feb CTEC
>D>	AB	10MG	A206693	003	Mar 26, 2019	Feb CTEC
>A>	AB1	10MG	A206693	003	Mar 26, 2019	Feb CTEC



TAVABOROLE

SOLUTION;TOPICAL  
TAVABOROLE

AB	CIPLA	5%	A212224	001	Feb 09, 2021	Jan NEWA	
>D>	AB	FLATWING	5.0%	A211963	001	Feb 03, 2021	Feb CAHN
	AB		5.0%	A211963	001	Feb 03, 2021	Jan NEWA
>A>	AB	IDENTIRX	5%	A211963	001	Feb 03, 2021	Feb CAHN
	AB	LUPIN LTD	5%	A212168	001	Feb 08, 2021	Jan NEWA

TELMISARTAN

TABLET;ORAL  
TELMISARTAN

>D>	@	CELLTRION	20MG	A078710	001	Jan 08, 2014	Feb CMFD
>A>	AB		20MG	A078710	001	Jan 08, 2014	Feb CMFD
>D>	@		40MG	A078710	002	Jan 08, 2014	Feb CMFD
>A>	AB		40MG	A078710	002	Jan 08, 2014	Feb CMFD
>D>	@		80MG	A078710	003	Jan 08, 2014	Feb CMFD
>A>	AB		80MG	A078710	003	Jan 08, 2014	Feb CMFD

TEMOZOLOMIDE

CAPSULE;ORAL  
TEMOZOLOMIDE

>D>	@	BARR	5MG	A078879	001	Mar 01, 2010	Feb CAHN
>D>	@		20MG	A078879	002	Mar 01, 2010	Feb CAHN
>D>	@		100MG	A078879	003	Mar 01, 2010	Feb CAHN
>D>	@		140MG	A078879	005	Mar 01, 2010	Feb CAHN
>D>	@		180MG	A078879	006	Mar 01, 2010	Feb CAHN
>D>	@		250MG	A078879	004	Mar 01, 2010	Feb CAHN
>A>	@	HERITAGE	5MG	A078879	001	Mar 01, 2010	Feb CAHN
>A>	@		20MG	A078879	002	Mar 01, 2010	Feb CAHN
>A>	@		100MG	A078879	003	Mar 01, 2010	Feb CAHN
>A>	@		140MG	A078879	005	Mar 01, 2010	Feb CAHN
>A>	@		180MG	A078879	006	Mar 01, 2010	Feb CAHN
>A>	@		250MG	A078879	004	Mar 01, 2010	Feb CAHN
	@	WATSON LABS TEVA	5MG	A203959	001	Apr 18, 2017	Jan DISC
	@		20MG	A203959	002	Apr 18, 2017	Jan DISC
	@		100MG	A203959	003	Apr 18, 2017	Jan DISC
	@		140MG	A203959	004	Apr 18, 2017	Jan DISC
	@		250MG	A203959	005	Apr 18, 2017	Jan DISC

>A> TEPOTINIB HYDROCHLORIDE

>A> TABLET;ORAL  
>A> TEPMETKO

>A>	+	EMD SERONO INC	EQ 225MG BASE	N214096	001	Feb 03, 2021	Feb NEWA
-----	---	----------------	---------------	---------	-----	--------------	----------

TERIFLUNOMIDE

TABLET;ORAL  
TERIFLUNOMIDE

>D>	AB	IMPAX	14MG	A209677	001	Jun 17, 2020	Feb DISC
>A>	@		14MG	A209677	001	Jun 17, 2020	Feb DISC

TESTOSTERONE

GEL;TRANSDERMAL  
TESTOSTERONE

>A>	AB2	ACTAVIS LABS UT INC	1.62% (20.25MG/1.25GM PACKET)	A204570	002	Jul 17, 2020	Feb NEWA
>A>	AB2		1.62% (40.5MG/2.5GM PACKET)	A204570	003	Jul 17, 2020	Feb NEWA

GEL, METERED;TRANSDERMAL  
TESTOSTERONE

>A>	AB	ALBOR DERMACEUTICALS	1.62% (20.25MG/1.25GM ACTUATION)	A213922	001	Mar 03, 2021	Feb NEWA
-----	----	----------------------	----------------------------------	---------	-----	--------------	----------

SOLUTION, METERED;TRANSDERMAL  
TESTOSTERONE

AT	FEMPHARM		30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Jan NEWA
----	----------	--	----------------------	---------	-----	--------------	----------

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL  
THIORIDAZINE HYDROCHLORIDE

MYLAN  
10MG  
25MG  
50MG  
!  
100MG  
@ SUN PHARM INDUSTRIES 10MG

A088004	002	Mar 15, 1983	Jan CTEC
A088004	003	Mar 15, 1983	Jan CTEC
A088004	004	Mar 15, 1983	Jan CTEC
A088004	001	Nov 18, 1983	Jan CTEC
A089953	004	Aug 01, 1986	Jan DISC

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE

@	25MG	A089953	003	Aug 01, 1986	Jan DISC
@	50MG	A089953	002	Aug 01, 1986	Jan DISC
@	100MG	A089953	001	Oct 07, 1988	Jan DISC

THIOTEPA

POWDER;INTRACAVITARY, INTRAVENOUS, INTRAVESICAL

THIOTEPA

>A>	AP	GLAND PHARMA LTD	15MG/VIAL	A214222	001	Mar 08, 2021	Feb NEWA
-----	----	------------------	-----------	---------	-----	--------------	----------

TIAGABINE HYDROCHLORIDE

TABLET;ORAL

TIAGABINE HYDROCHLORIDE

@	WILSHIRE PHARMS INC	2MG	A206857	001	Oct 13, 2017	Jan DISC
@		4MG	A206857	002	Oct 13, 2017	Jan DISC
@		12MG	A206857	003	Oct 13, 2017	Jan DISC
@		16MG	A206857	004	Oct 13, 2017	Jan DISC

TIZANIDINE HYDROCHLORIDE

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

>A>	AB	CADILA	EQ 2MG BASE	A208187	001	Mar 09, 2018	Feb CAHN
>A>	AB		EQ 4MG BASE	A208187	002	Mar 09, 2018	Feb CAHN
		@ MYLAN	EQ 2MG BASE	A076354	001	Mar 28, 2003	Jan DISC
>D>	AB		EQ 4MG BASE	A076354	002	Mar 28, 2003	Feb DISC
>A>		@	EQ 4MG BASE	A076354	002	Mar 28, 2003	Feb DISC
>D>	AB	ZYDUS PHARMS	EQ 2MG BASE	A208187	001	Mar 09, 2018	Feb CAHN
>D>	AB		EQ 4MG BASE	A208187	002	Mar 09, 2018	Feb CAHN

TOBRAMYCIN

SOLUTION;INHALATION

TOBRAMYCIN

AN		AUROBINDO PHARMA LTD	300MG/5ML	A210871	001	Jan 22, 2021	Jan NEWA
----	--	----------------------	-----------	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

>A>	AT	GLAND PHARMA LTD	0.3%	A212628	001	Mar 09, 2021	Feb NEWA
-----	----	------------------	------	---------	-----	--------------	----------

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

>A>	AP	GLAND PHARMA LTD	EQ 10MG BASE/ML	A209621	001	Feb 11, 2021	Feb NEWA
>A>	AP		EQ 40MG BASE/ML	A209621	002	Feb 11, 2021	Feb NEWA
		TOBRAMYCIN SULFATE (PHARMACY BULK)					
AP	!	FRESENIUS KABI USA	EQ 40MG BASE/ML	A065120	001	Nov 29, 2002	Jan CTEC
AP		GLAND PHARMA LTD	EQ 40MG BASE/ML	A209346	001	Feb 09, 2021	Jan NEWA

TOFACITINIB CITRATE

SOLUTION;ORAL

XELJANZ

>A>		+! PFIZER	EQ 1MG/ML BASE	N213082	001	Sep 25, 2020	Feb CMS1
		Xeljanz					
>D>		+! PFIZER	EQ 1MG/ML BASE	N213082	001	Sep 25, 2020	Feb CMS1

TOLCAPONE

TABLET;ORAL

TOLCAPONE

@	ALVOGEN	100MG	A207729	001	Jul 29, 2020	Jan DISC
---	---------	-------	---------	-----	--------------	----------

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

TOLTERODINE TARTRATE

AB		AJANTA PHARMA LTD	2MG	A213397	001	May 19, 2020	Jan CMFD
AB			4MG	A213397	002	May 19, 2020	Jan CMFD
AB		AMTA	2MG	A213858	001	Feb 02, 2021	Jan NEWA
AB			4MG	A213858	002	Feb 02, 2021	Jan NEWA

TOLVAPTANTABLET;ORAL  
SAMSCA

>A>	+	OTSUKA	15MG	N022275	001	May 19, 2009	Feb CAHN
>A>	AB	+	30MG	N022275	002	May 19, 2009	Feb CAHN
>A>		+	60MG	N022275	003	May 19, 2009	Feb CAHN
>D>		+	15MG	N022275	001	May 19, 2009	Feb CAHN
>D>	AB	+	30MG	N022275	002	May 19, 2009	Feb CAHN
>D>		+	60MG	N022275	003	May 19, 2009	Feb CAHN

TOPIRAMATECAPSULE, EXTENDED RELEASE;ORAL  
TOPIRAMATE

AB2		GLENMARK PHARMS LTD	25MG	A210278	001	Feb 01, 2021	Jan NFTG
AB2			50MG	A210278	002	Feb 01, 2021	Jan NFTG
AB2			100MG	A210278	003	Feb 01, 2021	Jan NFTG
AB2			150MG	A210278	004	Feb 01, 2021	Jan NFTG
AB2			200MG	A210278	005	Feb 01, 2021	Jan NFTG
AB1		ZYDUS PHARMS	25MG	A207382	001	Nov 24, 2017	Jan CTEC
AB1			50MG	A207382	002	Nov 24, 2017	Jan CTEC
AB1			100MG	A207382	003	Nov 24, 2017	Jan CTEC
		TROKENDI XR					
AB1	+	SUPERMUS PHARMS	25MG	N201635	001	Aug 16, 2013	Jan CTEC
AB1	+		50MG	N201635	002	Aug 16, 2013	Jan CTEC
AB1	+		100MG	N201635	003	Aug 16, 2013	Jan CTEC

TRAMADOL HYDROCHLORIDETABLET;ORAL  
TRAMADOL HYDROCHLORIDE

>D>		@	50MG	A206706	001	Jul 02, 2019	Feb CMFD
>A>	AB		50MG	A206706	001	Jul 02, 2019	Feb CMFD

TRANEXAMIC ACIDINJECTABLE;INJECTION  
TRANEXAMIC ACID

AP		PROVEPHARM SAS	100MG/ML	A212676	001	Jul 17, 2019	Jan CAHN
----	--	----------------	----------	---------	-----	--------------	----------

TRAZODONE HYDROCHLORIDETABLET;ORAL  
TRAZODONE HYDROCHLORIDE

>D>		@	50MG	A204852	001	Feb 05, 2020	Feb CMFD
>A>	AB		50MG	A204852	001	Feb 05, 2020	Feb CMFD
>D>		@	100MG	A204852	002	Feb 05, 2020	Feb CMFD
>A>	AB		100MG	A204852	002	Feb 05, 2020	Feb CMFD
>D>		@	150MG	A204852	003	Feb 05, 2020	Feb CMFD
>A>	AB		150MG	A204852	003	Feb 05, 2020	Feb CMFD
>D>		@	300MG	A204852	004	Feb 05, 2020	Feb CMFD
>A>	AB		300MG	A204852	004	Feb 05, 2020	Feb CMFD
		@	50MG	A072484	001	Apr 30, 1990	Jan CAHN

TREPROSTINILINJECTABLE;IV (INFUSION), SUBCUTANEOUS  
TREPROSTINIL

>A>	AP		1MG/ML	A211574	001	Feb 11, 2021	Feb NEWA
>A>	AP		2.5MG/ML	A211574	002	Feb 11, 2021	Feb NEWA
>A>	AP		5MG/ML	A211574	003	Feb 11, 2021	Feb NEWA
>A>	AP		10MG/ML	A211574	004	Feb 11, 2021	Feb NEWA

TRIAMCINOLONE ACETONIDECREAM;TOPICAL  
TRIAMCINOLONE ACETONIDE

AT		SAPTALIS PHARMS	0.025%	A040671	001	Jun 09, 2006	Jan CAHN
AT			0.1%	A040671	002	Jun 09, 2006	Jan CAHN

OINTMENT;TOPICAL  
TRIAMCINOLONE ACETONIDE

AT		PERRIGO ISRAEL	0.05%	A212460	001	Feb 05, 2021	Jan NEWA
----	--	----------------	-------	---------	-----	--------------	----------

TRIAZOLAM

TABLET;ORAL  
HALCION

>A>	AB	+	PFIZER	0.125MG	N017892	003	Apr 26, 1985	Feb	CAHN
>A>	AB	+	!	0.25MG	N017892	001	Nov 15, 1982	Feb	CAHN
>A>		@		0.5MG	N017892	002	Nov 15, 1982	Feb	CAHN
>D>	AB	+	PHARMACIA AND UPJOHN	0.125MG	N017892	003	Apr 26, 1985	Feb	CAHN
>D>	AB	+	!	0.25MG	N017892	001	Nov 15, 1982	Feb	CAHN
>D>		@		0.5MG	N017892	002	Nov 15, 1982	Feb	CAHN

TRILACICLIB DIHYDROCHLORIDE

>A>			POWDER; INTRAVENOUS							
>A>			COSELA							
>A>		+	!	G1 THERAP	EQ 300MG BASE/VIAL	N214200	001	Feb 12, 2021	Feb	NEWA

UMBRALISIB TOSYLATE

>A>			TABLET;ORAL							
>A>			UKONIQ							
>A>		+	!	TG THERAPS	EQ 200MG BASE	N213176	001	Feb 05, 2021	Feb	NEWA

URSODIOL

CAPSULE;ORAL  
URSODIOL

AB			STRIDES PHARMA	300MG	A210344	001	Jan 22, 2021	Jan	NEWA
----	--	--	----------------	-------	---------	-----	--------------	-----	------

VALGANCICLOVIR HYDROCHLORIDE

TABLET;ORAL  
VALGANCICLOVIR HYDROCHLORIDE

>A>	AB		MYLAN	EQ 450MG BASE	A205151	001	Mar 03, 2021	Feb	NEWA
-----	----	--	-------	---------------	---------	-----	--------------	-----	------

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION  
VANCOMYCIN HYDROCHLORIDE

>D>	AP		HIKMA	EQ 500MG BASE/VIAL	A203300	001	Aug 11, 2020	Feb	DISC
>A>		@		EQ 500MG BASE/VIAL	A203300	001	Aug 11, 2020	Feb	DISC
>D>	AP			EQ 1GM BASE/VIAL	A203300	002	Aug 11, 2020	Feb	DISC
>A>		@		EQ 1GM BASE/VIAL	A203300	002	Aug 11, 2020	Feb	DISC

VENLAFAXINE HYDROCHLORIDE

TABLET;ORAL  
VENLAFAXINE HYDROCHLORIDE

		@	MYLAN	EQ 25MG BASE	A077166	001	Jun 13, 2008	Jan	DISC
		@		EQ 37.5MG BASE	A077166	002	Jun 13, 2008	Jan	DISC
		@		EQ 50MG BASE	A077166	003	Jun 13, 2008	Jan	DISC
		@		EQ 75MG BASE	A077166	004	Jun 13, 2008	Jan	DISC
		@		EQ 100MG BASE	A077166	005	Jun 13, 2008	Jan	DISC

TABLET, EXTENDED RELEASE;ORAL  
VENLAFAXINE HYDROCHLORIDE

AB			DEXCEL PHARMA	EQ 75MG BASE	A213927	001	Jan 21, 2021	Jan	NEWA
----	--	--	---------------	--------------	---------	-----	--------------	-----	------

VERICIGUAT

TABLET;ORAL  
VERQUVO

		+	MERCK SHARP DOHME	2.5MG	N214377	001	Jan 19, 2021	Jan	NEWA
		+		5MG	N214377	002	Jan 19, 2021	Jan	NEWA
		+	!	10MG	N214377	003	Jan 19, 2021	Jan	NEWA

VIGABATRIN

FOR SOLUTION;ORAL  
VIGABATRIN

AA			ANNORA PHARMA	500MG/PACKET	A213519	001	Jan 26, 2021	Jan	NEWA
----	--	--	---------------	--------------	---------	-----	--------------	-----	------

TABLET;ORAL  
VIGABATRIN

AB			DR REDDYS	500MG	A211539	001	Jan 29, 2021	Jan	NEWA
----	--	--	-----------	-------	---------	-----	--------------	-----	------

VINORELBINE TARTRATE

INJECTABLE; INJECTION  
 VINORELBINE TARTRATE  
 @ FRESenius KABI USA

EQ 10MG BASE/ML

A076849 001 Apr 18, 2005 Jan DISC

VOCLOSPORIN

CAPSULE; ORAL  
 LUPKYNIS

+! AURINIA

7.9MG

N213716 001 Jan 22, 2021 Jan NEWA

VORICONAZOLE

INJECTABLE; INTRAVENOUS  
 VORICONAZOLE

>A> AP  
 >D> AP

ALMAJECT  
 ALVOGEN

200MG/VIAL  
 200MG/VIAL

A206398 001 Mar 23, 2016 Feb CAHN  
 A206398 001 Mar 23, 2016 Feb CAHN

ZONISAMIDE

CAPSULE; ORAL  
 ZONISAMIDE

AB  
 AB  
 AB

UNICHEM

25MG  
 50MG  
 100MG

A214492 001 Jan 26, 2021 Jan NEWA  
 A214492 002 Jan 26, 2021 Jan NEWA  
 A214492 003 Jan 26, 2021 Jan NEWA

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE

>A>	GRANULES	250MG; 250MG; 65MG	A214039	001	Feb 23, 2021	Feb	NEWA
-----	----------	--------------------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

@ APOTEX

10MG

A207235	001	Aug 12, 2016	Jan	DISC
---------	-----	--------------	-----	------

IBUPROFEN

SUSPENSION; ORAL

IBUPROFEN

GUARDIAN DRUG

100MG/5ML

A210149	001	Aug 17, 2018	Jan	CMFD
---------	-----	--------------	-----	------

>A>	STRIDES PHARMA	100MG/5ML	A211666	001	Feb 22, 2021	Feb	NEWA
-----	----------------	-----------	---------	-----	--------------	-----	------

KETOCONAZOLE

SHAMPOO; TOPICAL

NIZORAL A-D

>D>			N020310	001	Oct 10, 1997	Feb	CTNA
-----	--	--	---------	-----	--------------	-----	------

>D>	+! KRAMER	1%	N020310	001	Oct 10, 1997	Feb	CTNA
-----	-----------	----	---------	-----	--------------	-----	------

>A>	NIZORAL ANTI-DANDRUFF						
-----	-----------------------	--	--	--	--	--	--

>A>	+! KRAMER	1%	N020310	001	Oct 10, 1997	Feb	CTNA
-----	-----------	----	---------	-----	--------------	-----	------

LORATADINE

TABLET; ORAL

LORATADINE

UNIQUE PHARM

10MG

A214684	001	Jan 07, 2021	Jan	NEWA
---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

LORATADINE

@ GLAXOSMITHKLINE

10MG

A075822	001	Feb 10, 2003	Jan	DISC
---------	-----	--------------	-----	------

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

>A>	ALEMBIC PHARMS LTD	EQ 0.1% BASE	A209919	001	Dec 07, 2018	Feb	CMKT
-----	--------------------	--------------	---------	-----	--------------	-----	------

EQ 0.2% BASE

A209420	001	Apr 29, 2019	Jan	CMKT
---------	-----	--------------	-----	------

APOTEX INC

EQ 0.2% BASE

A090918	001	Dec 05, 2017	Jan	CMKT
---------	-----	--------------	-----	------

>A>	BARR LABS INC	EQ 0.2% BASE	A090848	001	Jul 13, 2015	Feb	CMKT
-----	---------------	--------------	---------	-----	--------------	-----	------

>A>	FDC LTD	EQ 0.1% BASE	A209282	001	Sep 26, 2019	Feb	CMKT
-----	---------	--------------	---------	-----	--------------	-----	------

>A>	MYLAN	EQ 0.1% BASE	A204392	001	Mar 21, 2018	Feb	CMKT
-----	-------	--------------	---------	-----	--------------	-----	------

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

@ WOCKHARDT

EQ 75MG BASE

A076760	001	Feb 24, 2006	Jan	DISC
---------	-----	--------------	-----	------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND  
RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 02 FEBRUARY 2021**

NO FEBRUARY 2021 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)



**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO FEBRUARY 2021 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 004	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 004	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	>A> 10894039	Oct 06, 2037	U-185			
	>A> 10894039	Oct 06, 2037	U-3			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 001	10888499	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 002	10888499	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 003	10888499	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 004	10888499	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 005	10888499	Feb 14, 2022	DP			
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENVU</u>						
N 209381 001	>A> 10918723	Sep 10, 2033	U-2310			
<u>ASENAPINE MALEATE - ASENAPINE MALEATE</u>						
A 206098 002					PC	Jun 08, 2021
<u>AXITINIB - INLYTA</u>						
N 202324 001	10869924	Nov 05, 2036	U-3044			
<u>AXITINIB - INLYTA</u>						
N 202324 002	10869924	Nov 05, 2036	U-3044			
<u>AZACITIDINE - ONUREG</u>						
N 214120 001					ODE-320	Sep 01, 2027
<u>AZACITIDINE - ONUREG</u>						
N 214120 002					ODE-320	Sep 01, 2027
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 001					NCE	Dec 03, 2025
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 002					NCE	Dec 03, 2025
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	RE48059	Dec 23, 2028	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	RE48059	Dec 23, 2028	DS			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001					NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002					NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003					NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004					NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005					NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001					NPP	May 10, 2021
<u>BUPIVACAINE - POSIMIR</u>						
N 204803 001	>A> 8153149	Sep 15, 2025	DP		>A> NP	Feb 01, 2024
	>A> 8153661	Sep 15, 2025	DP	U-3074		
	>A> 8753665	Sep 15, 2025	DP	U-3074		
	>A> 8846072	Sep 15, 2025	DP	U-3074		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	10874661	Sep 18, 2032	DP			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001					M-128	Dec 18, 2023
<u>CABOTEGRAVIR SODIUM - VOCABRIA</u>						
N 212887 001	>A> 8410103	Apr 28, 2026	DS DP U-3061		>A> NCE	Jan 21, 2026
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	>A> 6838464	Feb 26, 2021	DS DP		>A> NCE	Jan 21, 2026
	>A> 7125879	Apr 21, 2025	DS DP U-3059			
	>A> 8080551	Apr 11, 2023	DS DP			
	>A> 8410103	Apr 28, 2026	DS DP U-3060			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	>A> 6838464	Feb 26, 2021	DS DP		>A> NCE	Jan 21, 2026
	>A> 7125879	Apr 21, 2025	DS DP U-3059			
	>A> 8080551	Apr 11, 2023	DS DP			
	>A> 8410103	Apr 28, 2026	DS DP U-3060			
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	10864181	Mar 15, 2033	U-3017			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	>A> 10918608	Oct 14, 2035	U-3071			
	>A> 10918608	Oct 14, 2035	U-3072			
	>A> 10918608	Oct 14, 2035	U-3073			
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001	6706276	Mar 06, 2022	DP			
<u>COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455 001	10786518	Jul 19, 2038	U-2978			
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	>A> 10894012	Feb 07, 2037	U-3014			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001				>A> I-852		Jan 14, 2024
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002				>A> I-852		Jan 14, 2024
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	>A> 10905662	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	>A> 10905662	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 001	>A> 10905662	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 002	>A> 10905662	Aug 16, 2036	U-1399			
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	>A> 10918662	Jan 15, 2039	DP			
	>A> 10933089	Jan 15, 2039	DP			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	>A> 10905713	Jan 15, 2039	DP			
	>A> 10905714	Jan 15, 2039	DP			
	>A> 10912795	Jan 15, 2039	DP			
	>A> 10918662	Jan 15, 2039	DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	>A> 6087380	Dec 28, 2021	DS DP U-1931			
	>A> 6087380*PED	Jun 28, 2022				
	>A> 9034822	Jan 20, 2031	U-1759			
	>A> 9034822*PED	Jul 20, 2031				
	>A> 9925174	Jun 14, 2023	DP			
	>A> 9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	>A> 6087380	Dec 28, 2021	DS DP U-1931			
	>A> 6087380*PED	Jun 28, 2022				
	>A> 9034822	Jan 20, 2031	U-1759			
	>A> 9034822*PED	Jul 20, 2031				
	>A> 9925174	Jun 14, 2023	DP			
	>A> 9925174*PED	Dec 14, 2023				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 003	>A> 6087380	Dec 28, 2021	DS DP U-1931			
	>A> 6087380*PED	Jun 28, 2022				
	7866474	Aug 31, 2027	DP	Y		
	7866474*PED	Mar 02, 2028				
	>A> 7932273	Sep 07, 2025	DS DP			
	>A> 7932273*PED	Mar 07, 2026				
	>A> 9034822	Jan 20, 2031	U-1759			
	>A> 9034822*PED	Jul 20, 2031				
	>A> 9925174	Jun 14, 2023	DP			
	>A> 9925174*PED	Dec 14, 2023				
<u>DEFERIPRONE - DEFERIPRONE</u>						
A 208800 001					PC	Mar 27, 2021
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269 001	>A> 10940115	Oct 25, 2038	DP U-3083			
	>A> 10940116	Oct 25, 2038	DP			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	>A> 9550780	Sep 18, 2033	DS DP U-1995			
	>A> 9550780	Sep 18, 2033	DS DP U-3055			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	>A> 9550780	Sep 18, 2033	DS DP U-1995			
	>A> 9550780	Sep 18, 2033	DS DP U-3055			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	>A> 9550780	Sep 18, 2033	DS DP U-1995			
	>A> 9550780	Sep 18, 2033	DS DP U-3055			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	10864274	Oct 02, 2034	U-2720			
	>A> 7214506	Feb 22, 2026	U-281			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	10881659	Mar 14, 2034	U-2842			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10081621	Mar 25, 2031	DP U-2652		>A> ODE-323	Dec 21, 2027
	10081621	Mar 25, 2031	DP U-3032			
	10239867	Apr 09, 2027	DS DP U-2653			
	10239867	Apr 09, 2027	DS DP U-3033			
	10758534	Oct 06, 2035	DS DP U-2645			
	10758534	Oct 06, 2035	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-2645			
	10793547	Dec 08, 2037	DS DP U-3028			
	8324242	Aug 05, 2027	U-2645			
	8324242	Aug 05, 2027	U-3028			
	8354427	Jul 06, 2026	U-2646			
	8354427	Jul 06, 2026	U-3029			
	8415387	Nov 12, 2027	U-2645			
	8415387	Nov 12, 2027	U-3028			
	8598181	May 01, 2027	U-2645			
	8598181	May 01, 2027	U-3028			
	8629162	Jun 24, 2025	U-2648			
	8629162	Jun 24, 2025	U-3030			
	9670163	Dec 28, 2026	DP U-2650			
	9670163	Dec 28, 2026	DP U-3031			
	9931334	Dec 28, 2026	DP U-2650			
	9931334	Dec 28, 2026	DP U-3031			
	9974781	Apr 09, 2027	DP U-2645			
	9974781	Apr 09, 2027	DP U-3028			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494 001	10888544	Dec 13, 2038	U-3040			
	10888544	Dec 13, 2038	U-3041			
	10888547	Jan 31, 2031	U-3042			
	10888547	Jan 31, 2031	U-3043			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721 001					PC	Mar 09, 2021
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721 002					PC	Mar 09, 2021
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721 003					PC	Mar 09, 2021
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	10842938	Dec 21, 2037	DP U-2980			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003	10842938	Dec 21, 2037	DP U-2980			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	>A> 10898482	Feb 09, 2036	DP U-2518			
	>A> 10898482	Feb 09, 2036	DP U-3065			
	>A> 10898482	Feb 09, 2036	DP U-3066			
	>A> 10898482	Feb 09, 2036	DP U-3067			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	>A> 10898482	Feb 09, 2036	DP U-2518			
	>A> 10898482	Feb 09, 2036	DP U-3065			
	>A> 10898482	Feb 09, 2036	DP U-3066			
	>A> 10898482	Feb 09, 2036	DP U-3067			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	>A> 10898482	Feb 09, 2036	DP U-2518			
	>A> 10898482	Feb 09, 2036	DP U-3065			
	>A> 10898482	Feb 09, 2036	DP U-3066			
	>A> 10898482	Feb 09, 2036	DP U-3067			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	10869844	Sep 10, 2035	U-3034			
	10869844	Sep 10, 2035	U-3035			
	10869844	Sep 10, 2035	U-3036			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	10912781	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	10912781	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	10912781	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	10912781	Oct 23, 2028	DP			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001 >A>	RE47769	Feb 02, 2029	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002 >A>	RE47769	Feb 02, 2029	DP			
<u>ETHINYL ESTRADIOL; NORELGESTROMIN - ETHINYL ESTRADIOL AND NORELGESTROMIN</u>						
A 213950 001					>A> CGT	Aug 25, 2021
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MERZEE</u>						
A 212706 001					CGT	Jul 17, 2021
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001 >A>	10918649	Jun 21, 2039	DP			
	>A> 10925882	Jun 21, 2039	DP			
	>A> 10940157	Jun 21, 2039	DP			
<u>FERRIC CARBOXYMALTOSIDE - INJECTAFER</u>						
N 203565 001	10519252	Oct 20, 2023	DS DP U-2709			
	10519252	Oct 20, 2023	DS DP U-2710			
	10519252	Oct 20, 2023	DS DP U-2711			
	10519252	Oct 20, 2023	DS DP U-2712			
	10519252	Oct 20, 2023	DS DP U-3048			
	10519252	Oct 20, 2023	DS DP U-3049			
	7754702	Feb 15, 2028	U-1432			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
<u>FERRIC CARBOXYMALTOSIDE - INJECTAFER</u>						
N 203565 002	10519252	Oct 20, 2023	DS DP U-2709			
	10519252	Oct 20, 2023	DS DP U-2710			
	10519252	Oct 20, 2023	DS DP U-3048			
	10519252	Oct 20, 2023	DS DP U-3049			
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	9376505	Oct 20, 2023	DS DP			
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001 >A>	10933147	Dec 30, 2035	U-2450			
<u>GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11</u>						
N 212642 001					NCE W	Dec 01, 2025 Dec 01, 2025
<u>GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11</u>						
N 212643 001					NCE W	Dec 01, 2025 Dec 01, 2025
<u>GLUCAGON - BAQSIMI</u>						
N 210134 001	10894133	Jan 03, 2038	DP			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 001	>A> 9649280	May 12, 2034	DP U-3075			
	>A> 9675559	Jan 10, 2033	U-3075			
	>A> 9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 002	>A> 9649280	May 12, 2034	DP U-3075			
	>A> 9675559	Jan 10, 2033	U-3075			
	>A> 9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 003	>A> 9649280	May 12, 2034	DP U-3075			
	>A> 9675559	Jan 10, 2033	U-3075			
	>A> 9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 004	>A> 9649280	May 12, 2034	DP U-3075			
	>A> 9675559	Jan 10, 2033	U-3075			
	>A> 9717740	Nov 19, 2032	U-3075			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	>A> 10918635	Apr 30, 2030	U-1455			
	>A> 10918635	Apr 30, 2030	U-172			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10058546	Jul 15, 2033	U-2399			
	10058546	Jul 15, 2033	U-2572			
	10058546	Jul 15, 2033	U-3022			
	10058546	Jul 15, 2033	U-3023			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10081621	Mar 25, 2031	DP U-3024			
	10081621	Mar 25, 2031	DP U-3025			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10206877	Apr 14, 2035	DP U-3026			
	10206877	Apr 14, 2035	DP U-3027			
	8354427	Jul 06, 2026	U-3021			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	10058546	Jul 15, 2033	U-2399			
	10058546	Jul 15, 2033	U-2572			
	10058546	Jul 15, 2033	U-3022			
	10058546	Jul 15, 2033	U-3023			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10081621	Mar 25, 2031	DP U-3024			
	10081621	Mar 25, 2031	DP U-3025			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10206877	Apr 14, 2035	DP U-3026			
	10206877	Apr 14, 2035	DP U-3027			
	8354427	Jul 06, 2026	U-3021			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10882840	Jul 11, 2026	U-1524			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321	001				NPP	Dec 04, 2023
<u>LONAFARNIB - ZOKINVY</u>						
N 213969	001	>A> 7838531	Jul 26, 2024	U-3070	>A> ODE-324	Nov 20, 2027
		>A> 8828356	Oct 17, 2023	U-3070		
<u>LONAFARNIB - ZOKINVY</u>						
N 213969	002	>A> 7838531	Jul 26, 2024	U-3070	>A> ODE-324	Nov 20, 2027
		>A> 8828356	Oct 17, 2023	U-3070		
<u>MANNITOL - BRONCHITOL</u>						
N 202049	001				NP	Oct 30, 2023
<u>MELOXICAM - ANJESO</u>						
N 210583	001	10881663	Mar 08, 2039	U-3038		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044	001				M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044	002				M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270	001				M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270	002				M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311	001	>A> 10881618	Mar 23, 2032	U-2357		
		>A> 10905652	Mar 23, 2032	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311	002	>A> 10881618	Mar 23, 2032	U-2357		
		>A> 10905652	Mar 23, 2032	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311	003	>A> 10881618	Mar 23, 2032	U-2357		
		>A> 10905652	Mar 23, 2032	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311	004	>A> 10881618	Mar 23, 2032	U-2357		
		>A> 10905652	Mar 23, 2032	DP		
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311	005	>A> 10881618	Mar 23, 2032	U-2357		
		>A> 10905652	Mar 23, 2032	DP		
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623	001	10874655	May 30, 2038	U-2371		
		10874656	May 30, 2038	U-2371		
		10874657	May 30, 2038	U-2371		
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611	001	>A> 10842780	Sep 28, 2029	DP U-2996	>A> I-777	Apr 27, 2021
		>A> 10842780*PED	Mar 28, 2030			
		>A> 6346532	Mar 27, 2022	DS DP		
		>A> 6346532*PED	Sep 27, 2022			
		>A> 8772315	Oct 30, 2028	U-2300		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	>A> 8772315*PED	Apr 30, 2029				
	>A> 8835474	Nov 04, 2023	U-1527			
	>A> 8835474*PED	May 04, 2024				
	>A> RE44872	Nov 04, 2023	U-1527			
	>A> RE44872*PED	May 04, 2024				
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	>A> 10842780	Sep 28, 2029	DP U-2996		>A> I-777	Apr 27, 2021
	>A> 10842780*PED	Mar 28, 2030				
	>A> 6346532	Mar 27, 2022	DS DP			
	>A> 6346532*PED	Sep 27, 2022				
	>A> 8772315	Oct 30, 2028	U-2300			
	>A> 8772315*PED	Apr 30, 2029				
	>A> 8835474	Nov 04, 2023	U-1527			
	>A> 8835474*PED	May 04, 2024				
	>A> RE44872	Nov 04, 2023	U-1527			
	>A> RE44872*PED	May 04, 2024				
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	>A> 10918615	Aug 12, 2035	DP U-1384			
	>A> 10918616	Jun 03, 2035	U-1384			
	>A> 10918617	Aug 10, 2035	DP			
	>A> 10945985	Aug 14, 2035	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
A 212451 001					>A> CGT	Aug 10, 2021
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
A 212451 002					>A> CGT	Aug 10, 2021
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001	8669273	Jul 18, 2031	U-3047			
	9265784	Aug 04, 2029	U-3047			
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	10882840	Jul 11, 2026	U-1524			
<u>NIFURTIMOX - LAMPIT</u>						
N 213464 001					ODE-319	Aug 06, 2027
<u>NIFURTIMOX - LAMPIT</u>						
N 213464 002					ODE-319	Aug 06, 2027
<u>NITAZOXANIDE - NITAZOXANIDE</u>						
A 213820 001					>A> CGT	Jun 05, 2021
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860 001	10124142	Aug 18, 2025	U-3037			
	10814092	Oct 17, 2025	U-3037			
	>A> 10926054	Aug 13, 2029	DP			
	7947227	Oct 17, 2026	U-3037			
	8057742	Jan 18, 2026	U-3037			
	8226916	Aug 18, 2025	U-3037			
	8607785	Jul 14, 2030	DP			
	8609028	Aug 18, 2025	U-3037			
	8821801	Aug 18, 2025	DP			
	8944049	Aug 13, 2029	DP			
	9522249	Aug 18, 2025	DP			
	9701538	Jan 28, 2029	DP			
	9956373	Aug 18, 2025	U-3037			
<u>OBETICHOIC ACID - OCALIVA</u>						
N 207999 001	RE48286	Nov 16, 2027	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 002	RE48286	Nov 16, 2027	DS DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	>A> 8071579	Aug 12, 2027	U-2480			
	>A> 8071579	Aug 12, 2027	U-2819			
	>A> 8071579	Aug 12, 2027	U-2820			
	>A> 8071579	Aug 12, 2027	U-2821			
	>A> 8071579	Aug 12, 2027	U-2822			
	>A> 8071579	Aug 12, 2027	U-2823			
	>A> 8071579	Aug 12, 2027	U-2824			
	>A> 8071579	Aug 12, 2027	U-2832			
	>A> 8071579	Aug 12, 2027	U-2833			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 001				>A> NCE		Oct 30, 2025
<u>OLICERIDINE - OLINVYK</u>						
N 210730 002				>A> NCE		Oct 30, 2025
<u>OLICERIDINE - OLINVYK</u>						
N 210730 003				>A> NCE		Oct 30, 2025
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777	>A> I-853		Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289			
	10183020	Jan 02, 2035	DP U-3016			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777	>A> I-853		Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289			
	10183020	Jan 02, 2035	DP U-3016			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	>A> 9566252	Nov 02, 2022	U-1370			
<u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ</u>						
N 212520 001	10898573	Dec 16, 2039	DP			
	10912765	Aug 26, 2031	U-2849			
	>A> 10940138	Dec 16, 2039	U-2849			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	>A> RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	>A> RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	>A> RE47739	Mar 05, 2027	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001	>A> RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002	>A> RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003	>A> RE47739	Mar 05, 2027	DS DP			
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001	>A> 10391075	Feb 12, 2027	U-2622			
	>A> 10391075	Feb 12, 2027	U-3069			
	>A> 8778997	May 07, 2027	U-1627			
	>A> 8778997	May 07, 2027	U-2622			
	>A> 8778997	May 07, 2027	U-3069			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001					M-14 PED	Nov 20, 2023 May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002					M-14 PED	Nov 20, 2023 May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003					M-14 PED	Nov 20, 2023 May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004					M-14 PED	Nov 20, 2023 May 20, 2024
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001					I-849	Dec 18, 2023
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002					I-849	Dec 18, 2023
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	8114874	Jan 24, 2027	DS DP		I-849	Dec 18, 2023
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 004	8114874	Jan 24, 2027	DS DP		I-849	Dec 18, 2023
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001	10350170	Feb 25, 2036	DP		NCE	Dec 18, 2025
	10449191	Sep 29, 2037	U-3020			
	10786501	Sep 29, 2037	U-3020			
	7300935	Jan 28, 2024	DS			
	8058280	Jan 28, 2024	DS DP			
	8735401	Feb 04, 2024	U-3019			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	>A> 7125879	Apr 21, 2025	DS DP U-1153			
	>A> 7125879	Apr 21, 2025	DS DP U-1307			
	>A> 7125879	Apr 21, 2025	DS DP U-1740			
	>A> 7125879	Apr 21, 2025	DS DP U-3068			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	>A> 7125879	Apr 21, 2025	DS DP U-1153			
	>A> 7125879	Apr 21, 2025	DS DP U-1307			
	>A> 7125879	Apr 21, 2025	DS DP U-1740			
	>A> 7125879	Apr 21, 2025	DS DP U-3068			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001					>A> M-82	Feb 16, 2024
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002					>A> M-82	Feb 16, 2024
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003					>A> M-82	Feb 16, 2024
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	10519139	Aug 14, 2035	DS DP U-2584			
	10519139	Aug 14, 2035	DS DP U-2855			
	10519139	Aug 14, 2035	DS DP U-3018			
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	10864181	Mar 15, 2033	U-1532			
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	>A> 10912814	Jun 01, 2037	DP			
	>A> 8957046	Mar 21, 2028	U-2039			
	>A> 8957046	Mar 21, 2028	U-2040			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	>A> 10912754	Jun 01, 2038	U-3082			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	>A> 10912754	Jun 01, 2038	U-3082			
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478 001	10888570	Oct 28, 2036	DP			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	>A> 10925896	Nov 13, 2028	DP			
	>A> 10925897	Nov 13, 2028	DP			
	>A> 10933090	Nov 13, 2028	DP			
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	10896751	Mar 16, 2030	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAFENOQUINE SUCCINATE - ARAKODA</u>						
N 210607 001	10888558	Dec 02, 2035	U-2582			
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514 001	10864159	May 28, 2029	DP U-778			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	10610511	Oct 10, 2034	U-2615		I-850	Dec 01, 2023
	10610511	Oct 10, 2034	U-3007			
<u>TASIMELTEON - HETLIOZ LQ</u>						
N 214517 001					NP	Dec 01, 2023
<u>TAVABOROLE - TAVABOROLE</u>						
A 211963 001					>A> PC	Apr 17, 2021
<u>TEPOTINIB HYDROCHLORIDE - TEPMETKO</u>						
N 214096 001	>A> 8329692	Oct 30, 2029	DS DP		>A> NCE	Feb 03, 2026
	>A> 8580781	Mar 19, 2030	DS DP		>A> ODE-325	Feb 03, 2028
	>A> 8658643	Jul 04, 2028		U-3077		
	>A> 8921357	May 30, 2028	DS DP			
	>A> 8927540	Jul 21, 2028		U-3078		
	>A> 9062029	Jul 04, 2028	DP			
	>A> 9284300	Apr 29, 2028	DP			
	>A> 9403799	Jul 04, 2028		U-3077		
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	10881798	Feb 11, 2034	DP			
	>A> 10905827	Aug 21, 2031	DP			
	>A> 10912782	Feb 19, 2035	DP U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	10881798	Feb 11, 2034	DP			
	>A> 10905827	Aug 21, 2031	DP			
	>A> 10912782	Feb 19, 2035	DP U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	10881798	Feb 11, 2034	DP			
	>A> 10905827	Aug 21, 2031	DP			
	>A> 10912782	Feb 19, 2035	DP U-2418			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001					>A> I-851	May 28, 2023
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002					>A> I-851	May 28, 2023
<u>TIRBANIBULIN - KLISYRI</u>						
N 213189 001	10323001	Dec 28, 2027	DP		NCE	Dec 14, 2025
	10617693	Mar 12, 2038		U-3015		
	10669236	Sep 07, 2038	DS DP			
	7300931	Feb 06, 2026	DS DP			
	7851470	Feb 02, 2029	DS DP	U-3015		
	8236799	Dec 28, 2025	DS DP			
	8980890	Dec 28, 2025	DS DP			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	>A> 10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	>A> 10905694	Apr 07, 2030	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	>A> 10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 001	>A> 10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 002	>A> 10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 003	>A> 10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 004	>A> 10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 005	>A> 10905694	Apr 07, 2030	DP			
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	>A> 10085992	Mar 14, 2034	U-3081		>A> NCE	Feb 12, 2026
	>A> 10189849	Oct 25, 2031	DS			
	>A> 10189850	Oct 25, 2031	DP			
	>A> 10927120	Oct 25, 2031	DP			
	>A> 8598186	Oct 25, 2031	DS DP			
	>A> 8598197	Oct 25, 2031	DS DP			
	>A> 9487530	Mar 14, 2034	U-3079			
	>A> 9487530	Mar 14, 2034	U-3080			
	>A> 9957276	Oct 25, 2031	DS			
<u>UMBRALISIB TOSYLATE - UKONIO</u>						
N 213176 001	>A> 10072013	Jul 02, 2033	U-3063		>A> NCE	Feb 05, 2026
	>A> 10072013	Jul 02, 2033	U-3064			
	>A> 10414773	May 26, 2035	DS DP U-3063			
	>A> 10414773	May 26, 2035	DS DP U-3064			
	>A> 10570142	Jul 02, 2033	DS DP U-3063			
	>A> 10570142	Jul 02, 2033	DS DP U-3064			
	>A> 9150579	Jul 02, 2033	DS DP			
	>A> 9669033	Jul 02, 2033	U-3063			
	>A> 9669033	Jul 02, 2033	U-3064			
	>A> 9969740	May 26, 2035	DS DP U-3063			
	>A> 9969740	May 26, 2035	DS DP U-3064			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	>A> 10906902	Dec 22, 2036	DS DP			
	>A> 10906903	Dec 22, 2036	DS DP			
	>A> 10912771	Oct 10, 2037	U-1995			
	>A> 10912771	Oct 10, 2037	U-3076			
	>A> 10919892	Dec 22, 2036	DS DP			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 002	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	>A> 10906902	Dec 22, 2036	DS DP			
	>A> 10906903	Dec 22, 2036	DS DP			
	>A> 10912771	Oct 10, 2037	U-1995			
	>A> 10912771	Oct 10, 2037	U-3076			
	>A> 10919892	Dec 22, 2036	DS DP			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 001	>A> 10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	>A> 8420656	May 19, 2031	DS DP			
	>A> 8921377	May 19, 2031	U-3062			
	>A> 9604948	Nov 26, 2032	DS DP U-3062			
	>A> 9993476	May 19, 2031	U-3062			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VERICIGUAT - VEROUVO</u>						
N 214377 001	>A> 10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	>A> 8420656	May 19, 2031	DS DP			
	>A> 8921377	May 19, 2031		U-3062		
	>A> 9604948	Nov 26, 2032	DS DP	U-3062		
	>A> 9993476	May 19, 2031		U-3062		
<u>VERICIGUAT - VEROUVO</u>						
N 214377 002	>A> 10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	>A> 8420656	May 19, 2031	DS DP			
	>A> 8921377	May 19, 2031		U-3062		
	>A> 9604948	Nov 26, 2032	DS DP	U-3062		
	>A> 9993476	May 19, 2031		U-3062		
<u>VERICIGUAT - VEROUVO</u>						
N 214377 003	>A> 10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	>A> 8420656	May 19, 2031	DS DP			
	>A> 8921377	May 19, 2031		U-3062		
	>A> 9604948	Nov 26, 2032	DS DP	U-3062		
	>A> 9993476	May 19, 2031		U-3062		
<u>VIBEGRON - GEMTESA</u>						
N 213006 001	8247415	Dec 01, 2030	DS DP	U-3045	NCE	Dec 23, 2025
	8653260	Apr 02, 2029	DS			
<u>VIGABATRIN - VIGABATRIN</u>						
A 211539 001					CGT	Jul 31, 2021
<u>VILTOLARSEN - VILTEPSO</u>						
N 212154 001	10870676	Aug 31, 2031	DS DP	U-3039	ODE-280	Aug 12, 2027
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	>A> 10286036	Dec 07, 2037		U-3056	>A> NCE	Jan 22, 2026
	>A> 7332472	Oct 17, 2022	DS DP	U-3056		

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 41<sup>ST</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)